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ABSTRACT
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease,
and related tauopathies, are a global health care challenge due to the lack of early
treatment and diagnostic options. These diseases take an emotional and physical
toll on patients, caretakers, and a rather large economic toll on taxpayer-based
health care systems. The pathologies of these diseases are characterized by the
aggregation of misfolded proteins, amyloid-β (Aβ) and tau, into β-sheet rich
structures called amyloids. Research has found that the presence of protein
aggregates predates cognitive symptoms by years. Current diagnostic tools are
based on the detection of these amyloid aggregates, historically by using
histological stains to confirm disease diagnosis postmortem. This research
investigated the sensing and potential for therapeutic application of a novel class
of luminescent molecular sensors, oligo-p-phenylene ethynylenes (OPEs) in
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vitro, ex vivo, and their permeability through the blood-brain barrier. First, a small
library of OPEs was tested for their amyloid aggregate sensing selectivity and
sensitivity using model proteins hen-egg white lysozyme and bovine insulin to
identify optimal sensors through fluorimetry assays (Chapter 2). The top
candidates were further tested with pathology relevant proteins: tau hexapeptide
306

VQIVYK311, Aβ40, Aβ42, and α-synuclein (Chapters 3-4). From here we

moved to evaluate OPEs as histochemical markers of disease by staining
transgenic mice (rTg4510), transgenic rats (TgF344-AD), and human brain
sections from patients diagnosed with frontotemporal dementia (Chapter 5).
Next, we moved to test the OPEs blood-brain barrier permeability. We worked
towards this goal by visualizing the partition using the molecule’s equilibrium in
octanol/water phases and using a 3-D microfluidic “blood-brain barrier on a chip”
Synvivo BBB (Chapter 6). Lastly, OPEs photosensitizing properties were
studied by creating a detergent-OPE model system. Using transient absorption
and singlet oxygen chemical traps, we found that OPEs can generate singlet
oxygen through a controllable, binding induced, fluorescence-dependent,
mechanism. This targeted photosensitizing action gives OPEs potential as
therapeutic agents in photodynamic therapy applications (Chapter 8). This
research is aimed at providing a research tool for identifying patients in the early
stages of disease who would then be eligible and ideal candidates for clinical

vii

trials and has the power to become a critical technology with broad protein
detection for researchers by providing a tool for monitoring treatment effects and
efficacy.
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Chapter 1 Introduction
1.1 Neurodegeneration and protein aggregation
Research towards the discovery, diagnosis, prevention, and treatment of neurodegeneration is
crucial for our society which is facing the tripling of Alzheimer’s Disease cases in the next 30
years, from 5 million to nearly 14 million. Without diminishing the personal effect this disease
has on people and their families it is advisable to mention the financial burden it imposes. Also
tripling by 2050 is the cost that AD and other dementias will inflict on us, $305 billion to $1.1
trillion. These costs include medical costs incurred by patients alongside wages lost by patients
and their caregivers. (Alzheimer's Assocation , 2020) The above-stated numbers highlight AD
patients however 1 in 3 seniors dies with AD or another dementia. Regardless of the diagnosis,
a spectrum of neurodegenerative disorders share a common microscopic marker, proteinaceous
aggregates composed of misfolded, aggregated, fibrillar proteins (AD, Parkinson’s Disease,
Traumatic Brain Injuries, Huntington’s Disease, Spongiform encephalopathies, amongst
others).
These pathologies are characterized by the aggregation of misfolded proteins into βsheet rich structures1,2. Specifically, in tauopathies the microtubule stabilizing tau protein
aggregates intracellularly into paired helical filaments (PHFs) to form neurofibrillary tangles
(NFTs) and in AD amyloid-β aggregates extracellularly to form plaques. Amyloid β protein is
the proteolytic product of the transmembrane amyloid precursor protein (APP). It is cleaved
by β-secretase and γ-secretase to produce peptides 37-49 amino acids long3. The most
commonly found in AD are Aβ40, Aβ424,5. For many years the amyloid cascade hypothesis
has been the focus of research and starting point for diagnosis and treatment. The amyloid
cascade hypothesis is centered around Aβ40 and Aβ42 accumulation leading to Aβ plaque
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formation causing neurotoxicity, tau pathology, and the beginning of neurodegeneration6,7. For
over 20 years this has been the basis for developing AD therapeutics. This has been a hurdle
for scientists due to the continued failed drug trials and tools to treat the disease8. Research has
since moved towards including tau pathology as an indicator or originator in the progression
of AD9,10. Tau is a major microtubule associated protein product of the MAPT gene found on
chromosome 17 with six isoforms which differ in how many microtubule binding repeats they
carry, three or four (3R or 4R) as a result of alternative splicing9,11,12 The presence or lack
thereof of certain isoforms aid in diagnostic distinctions and could serve to explain the fibril
polymorphism observed in tau neurofibrillary tangles13. Tau’s biological role includes the use
of phosphate groups to moderate binding activity to microtubules, it is a dynamic system in
which the protein is regularly dephosphorylated. In disease, the tau protein becomes hyperphosphorylated, preventing tau-microtubule interaction and leads to protein aggregation
ultimately resulting in paired helical filament (PHFs) formation12.
Independent of the protein identity, amino acid sequence, function, or location, these
proteins display similar aggregation behaviors all resulting in extracellular plaques or
intracellular inclusion formation1,2 (Figure 1-1). The process of aggregation, after protein
misfolding, is thought to be the cause for cytotoxicity rather than the deposited aggregates
themselves14–16. It has been established that fibril growth and aggregation occur through
nucleated events – there is a lag phase followed by an exponential growth producing fibrils17,18.
During the nucleation, the lag phase, the oligomerization of proteins has garnered attention as
it has been shown these small, soluble aggregates are highly toxic to neurons14,19. The
morphology of these oligomers varies, some maintain some native folds while others adapt a
high β sheet content, protofibrils, and can be detected by β-sheet specific molecular dyes such
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as Thioflavin T and Congo Red20. Despite the structural differences, generally the aggregation
process is shared for amyloidogenic proteins which provides a framework for understanding
and a general target for developing diagnostic and treatments tools.

Figure 1-1 Schematic of protein aggregation resulting in cross β sheet fibrillar structures2.

1.2 Current Sensing Technology
Through imaging, cerebrospinal fluid (CSF) assays, and autopsy reports it has been found that
protein abnormalities are observed 5-10 years prior to a dementia diagnosis21–23. Presently, an
AD diagnosis is made from empirical observations and neuropsychological evaluations by a
physician CSF24. Symptomatic treatment options include medications to ameliorate the
cognitive symptoms and slow down disease progression, but these are prescribed post disease
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confirmation by which point the neurological damage is widespread25. The coappearance and
comorbidity of these proteins years prior to symptom onset calls for diagnostic tools that could
serve as broad amyloid detectors, as a possible first line of preventative medicine and be used
to detect disease during the asymptomatic window26. In order to create a diagnostic tool to
detect neurodegeneration, we must define a trend or a series of reliable biomarkers. A current
method for tracking and differentiating disease progression has been found in characterizing
protein identities and concentrations in CSF27. This has proved to be a successful method for
disease detection and is laying out a roadmap for future diagnostic work however there is more
to do to grow the detection window into the earlier asymptomatic times for early intervention
therapies.
The standard in histochemical stains to confirm amyloidogenic pathology are
Thioflavin T (ThT) and Congo Red (CR) (Table 1-1) which bind to the organized cross β
structure shared by proteinaceous aggregates.

Table 1-1 Molecular structures of amyloid stains Thioflavin T, Congo Red, and Pittsburg
Compound B
Compound

Molecular Structure

Thioflavin T

Congo Red

Pittsburg Compound B

Thioflavin T is a small rod-like conjugated molecule. After an excitation event in its free state
the molecule can release energy by rotation across the single bond in between the rings. If
4

bound to a fibrillar surface the molecule, not free to rotate, will release energy by emitting
fluorescence28. Similarly, Congo red has been used for over 80 years. CR binding to Aβ fibrils
has been reported to be parallel to the beta sheet, intercalated in the grooves, guided by
hydrophobic and electrostatic interactions20,29. If bound, the dye displays gold-green
birefringence under polarized light. Attempts were made to use CR in vivo to diagnose
systemic amyloidosis but the practice was stopped due to the crude results and some patients
experienced anaphylactic shock29,30. Although they continue to serve as gold standards for
post-mortem diagnostic confirmation, these historical dyes have limitations such as a narrow
range of amyloid deposit detection and failing to recognize protein polymorphism in the
aggregates31. Thioflavins and Congo Red molecules have served as a springboard for the
synthesis of novel sensing molecules aimed at the detection of disease associated fibrillar
protein deposits most notably the Pittsburg Compound B (PIB)32. There are three derived FDA
approved Aβ positron emission tomography (PET) ligands for clinical use to confirm AD diagnosis
in patients presenting dementia symptoms, [18F] Florbetapir33 (Amyvid), [18F] Florbetan34
(Neuraceq), and [18F] Flutemetamol34 (Vizamyl)35. These three PET agents are designed to bind
and allow quantification of Aβ plaque load density35. Research and pre-clinical PET agents for tau
imaging include THK5117, THK5351, and PBB3 amongst others36–38. The limitations of current
PET ligands are their expensive nature and the lack of use in early disease diagnosis.

Detection of the fibrillar protein aggregates originating from tau or Ab protein, is of
limited scope in early diagnosis, in aiding tracking of pathology, in relating it to symptom
progression, and evaluating therapeutic intervention32,39. With this research we introduce and
evaluate a novel class of conjugated polyelectrolytes as sensors for protein aggregate diseases.
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1.3 Oligo-p-phenylene Ethynylenes as Biosensors
A novel library of conjugated polyelectrolytes, oligo-p-phenylene ethynylene (OPEs), (Figure
1-2)40,41 has been synthesized over the years by the laboratory of Dr. David Whitten. With an
origin in biocidal activity, these compounds have been applied in a variety of fields the latest,
presented in this work, is biosensing and therapeutics40. OPEs have tailorable chemical
properties including the length, side group charges, and the identity of the capping end groups,
providing tunability and numerous sensing modes. These chemical differences have proven to
be effective in narrowing down applications, yet, leaving the possibility for newly synthesized
compounds with higher affinity for their intended target.

Figure 1-2 General structure of OPEs42. OPEnx where n is the number of repeats and x is the
charge.

The backbone, regardless of length possesses conjugated pi system including aromatic rings
and a certain hydrophobicity nature ensuring the stable binding along grooves on beta sheet
surfaces resulting in increased fluorescence following planarization through bond rotation
restriction43,44 . The end groups have been found to be responsible for the molecules quenched
and unquenched states in water and other organic solvents. The carboxy ester end groups
provide the quenched state in water due to energy transfer interactions with the water molecules
in the excited state. After a binding event, water molecules are displaced preventing the
diffusion of energy through solvent resulting in fluorescence emission. The charge of the side
groups is seemingly involved with the affinity and interactions with monomeric proteins42.
6

Cationic OPE molecules have been shown to be effective broad-spectrum antimicrobial
compounds. The positively charged groups are sufficient to bind OPE molecules to the
negatively charged bacterial surface causing cell death through membrane disruption in dark
conditions or singlet oxygen production under irradiation conditions45. Following the
discovery of the seemingly controllable quenched state of these molecules in water versus
ethanol and the similarity in molecular structure to known amyloid stains (ThT and CR), a
jump was made from biocidal applications to testing their efficiency as molecular sensors of
protein aggregation. Previous work, highlighted four OPE molecules as selective fibrillar
aggregate sensors against model hen-egg white lysozyme proteins42. This work laid the
foundation for the research presented herein. They reported that OPEs detected fibrillar
aggregates over their monomeric counterparts as seen by a large increase in fluorescence due
to the lack of intramolecular motion as well as additional sensing modes including hydrophobic
dequenching and dye-dye interactions forming superluminescent chiral J aggregates (Figure
1-3). These results posed the need to evaluate OPEs further as biosensors for the detection of
disease relevant proteins aggregates.

Figure 1-3 OPEs multiple modes of detection of amyloids42.
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Lastly, we explored the feasibility of OPEs as potential therapeutic agents with an OPEdetergent complex. Based on the knowledge that bacterial toxicity of cationic OPEs under
irradiation is caused by the production of reactive oxygen species (ROS), specifically singlet
oxygen we created a model system in which OPE12- would generate ROS as a downstream
product of fluorescence. Based on energy flow through the electronic states of the OPE
molecules (Figure 9-3) ROS production was postulated to be controllable. The application of
ROS species for therapeutic purposes is a longstanding practice in medicine to treat cancers,
acne, or destruction of pathogenic bodies on surfaces46–48.

With this idea, a targeted

photoactivated sensitizer could be delivered to aggregates for photodynamic like therapies.
Work done by Dr. Adeline M. Fanni as presented in her dissertation “Detection and
Remodeling of Toxic Amyloid Aggregates by Novel Conjugated Polyelectrolytes” and
previous undergraduate student Jonathan Hulse further describe the use of OPEs in therapeutic
applications including the oxidation of Ab fibrils as measured by mass spectrometry and
singlet oxygen effect on biologically relevant lipid membranes. With this project we
characterized and evaluated feasibility of OPEs as in vitro and ex vivo sensors through
screening assays to identify highly selective and sensitive molecules. Our aim is to pave the
road for in vivo sensor development.
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Chapter 2 Substituent, Charge, and Size Effects on the Fluorogenic
Performance of Amyloid Ligands: A Small-Library Screening Study
(This chapter has been published in ACS Omega and appears as Patrick L. Donabedian,
Mallory Evanoff, Florencia A. Monge, David G. Whitten, and Eva Y. Chi. 2017.
Substituent, Charge, and Size Effects on the Fluorogenic Performance of Amyloid Ligands: A
Small-Library Screening Study, ACS Omega. 2: 3192-3200)

2.1 Abstract

Figure 2-1 Table of contents graphic

Developing new molecular ligands for the direct detection and tracking of amyloid protein
aggregates is key to understanding and defeating myriad neurodegenerative and other disorders
including Alzheimer’s and Parkinson’s diseases. A crucial factor in the performance of an
amyloid dye is its ability to detect the amyloid structural motif independent of the sequence of
the amyloid-forming protomer. The current study investigates structure−function relationships
of a class of novel phenylene ethynylene (PPE)- based dyes and fluorescent polymers using
amyloid fibrils formed by two model proteins: lysozyme and insulin. A small library of 18 PPE
compounds that vary in molecular weights, charge densities, water solubilities, and types and
geometries of functional groups was tested. One compound, the small anionic oligo(pphenylene ethynylene) electrolyte OPE1, was identified as a selective sensor for the amyloid
conformation of both lysozyme and insulin. On the basis of protein binding and photophysical
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changes observed in the dye from this set of PPE compounds, keys to the selective detection
of the amyloid protein conformation include moderate size, negative charge, and substituents
that provide high microenvironment sensitivity to the fluorescence yield. These principles can
serve as a guide for the further refinement of the effective amyloid-sensing molecules.
2.2 Introduction
The function of a protein in living cells depends on the folding and stabilization of a native
structure or set of conformers. Misassembly of proteins into β-sheet-enriched fibrillar
aggregates is a hallmark of protein misfolding disorders such as, among many others,
Alzheimer’s disease (AD) and Parkinson’s disease2,49–53. Amyloid protein aggregation is a
complex and heterogeneous process that begins with protomeric proteins that differ widely in
sequence, structure, size, and function and ends with highly ordered fibrils that accumulate in
the affected tissues54,55. In AD, protein aggregation is believed to initiate a cascade of events
culminating in neurodegeneration and cognitive decline decades before the onset of clinical
symptoms54,56, protein aggregates are thus ideal biomarkers for early disease detection and
therapeutic intervention.
Many studies have been launched to develop probes for detecting the aggregated
conformation of disease-associated proteins, and conformation- and sequence-specific
antibodies have been developed for protein aggregates57. However, the myriad of challenges
associated with antibody-based detection and failures of a number of clinical trials58,59 have
spurred renewed efforts in developing small-molecule probes. Several amyloid plaque-specific
positron emission tomography (PET) imaging probes have been reported,34,60–62 including
[11C] Pittsburgh compound B, [18F] florbetapir, and [18F] flutemetamol. Although these
compounds are capable of detecting fibrillar aggregates of the amyloid-β protein (Aβ) that
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constitute the amyloid plaques in the brain, they are of limited clinical use. These probes are
insensitive toward neurofibrillary tangles composed of fibrillar aggregates of the tau protein,
undermining their diagnostic value as AD entails a complex regional localization of both Aβ
and tau deposits63,64.
The shortcomings of existing PET probes partly stem from the molecular scaffolds
from which they are derived, primarily the 2-phenylbenzothiazole dye thioflavin T (or the
mixture of related dyes “thioflavin S”), commonly used for the histologic detection of amyloid.
All amyloid-binding agents share a common rigid or semiflexible “conjugated rod” motif,
which allows them to favorably bind to the hydrophobic surface grooves on amyloid fibrils65.
When used for fluorescence imaging, these ligands primarily function on a “molecular rotor”
basis, in which fluorescence shift or enhancement occurs because of planarization of the
conjugated region and prevention of fast nonradiative decay by intramolecular rotation66,67.
New sensors based on different scaffolds with improved sensing capabilities are thus urgently
needed to unravel the underlying pathogenesis of amyloid-related diseases. While
radiopharmaceutical tracers have the advantage in the preclinical and clinical setting, optical
sensors are uniquely suited to broad adoption because of the wide availability of
instrumentation for imaging and spectroscopy31,68. Along with high sensitivity for the
aggregated protein conformation and a large increase in brightness upon binding, the critically
important property of a sensor is its ability to detect the aggregates formed from a wide set of
promoter proteins.
Recently,42 we have reported the use of novel oligo(p-phenylene ethynylene)
electrolytes (OPEs) as optical sensors for amyloid fibrils formed from hen egg-white
lysozyme.69 The fibrils formed by incubating the lysozyme under acidic conditions are
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structurally and morphologically indistinguishable from those formed from the diseaseassociated proteins. Lysozyme oligomers and fibrils have also been shown to be cytotoxic
toward the human neuroblastoma cells,70 indicating that the aggregates of lysozyme
recapitulate the biological activities of the known disease-associated proteins. Four OPEs
(Table 2-1, compounds B4, B5, B6, and OPE1), differing in charge and size, were tested and
found to selectively detect lysozyme fibrils in vitro by binding-activated increase in the
fluorescence yield, with low micromolar affinity and high selectivity for the amyloid
conformation of lysozyme over the native conformation of protein.42 On the basis of spectral
properties and previous work in analogous systems, we posit that the fluorescence turn-on
mechanism is a combination of OPE backbone planarization, reduction of solvent-mediated
quenching of the OPE ethyl ester end groups, and the formation of chiral J-type OPE
aggregates templated on the lysozyme fibril surface.42
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Table 2-1 Structures of the 18-PPE-Based Oligomers and Polymers Used in this Study

To validate that the OPEs are useful optical sensors that can selectively detect the
fibrillar amyloid conformation of proteins independent of the properties of the underlying
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protomer, we report here the binding and fluorescence of the OPE compounds to the fibrils
formed from another model amyloid protein, bovine insulin. Similar to lysozyme, insulin
readily forms fibrillar aggregates when incubated under acidic and high temperature
conditions. Moreover, while lysozyme is positively charged at neutral pH, insulin is negatively
charged at the same pH. The common fibrillar morphology of lysozyme and insulin aggregates,
combined with large differences in the charge states of the proteins, allowed for testing the
selectivity of the OPE sensors for fibrillar over monomeric protein conformations. In this
study, we additionally tested a small library of oligomeric and polymeric phenylene
ethynylenes (PPEs) (Table 2-1) to further probe the effects of charge and substituents on
fluorophore amyloid binding and recognition and compare the amyloid interactions of the
conjugated small molecules of varying size and conjugated polymers. The results of this study
support previous research into the molecular mechanism of amyloid detection by small
molecules and provide insights into new properties that may allow enhanced detection of these
important analytes.
2.3 Results and Discussion
The library of 18 conjugated compounds tested (Table 2-1) comprises a variety of molecular
weights, charge densities, water solubilities, and types and geometries of functional groups, all
based on the linear PPE molecular scaffold. Twelve oligomeric PPE compounds with welldefined molecular weights were used. Compounds A1, A2, and A3 are cationic and relatively
small molecules with no side chains and charged end groups with varying hydrophobicity. The
B series compounds and OPE1 have side chains that are either cationic (B1−B8) or anionic
(OPE1) and have different end groups and a varying number of repeat units (n = 1, 2, or 3).
The six polymeric compounds have high and not well-defined molecular weights (n < 1000)
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and vary in the conjugated backbone structure and cationic side chains. The oligomeric
compounds are water-soluble and well-dispersed in aqueous solutions. Although the charged
polymers are also water soluble, they form aggregates in aqueous solutions.71 From this
structural diversity, we expect to validate and glean some guiding principles for functional
amyloid sensor molecules and investigate structure−property relationships for bindingactivated photophysical changes.
To test the efficacy of the library of PPE-based compounds to selectively detect protein
aggregates, the excitation and emission fluorescence spectra of each compound were measured
after incubation with the monomeric or fibrillar hen egg-white lysozyme and bovine insulin.
As these two proteins differ in their charge, hydrophobicity, and surface residues, they are
well-suited to test the robustness of amyloid sensing. The amyloid aggregates of these two
proteins were prepared by the incubation of the stirred protein solutions at low pH and high
temperatures for 24 h. Lysozyme42 and insulin amyloid aggregates were thioflavin T-positive
(Figure S1). Far ultraviolet (UV) circular dichroism (CD) spectra of the protein solutions
(Figure 2-2 b, d) confirmed the transformation of the primary α-helical native structures of
both proteins, as shown by the negative bands at 208 and 222 nm, into the characteristic βsheet structures of amyloid fibrils, as shown by the negative band at 218 nm. Atomic force
microscopy (AFM) images of the incubated protein solutions deposited on mica (Figure 2-2
a, c) showed short fibrillar aggregates, with individual linear structures composed of two or
more twisted subfibrils, and average dimensions of about 100 nm long and 20 nm wide. The
short fibril morphology is consistent with incubation conditions where low pH and high
temperature caused fast fibril nucleation and growth, and agitation caused competing fibril
fragmentation.
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Figure 2-2 AFM images of insulin (a) and lysozyme (c) fibrils deposited on mica (imaged in
air by the tapping mode). Far-UV CD spectra of insulin (b) and lysozyme (d) monomers and
amyloid fibrils indicate the loss of native α-helical structures to the formation of β-sheet
secondary structures. The error bars in the CD spectra are standard errors of replicate
measurements of the same sample.
The in vitro formed amyloid aggregates of lysozyme and insulin were tested against
the 18 different PPE dyes with a significant structural heterogeneity (Table 2-1). The
fluorescence emission and excitation spectra of the dyes alone in buffer, with a monomeric
protein, and with an aggregated protein were recorded, with the main readout of interest being
the changes in emission intensity and the shifts in excitation or emission wavelengths.
Complete spectral data can be found in the Supporting Information. To ease the evaluation of
amyloid sensing, that is, whether a compound exhibits selective sensing of the fibrillar
conformation of a protein over its native structure, the fluorescence spectral data were
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processed and reduced to a factor quantifying the selective amyloid-sensing performance, the
amyloid detection factor (ADF), using eq 1
𝐴𝐷𝐹 =

𝐹("#$%&'()'*) − 𝐹("#$%,-.-,$))
𝐹"#$ '. (0&&$)

(1)

where Fdye+monomer is the integrated fluorescence signal of the dye in solution with the native
protein, Fdye+fibril is the fluorescence signal of the dye in solution with amyloid aggregates of
the protein, and Fdye in buffer is the fluorescence signal of the dye alone in buffer. Integrated
rather than the peak fluorescence intensity values were used to better model the situation in the
microscope, where all photons that pass through the filter set are integrated at the detector. As
defined, the ADF value is thus indicative of the ability of a dye to selectively detect the amyloid
conformation of a protein from its native confirmation relative to the background fluorescence
of the dye in buffer. As such, the ADF values near zero indicate that the dye does not
distinguish between the monomeric and fibrillar states of a protein. This effect is due to the
lack of dye binding or binding without a concomitant increase in the fluorescence signal. The
negative ADF values indicate that the dyes exhibited higher fluorescence in the presence of
protein monomers than protein fibrils; the dyes are thus selective sensors for the monomeric
protein conformation. The positive ADF values indicate that the dyes yielded higher
fluorescence in the presence of fibrillar aggregates of a protein than monomers; these dyes are
thus selective sensors for the protein amyloid state and potentially useful sensors for protein
aggregate biomarkers. Furthermore, the magnitude of the ADF value indicates the extent by
which the dye distinguishes the fibrillar versus the monomeric state of the protein over
background fluorescence of the dye. The larger the ADF value, the better the sensor signal.
This data processing and reduction approach allowed us to easily identify compounds in the
library that exhibited useful photophysical changes when interacting with amyloid. Figure 2-
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3 summarizes the ADF values obtained for the 18 conjugated compounds for both lysozyme
and insulin proteins.
As shown in Figure 2-3, many of the tested compounds gave rise to the ADF values
close to 0 (within the gray “insensitive” zone in the figure), indicating that either these
compounds did not bind to the proteins or any interaction with the proteins did not lead to
changes in fluorescence. The oligomeric compounds A1, A2, and A3 had significant
background fluorescence in buffer and did not exhibit increased fluorescence in the presence
of either monomeric or fibrillar lysozyme or insulin (Figure S4). Most of the polymeric
compounds, C1, C3, C4, C5, and C6, also gave rise to the ADF values close to 0. These
compounds have significant background fluorescence in buffer, and although some
compounds exhibited increases in fluorescence when added to protein monomers or fibrils,
their fluorescence signals were not useful as they were not selective for either the fibrillar or
the monomeric state of lysozyme or insulin (Figures S8 and S9). However, enhanced
fluorescence was observed for many compounds when they were mixed with protein
monomers or fibrils as the dyes gave rise to large positive ADF values (fibril selective) or large
negative values (monomer selective), including most oligomeric compounds in the B series
and the polymeric compound C2. A few of the dyes were effective sensors for the fibrillar
conformation of one protein (positive ADF values) and for the monomeric conformation of the
other protein (negative ADF values), including B3, B5, and B6. Importantly, two small dyes,
cationic B4 and anionic OPE1, are identified as selective sensors for both lysozyme and insulin
fibrils, as the positive ADF values were obtained for each dye for both proteins. As the
magnitude of the ADF values for OPE1 was larger than that for B4, the anionic OPE1
compound appears to be the more sensitive selective amyloid sensor from the library of PPE
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compounds screened. In addition to identifying useful sensors, other useful observations about
the effects of substituents on the conjugated backbone, charge, and molecular size on the
amyloid-sensing effectiveness of the dyes can be gleaned from the ADF results.

Figure 2-3 ADF values of 18 PPE-based dyes for insulin and lysozyme amyloids. Dye and
protein concentrations were 2 μM and 1.88 μg/mL, respectively
The effect of substituents on dye sensing is especially stark. Except for the polymers
(C2), the only dyes with significant positive ADF values, that is, selective detectors of amyloid,
were B4, B5, B6, and OPE1, all bearing ethyl ester end groups. This small structural
substitution has profound effects on the photophysical properties of the compounds. Whereas
the fluorescence quantum yields of H- and ester-terminated dyes such as B1, B2, B3, and B8
were similar in methanol and water, the quantum yields of the ethyl ester terminated dyes B4,
B5, B6, and OPE1 are dramatically reduced in water compared to those in methanol (Table 22), providing a mechanism for the hydrophobicity-induced unquenching. The ester groups
provide, through a complex mechanism72 that is not yet completely understood, a means for
the efficient nonradiative transfer of excited-state energy to solvent modes in aqueous
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solutions, massively reducing the fluorescence yield. The ester terminated series of PPE
compounds is thus highly sensitive to detecting their solvation environment. The binding of
dyes containing ethyl ester groups to proteins, likely mediated by hydrophobic interactions
between protein residues and the hydrophobic backbone of the PPE compounds,73 is indeed
dramatically transduced to large increases in fluorescence (see Figure S6 and OPE1 spectra in
Figure S7). As the molecular level details of dye−protein interactions and influence of
different substituents on the electronic properties of these structurally related dyes are unclear,
further exploration is warranted.
Table 2-2 Quantum yield of fluorescence (φfl) values of select PPE compounds in methanol
(MeOH) and water (H2O). aFrom reference 74 bFrom reference 75

Charge had a major effect on the ADF performance of all dyes, especially on their
ability to selectively distinguish between the monomeric and fibrillar protein conformations.
Figure 2-4 shows the integrated fluorescence intensities of the dyes that were identified from
the ADF values (Figure 2-3) to exhibit selective sensing of either the monomeric state
(negative ADF values) or the fibrillar state (positive ADF values) of lysozyme or insulin. As
shown, the larger cationic ethyl ester terminated dyes, B5 (n = 2) and B6 (n = 2), were very
effective at selectively detecting lysozyme fibrils, for which large increases in fluorescence
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intensities were observed when the compounds were mixed with lysozyme fibrils and only
small increases were observed when the compounds were mixed with lysozyme monomers.
However, sensing selectivity was reversed when the dyes were mixed with insulin fibrils: large
increases in fluorescence intensities were observed when the compounds were mixed with
insulin monomers and only small or no increase was observed when the compounds were
mixed with insulin fibrils. The significant increases in the fluorescence of the B5 and B6
compounds to insulin monomers can be attributed to binding because of attractive Coulombic
interactions between the cationic compounds and a negatively charged insulin monomer at
neutral pH. This long-range attractive interaction allows the dye and an insulin monomer to
approach close enough for the dye to bind to the hydrophobic pockets on the protein surface.
Once bound, the ethyl ester terminated compounds exhibit hydrophobicity-induced
unquenching, yielding large increases in the fluorescence intensity. Overall, the larger cationic
ethyl ester terminated B5 and B6 compounds are good sensors as the binding of these
compounds to lysozyme fibrils and insulin monomers resulted in large increases in the
fluorescence signal. However, they are not suitable amyloid sensors, as their sensing is proteinspecific and they did not detect the amyloid conformation of the insulin protein (Figure 2-4).
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Figure 2-4 Background-subtracted-integrated fluorescence signals from various dyes of
interest with different protein preparations. “ns” indicates no significant difference at p < 0.10.
On the basis of Coulombic interactions, the anionic dyes B7, B8, and OPE1 are
expected to exhibit favorable binding to the positively charged lysozyme monomers at neutral
pH. However, significant enhancement in fluorescence was not observed (Figure S7).
Compounds B7 and B8 do not possess the ethyl ester end groups that give rise to fluorescence
quenching in aqueous solutions, as shown by the comparable fluorescence quantum yield
values of these two compounds in methanol and water (Table 2-2). Thus, even if these
compounds bind to lysozyme based on favorable Coulombic interactions, the dyes are not
useful sensors as the binding is not accompanied by increases in the fluorescence signal. By
contrast, the fluorescence of B7 and B8 decreased in the presence of lysozyme monomers and
fibrils compared to the fluorescence of the dye in buffer (Figures 2-5c and S7). The best
selective amyloid sensor identified in this screening study is the small anionic OPE1 compound
as it exhibited increased fluorescence in the presence of both lysozyme and insulin fibrils
(Figures 2-4 and 2-5). Importantly, only small increases in the fluorescence of OPE1 were
observed in the presence of a monomeric lysozyme or insulin. On the basis of Coulombic
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interactions, the anionic OPE1 compound is expected to favorably bind to the cationic insulin
monomers. However, very little binding between OPE1 and insulin monomer was observed.
Although this effect cannot yet be fully explained, we postulate that this effect is due to the
higher solvation energy of the anionic −SO3 − group as compared to that of the −NMe3 +
group in B5 and B6, reducing the propensity of the OPE1 molecule to desolvate and bind to
hydrophobic patches on the protein monomer. Experimental76 and theoretical77 studies show
that the Gibbs free energies of the aqueous solvation for −SO3 − versus −NMe3 + differ by
several hundred kcal/mol because of the larger size of the anion and its greater number of Hbond acceptors.
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Figure 2-5 Emission spectra of the anionic ethyl ester terminated OPE1 (a and b) vs the anionic
H-terminated B7 (c and d) with lysozyme (a and c) and insulin (b and d) proteins.
Chromophoric ethyl ester substitution has profound effects on the fluorescent response to
protein aggregates.
Size is the third major characteristic affecting the dye performance. The small-endsubstituted dyes A1, A2, and A3, although perhaps capable of binding appropriately, lack a
mechanism for enhancement in the fluorescence signal upon binding. In fact, these molecules
have been shown to lose the fluorescence yield when complexed because of the formation of
H-type aggregates.78 Polymers (compounds C1−C6), for the most part, did not perform well
either. Increases in fluorescence were observed when a few of the cationic polymers were
added to anionic lysozyme fibrils (Figure S8). However, as no fluorescence increases were
observed when the compounds were added to insulin fibrils, these dyes were not useful
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amyloid sensors. Performance of these polymeric compounds was likely affected by the size
mismatch with a binding site or solubility problems. Because of their extended hydrophobic
backbone, many of these polymers are highly self-aggregated in aqueous solutions, resulting
in low solubility and depressed emission intensity71. These high-molecular-weight polymers
are unlikely candidates for tissue stains or in vivo fluorescent probes because they are unlikely
to transit membranes readily or diffuse very far. The series of cationic ethyl ester terminated
oligomeric B4, B5, and B6 compounds provide an extremely useful insight into size effects on
the amyloid detection performance. These three dyes vary only in the number of repeat units,
and their ADF values of lysozyme sensing shown in Figure 2-3 (gray bars) show a clear
optimum at the size of B5 (n = 2), with five phenyl rings in the PPE chromophore. B4 (n = 1)
is too small to have enough exposed hydrophobic surface to bind strongly to yield large
increases in fluorescence, and B6 does not have enough of the chromophore bound to protein
to elicit unquenching of the ethyl ester end groups, or possibly the end groups are not
sufficiently shielded from water in the bound state. The typical twisted amyloid structural
model, which places the hydrophobic binding grooves at an angle to the fibril axis, indicates
the possibility of a maximum effective size for a linear chromophore to bind: if the
chromophore is too long, it cannot conform to the curvature of the binding site. Possibly longer
chromophores may be effective if they have a flexible backbone structure.30
Overall, our results show that small changes in the dye structure can have a profound
effect on the amyloid sensor performance. The least effective sensors were the dyes with
charged groups on the ends (A1, A2, and A3) and those with charged groups on the sides of
the chain and no moiety on the terminal phenyl rings (B1, B2, and B3). The cationic ester
terminated dyes (B4, B5, and B6) were more responsive to the presence of protein but had
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significant drawbacks. These compounds interacted with and exhibited enhanced fluorescence
with both native and fibrillar insulin, as indicated by their negative ADF values in Figure 2-3
(see also Figure S6), and the longer dyes (B5 and B6, with n = 2 and 3 repeat units,
respectively) had some selectivity for lysozyme amyloid, but overall none of these dyes
performed well relative to others in the screening set.
The sole dye found to perform effectively as a selective sensor for the amyloid
conformation of the two model proteins was the small anionic OPE1 that vastly outperformed
even very close structural analogues. Fluorescence of the anionic OPE1 was low in the
presence of both cationic lysozyme monomers and anionic insulin monomers (Figure 2-5 a,
b). In the presence of fibrillar aggregates, OPE1 exhibited large increases in the bindingactivated fluorescence. Thus, OPE1 is a protein conformation selective sensor and not a
protein-specific sensor. OPE1 binds to lysozyme and insulin amyloid fibrils with dissociation
constants (Kd) in the low micromolar range (Table 2-3), similar to those previously reported
by our group for similar ethyl ester substituted PPE small molecules.42 Reported dissociation
constants for thioflavin T binding to insulin and lysozyme amyloid vary but range between 500
nM and 23 μM for insulin fibrils20 and between 150 nM and 25 μM for lysozyme fibrils,79
putting OPE1 well in the useful range of affinities. Induced CD was also observed for OPE1
with insulin and lysozyme amyloids (Figure S2), indicating that the dye binds as a chiral
complex, possibly a chirally biased J-type dimer. The peak of the emission spectrum for OPE1
bound to the insulin amyloid is blue-shifted with respect to the emission peak of OPE1 bound
to the lysozyme amyloid (Figure 2-5 b), indicating that the J-aggregate character is more
dominant in the insulin-bound population. Comparison of the fluorescence spectra of OPE1
with those of its structural analogue B7 (Figure 2-5, top and bottom) demonstrates the
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importance of a substituent on effective sensing. B7 and OPE1 are identical except that OPE1
bears ethyl esters on both ends of the conjugated backbone, whereas B7 does not. B7 loses
some fluorescence yield in the presence of lysozyme monomers or fibrils and is completely
insensitive to insulin in any form. The anionic OPE1 is the only molecule with positive ADF
values for both lysozyme and insulin amyloid.

Table 2-3 Binding constants (Kd) of OPE1 to lysozyme and insulin amyloid. Kd values of
thioflavin T are included as a reference aFrom reference 20 bFrom reference 67

2.4 Conclusions
This study evaluated a small library of 18 different fluorescent compounds based on a p-PPE
backbone for their ability to selectively detect the amyloid aggregate conformers of two model
amyloid proteins. Most of the compounds showed some nonspecific binding to protein
monomers, and some were able to detect amyloids of either insulin or lysozyme, but only one
compound performed effectively with both proteins: a shorter compound with anionic
sulfonate solubilizing groups and ethyl ester end groups (Figure 2-6).
The very small and hydrophobic end-functionalized compounds (A1, A2, and A3) did
not effectively sense the amyloid state, possibly because they can nonspecifically interact with
many binding sites. These compounds have been shown to have high toxicity to bacterial cells
and to inactivate viruses, suggesting that they can interact destructively with proteins. We
might have expected that the very large repeating polymeric dyes would sense amyloids with
high selectivity because of their long linear chains binding to equally long linear aggregate
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structures. The results show that this was not the case- some polymers bound to amyloids with
moderate sensitivity, but none bound well to both insulin and lysozyme amyloid.
Exchanging cationic quaternary ammonium groups for anionic sulfonate groups has
multiple profound effects on the mechanics of binding, as evidenced by the formation of less
emissive states by B7 and B8 dyes and the very different behavior of OPE1 and B5 (Figure 26). For small molecules, the anionic groups seem to reduce nonspecific binding to monomers
appreciably, especially for insulin. We postulate that this effect is due to the higher solvation
energy of the −SO3− group as compared to that of the −NMe3+ group, reducing the propensity
of the molecule to desolvate and bind to hydrophobic patches on the protein monomer.

Figure 2-6 Schematic of the sensing modes of two OPEs: anionic OPE1 and cationic B5 to
lysozyme and insulin monomers and fibrils. Red indicates the positively charged species, and
blue indicates the negatively charged species.
The results of this study have provided some structural insights into the binding and
fluorescence sensing of amyloids by PPE-based dyes. For this class of compounds, restriction
of intramolecular motion by binding alone does not seem to be sufficient for the sensitive
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monomer-independent detection of amyloids-that is, they do not function like a molecular
rotor. A secondary mechanism of binding-activated quantum yield increase (in this case,
unquenching by reduced water accessibility) is necessary to produce an effective sensor.
Overall, anionic structures are less prone to nonspecific binding and more broadly
biocompatible, and smaller size seems to be crucial for effective interaction. These results will
provide guidelines for future investigation of amyloid-binding fluorogenic dyes.
2.5 Experimental Section
Synthesis of PPE dyes was reported previously.43,75,80–82 Hen egg-white lysozyme and bovine
insulin were obtained as lyophilized powders from Sigma-Aldrich (St. Louis, MO) and used
without further purification. Salts and reagents used to make buffers were obtained from
Sigma-Aldrich. Thioflavin T (ThT) was obtained from VWR International (Radnor, PA).
Water used was purified to a resistivity of 18.2 MΩ at 25 °C (Millipore Synergy UV
purification system, EMD Millipore, Billerica, MA). All experiments were performed in
duplicate, and the mean values were reported with standard error. Paired t-test was carried out
to assess the statistical significance of the difference between the PPE fibril fluorescence and
the PPE monomer fluorescence. The spectra reported are a single representative experiment.
Lysozyme and insulin fibrils were prepared by dissolving each protein at 5.46 mg/mL
in 10 mM sodium citrate buffer at pH 3 with 0.1 M NaCl and by incubating at 70 °C for 12 h
with 250 rpm magnetic stirring. Extinction coefficients at 280 nm of 1.0 L/(g·cm) for insulin83
and 2.63 L/(g·cm) for lysozyme84 were used to determine the concentrations. Both protein
solutions, initially clear, formed a cloudy precipitate within an hour of heating. For ThT assay,
protein and ThT stock solutions were mixed in pH 7.4 10 mM phosphate buffer (PB) to a final
concentration of 5 μg/mL protein and 20 μM ThT, and the emission spectra were obtained at
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440 nm excitation (Figure S1). Presence of amyloids was confirmed by the direct observation
of fibril morphology with AFM on mica in air (Figure 1).
In the wells of a 96-well plate, a monomeric protein, an amyloid, or a buffer blank was
diluted with dye stocks into PB to a final concentration of 2 μM OPE or 1.88 μg/mL PPE (the
same monomer concentration as the intermediate-size OPEs) and 5 μg/mL protein. The final
sample volume was 200 μL, and each well was prepared in duplicate. The absorption and
emission spectra of the samples were then measured on a plate reading spectrophotometer
(SpectraMax M2e, Molecular Devices, Sunnyvale, CA). For the higher resolution evaluation
of spectral changes, a steady-state cuvette-reading fluorimeter (PTI QuantaMaster 40,
HORIBA Scientific, Edison, NJ) was used. The same concentration and sample volumes were
prepared and transferred to a small-volume quartz fluorimetry cuvette (Starna Cells,
Atascadero, CA), and the excitation and emission spectra were obtained. To determine the
secondary structures of a protein (Figure S3), CD spectra of the protein samples, diluted in pH
3 10 mM sodium citrate buffer without NaCl to a concentration of 0.14 mg/mL, were recorded
using an Aviv 410 CD spectrometer (Aviv Biomedical, Lakewood, NJ) with a 15 s averaging
time. A blank spectrum (buffer only) was subtracted from that of each sample to remove the
background signal. The error bars are standard deviations over multiple reads of a single
sample as reported by the AVIV software. For OPE-induced CD, OPEs and protein were
diluted in PB to an OPE and a protein concentration of 5 μM, and the data were obtained and
processed identically to the protein CD experiments. For binding constant determinations, the
matured fibrils were first separated from the residual monomeric and smaller aggregated
proteins by repeatedly passing the diluted solutions through a 30 kDa molecular weight cutoff
Amicon centrifugal filter (EMD Millipore, Billerica, MA). The concentration of the fibril
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solution was determined by measuring the absorbance at 280 nm. The fluorescence of the
samples containing a fixed fibril concentration (500 nM) and a range of OPE concentrations
was measured using a spectrofluorometer. Peak fluorescence values versus the OPE
concentration was subsequently plotted and fitted to the Hill equation84 using OriginPro 9 to
obtain the equilibrium dissociation constant (Kd) values.
2.6 Supporting Information

Figure S1 Thioflavin T fluorescence assay of insulin protein preparations. The large increase
in fluorescence in the presence of aggregated protein is indicative of binding of thioflavin T
to amyloid-specific sites and increase in quantum yield.

31

Figure S2. Induced circular dichroism spectra of OPE1 bound to amyloid fibrils of lysozyme
(left) and insulin (right).

Figure S3. Saturation binding plots for OPE1 binding to purified lysozyme (left) and insulin
(right) fibrils. Binding data (filled square points) were fitted to the Hill equation using
OriginPro 9 to obtain equilibrium dissociation constants (Kd),
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Figure S4. Emission spectra of compounds A1, A2 and A3 with lysozyme (left) and insulin
(right) monomers and fibrils.
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Figure S5. Emission spectra of compounds B1, B2 and B3 with lysozyme (left) and insulin
(right) monomers and fibrils.
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Figure S6. Emission spectra of compounds B4, B5 and B6 with lysozyme (left) and insulin
(right) monomers and fibrils.
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Figure S7. Emission spectra of compounds B7, B8 and OPE1 with lysozyme (left) and
insulin (right) monomers and fibrils.
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Figure S8. Emission spectra of polymers C1, C2 and C3 with lysozyme (left) and insulin
(right) monomers and fibrils.
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Figure S9. Emission spectra of polymers C4, C5 and C6 with lysozyme (left) and insulin
(right) monomers and fibrils.
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Chapter 3 High Selectivity and Sensitivity of Oligomeric p-Phenylene
Ethynylenes for Detecting Fibrillar and Prefibrillar Amyloid Protein
Aggregates
(This chapter has been published in ACS Chemical Neuroscience and appears as Adeline M
Fanni, Florencia A. Monge, Chia-Yu Lin, Arjun Thapa, Kiran Bhaskar, David G. Whitten,
and Eva Y. Chi. 2019. High Selectivity and Sensitivity of Oligomeric p-Phenylene
Ethynylenes for Detecting Fibrillar and Prefibrillar Amyloid Protein Aggregates, ACS
Chem. Neurosci. 10: 1813-1825)
3.1 Abstract

Figure 3-1 Table of contents graphic

Misfolding and aggregation of amyloid proteins into fibrillar aggregates is a central pathogenic
event in neurodegenerative disorders such as Alzheimer’s (AD) and Parkinson’s diseases (PD).
Currently, there is a lack of reliable sensors for detecting the range of protein aggregates
involved in disease etiology, particularly the prefibrillar aggregate conformations that are more
neurotoxic. In this study, the fluorescent sensing of two novel oligomeric p-phenylene
ethynylenes (OPEs), anionic OPE1− and cationic OPE2+, for detecting prefibrillar and fibrillar
aggregates of AD-associated amyloid-β (Aβ40 and Aβ42) and PD-associated α-synuclein
proteins (wildtype, and single mutants A30P, E35K, and A53T) over their monomeric
counterparts, were tested. Furthermore, the performance of OPEs was evaluated and compared
to thioflavin T (ThT), the most widely used fibril dye. Our results show that OPE1− and OPE2+
exhibited aggregate-specific binding inducing large fluorescence turn-on and spectral shifts
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based on a combination of backbone planarization, hydrophobic unquenching, and
superluminescent OPE complex formation sensing modes. OPEs exhibited higher selectivity,
higher binding affinity, and comparable limits of detection for Aβ40 fibrils compared to ThT.
OPE2+ exhibited the largest fluorescence turn-on and highest sensitivity. Significantly, OPEs
detected prefibrillar aggregates of Aβ42 and α-synuclein that ThT failed to detect. The superior
sensing performance, the nonprotein specific detection, and the ability to selectively detect
fibrillar and prefibrillar amyloid protein aggregates point to the potential of OPEs to overcome
the limitations of existing probes and promise significant advancement in the detection of the
myriad of protein aggregates involved in the early stages of AD and PD.
3.2 Introduction
Neurodegenerative disorders such as Alzheimer’s (AD) and Parkinson’s diseases (PD) are one
of the biggest global health crises of the 21st century, with about 50 million people affected
worldwide and at a cost that is projected to rise to $2 trillion per year by 2030 in the United
States.79 AD and PD are complex and multifactorial.85–88 While many factors may contribute
to disease etiology,2,89 including inflammation90–93 and microbial infection,21,94–96 the
misfolding and aggregation of largely intrinsically disordered proteins into highly ordered
fibrillar amyloid aggregates is still recognized as a central pathogenic event and one that is
believed to occur decades before the onset of neurodegeneration and cognitive
impairment.21,88,97,98 Monitoring the course of amyloid formation at the biochemical, cellular,
and tissue levels is thus vital to understanding and combating these diseases.63
Amyloid formation is complex and heterogeneous, and proceeds through the formation
of a range of oligomeric intermediates that have been shown to be the primary toxic species
that lead to neuronal loss and synaptic dysfunction.2,49,99–105 Thus, useful probes for tracking
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the disease process need to exhibit sufficient sensitivity to detect an array of aggregate
conformations, including oligomers as well as fibrils. In addition, comorbidities among the
diseases,87 for example, 80% of PD patients develop dementia,106 caused by the codeposition
of multiple pathological proteins necessitates that useful probes simultaneously detect
aggregates formed by different proteins. For instance, Alzheimer’s disease is characterized by
the accumulation of both amyloid plaques composed of the amyloid-β (Aβ) peptide and
neurofibrillary tangles made of the tau protein.107 In the case of Parkinson’s disease, the
deposition of Lewy bodies composed of the α synuclein protein are observed as well as the
accumulation of tau aggregates.108,109 Probes that can detect aggregates made of a variety of
proteins are therefore potentially clinically useful. Unfortunately, no such probes are currently
available.
Many studies have sought to develop probes for protein aggregates, including
conformation- and sequence-specific antibodies.57 However, the myriad of challenges
associated with antibody-based detection and failures of immunotherapy clinical trials58,59 have
spurred renewed efforts in developing small-molecule probes for detecting and localizing
amyloids. Fluorescent dyes,110 radiolabeled positron-emission tomography (PET), single
photon emission computed tomography (SPECT) ligands,60,62,111,112 and metal-ligated
magnetic resonance imaging (MRI) contrast agents113 have been developed but their diagnostic
value is thus far limited. For example, Pittsburgh Compound B35 and 18F-AV-4536 only
detect amyloid-β (Aβ) fibrillar deposits in the AD brain. They are of limited use because they
fail to detect neurotoxic prefibrillar aggregates that better correlate with clinical symptoms.
They also do not detect tau aggregates, further undermining their diagnostic value as AD is
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characterized by complex regional localization of both Aβ and tau deposits. Additionally, no
clinically tested probes are available for imaging PD-related αsynuclein aggregates.114
Compounds that bind specifically to amyloids tend to share a common “rigid
conjugated rod” motif, where the linear shape and aromaticity favors binding to hydrophobic
sites on the amyloid fibril.65,115 Probes that have been investigated include molecules derived
from Congo red, curcumin,116–118 thioflavin T (ThT),119–121 and oligothiophenes.122–127 These
ligands, when used for fluorescent imaging, primarily function on a “molecular rotor” basis,
in which fluorescence enhancement and red shift arise from backbone planarization (restriction
to rotation) of the conjugated region within the fluorophore when bound to a planar site on the
amyloid fibril. This single sensing mode gives rise to the probes’ ability to detect primarily the
fibrillar conformation of amyloid proteins.
Recently, we tested a novel class of fluorescent sensors, oligomeric p-phenylene
ethynylenes (OPEs) for the selective detection of fibrillar aggregates of model proteins over
their monomeric counterparts.42,128 The phenylene ethynylenes (PE) backbone of the OPEs has
a delocalized electronic structure, which gives rise to strong absorption and emission.129–131
Importantly, the rapid transport of the electronic excited state along the backbone contributes
to increased sensitivity, leading to signal amplification when interacting with analytes.129–131
Water-soluble PE compounds suitable for biological applications such as OPEs have shown
greater than 106 -fold amplification sensitivity to quenching, that is, the probes are quenched
in water through partial proton transfer from an interfacial water molecule to the OPE terminal
oxygen causing rapid deactivation of the excited singlet state, and exhibit fluorescence “turnon” in response to release of interfacial water, changes in their conformation, and/or ligand
interactions.72,74,132,133 In addition to backbone planarization induced fluorescence increase,74
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bathochromic shift, hydrophobic unquenching (e.g., from binding to a hydrophobic site) and
formation of superluminescent OPE-complexes offer additional fluorescence “turn-on”
sensing mechanisms.42,128,134
OPEs have been shown to selectively bind to β-sheet enriched fibrillar aggregates made
of the model amyloid protein hen egg white lysozyme (HEWL).42 Upon binding, OPEs
exhibited fluorescence turn-on and red-shifted spectra; complexation of the OPEs to form Jdimers was also observed.42,74,128 A library of 18 PE-based oligomers and polymers that vary
in size, charge, water solubility, and the types and geometries of functional groups, was
screened for their capability to selectively detect the amyloid conformation of two model
proteins that are oppositely charged at physiological pH, bovine insulin and HEWL. We found
that characteristics contributing toward fibril-selective, but not protein-specific detection
included moderate size, negative charge, and high environmental sensitivity of the ethyl ester
termini to fluorescence quenching in water.135 One compound in particular, the anionic OPE1−
(Table 3-1), was found to show high binding selectivity toward both insulin and HEWL, and
the cationic OPE2+ (Table 3-1), although displayed stronger fluorescence enhancement in the
presence of HELW fibrils, did not detect insulin fibrils.135
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Table 3-1 Structures of Thioflavin T, OPE1−, and OPE2+

To evaluate the efficacy of the OPEs for detecting disease relevant protein aggregates,
we evaluated in this study the capability of OPE1− and OPE2+ to selectively detect fibrillar
and prefibrillar aggregates of AD associated Aβ40 and Aβ42 peptides and four variants of PD
associated α-synuclein proteins over their monomeric counterparts. First, fibrillar and
prefibrillar aggregates of the proteins were prepared and characterized. Next, selectivity and
specificity of OPE1− and OPE2+ to detect the aggregated conformation of the proteins were
quantified and compared to ThT.
3.3 Results and Discussion
In this study, we tested the sensing capability of two ethyl ester-terminated OPEs, the
negatively charged OPE1− characterized by one repeat unit and two side chains each
terminated with a sulfonate group and the positively charged OPE2+ with two repeat units and
two side chains each terminated with a quaternary amine group (Table 3-1). OPE sensing of
Aβ40 and Aβ42 fibrils associated with AD as well as protofibrils and fibrils made of four
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different α-synuclein proteins involved in PD was evaluated. Additionally, performance of the
OPE sensors was compared to the most commonly used amyloid dye ThT (Table 3-1).

3.3.1 Formation and Characterization of Aβ40 Fibrils
Aβ40 fibrils are known to display high polymorphism at the molecular level where the
morphology and structure of the fibrils are highly sensitive to incubation conditions.136,137 A
useful sensor needs to robustly detect the common fibrillar conformation even if their
structures differ at the molecular scale. In this study, we tested OPE1− and OPE2+ detection
of Aβ40 fibrils produced in two different conditions: Tris buffer at pH 8.0 (protein net charge:
−4.4),138,139 and phosphate buffer (PB) at pH 7.4 (protein net charge: −2.9).140 The morphology
and secondary structures of Aβ40 fibrils formed after 21 days of incubation at 37 °C and 100
μM were analyzed by TEM imaging and circular dichroism (CD) spectroscopy, respectively.
Kinetics of Aβ40 fibril formation was also monitored using the standard ThT fluorescence
assay.
TEM images of unincubated Aβ40 samples (Figure 3-2 A and C) show very few
features; the dark spots are likely artifacts of the TEM grid or sample preparation. Sizeexclusion higher performance liquid chromatogram (SEC) of the unincubated sample shows a
single well-defined protein peak (see Figure S1 in the Supporting Information) corresponding
to a low molecular weight species. Thus, Aβ in the unincubated sample was soluble and likely
monomeric. TEM images of Aβ40 fibrils produced in pH 8.0 Tris (Figure 3-2B) and in pH 7.4
PB (Figure 3-2D) show twisted fibrils with similar widths (Tris: 11.5 ± 2.8 nm; PB: 13.3 ± 1.5
nm). However, the fibrils produced in Tris buffer appear to be longer (766 ± 250 nm) than
those produced in PB buffer (261 ± 150 nm). Fibril samples were also centrifuged to remove
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insoluble aggregates and the supernatant was analyzed by SEC. Results show that 8% and 21%
of monomers were left after 21 days of incubation in Tris and PB, respectively, and no
oligomeric aggregates were present (Figure S1).

Figure 3-2 TEM images of unincubated Aβ40 (A, C) and after 21 days of incubation at 37 °C
and 100 μM (B, D) in pH 8.0 Tris (A, B) or in pH 7.4 PB (C, D). Scale bars represent 200 nm.
The secondary structures of unincubated Aβ40 and fibrils were analyzed using CD
(Figure 3-3 and Figure S2 in Supporting Information). CD spectra show a well-defined peak
at 200 nm for unincubated Aβ40, which is characteristic of random coils (Figure S2). Fibrils
produced in both Tris and PB showed structures rich in β-sheets as evidenced by the presence
of the peak at 218 nm (Figure 3-3).
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Figure 3-3 Molar ellipticity of Aβ40 after 21 days of incubation in Tris pH 8.0 and PB pH 7.4
at 37 °C. The peak at 218 nm arises from βsheet structures.

Figure 3-4 Fluorescence profiles of ThT (20 μM) and OPE (1 μM) mixed with Aβ40 (5 μM)
incubated in Tris pH 8.0 (A) or PB pH 7.4 (B) for different days. Integrated fluorescence
intensities were background subtracted and normalized to signal obtained from samples
incubated for 21 days. Errors bars are standard deviations from triplicate samples.
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Fibril formation was additionally confirmed and tracked by the standard ThT
fluorescence assay141,142 (Figure 3-4). Aβ40 samples incubated at different times were mixed
with ThT at final concentrations of 5 μM Aβ and 20 μM ThT and the emission spectra of ThT
were recorded at an excitation wavelength of 440 nm. Integrated emission intensities were
normalized to that of mature fibrils (Figure 3-4). ThT fluorescence profiles of Aβ incubated
in the two buffers were remarkably similar and showed characteristic features of nucleationcontrolled aggregation kinetics, where a lag phase of about 7 days was followed by a rapid
fibril growth phase and finally a plateau phase during which most of the monomeric proteins
had been converted to fibrils. Taken together, Aβ40 fibrils rich in β-sheets were successfully
prepared by incubating the peptide in two different solution conditions. The fibrils were
morphologically similar but appear to differ in lengths. Molecular-level structural differences,
for example, parallel vs antiparallel β-sheet architectures,143–145 may exist between the fibrils.
However, they were not characterized further using high-resolution methods in this study.

3.3.2 Fluorescence of OPE Binding to Aβ40 Fibrils and Monomers
To assess OPE binding to Aβ40 fibrils, fluorescence of each OPE mixed with Aβ samples
incubated for different times was measured (Figure 3-4) at a low concentration of 1 μM OPE.
As shown in Figure 3-4, normalized fluorescence intensities of the two OPEs yielded similar
profiles compared to those obtained from ThT, indicating that the OPEs selectively detected
Aβ40 fibrils as well as ThT at a higher concentration of 20 μM.
To further investigate the photophysical properties of OPE sensing, emission and
excitation spectra of ThT, OPE1− and OPE2+ in the presence of unincubated and fibrillar
Aβ40 at 5 μM protein and 1 μM sensor were analyzed (Figure 3-5). The integrated emission
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intensities were also calculated and statistically analyzed (Figure S4). Absorbance spectra
were additionally recorded and shown in Figure S3.
Both OPEs are highly quenched in buffers showing low fluorescence intensities (black
spectra in Figure 3-5). No significant fluorescence increases were observed in the presence of
Aβ40 monomers over the OPE background, except for OPE2+ with Aβ monomers (blue
spectra in Figure 3-5 A3 and B3). These small increases in OPE2+ fluorescence could be due
to weak electrostatic interactions between the negatively charged peptide and the positively
charged OPE. In contrast, large fluorescence enhancements were observed when OPEs were
mixed with Aβ40 fibrils produced in both Tris and PB. Additionally, red shifts in the excitation
spectra were observed for OPE1− and OPE2+ (Table 3-2); blue shifts, albeit smaller, were
also observed in emission spectra (Table 3-2 and Figure 3-5). Bathochromic red shifts can
arise from OPE J-dimer formation driven by stacking interactions in the presence of two side
chains located on opposite sides of the central phenyl ring,78 and/or planarization during
complex formation, and/or desolvation of the terminal ethyl ester groups.146 This result is
consistent with the binding patterns of OPE1− and OPE2+ to HEWL and insulin fibrils
previously reported.42,135 In contrast, ThT at 1 μM exhibited small increases in fluorescence
intensity in the presence of both fibrils (10- to 30-fold lower by comparison with OPEs
fluorescence).
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Table 3-2 Maximum Excitation and Emission Wavelengths of 1 μM ThT, OPE1−, or OPE2+
Sensors in the Presence of 5 μM Aβ40 Monomers or Fibrils

Figure 3-5 Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1, B1),
OPE1− (A2, B2), or OPE2+ (A3, B3) alone (black) in the presence of Aβ40 monomers
(blue) or Aβ40 fibrils (red) incubated in Tris pH 8.0 (A) and PB pH 7.4 (B). Fluorescence
was recorded in the presence of 5 μM protein and 1 μM sensor.
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3.3.3 Quantitative Evaluation of Sensor Performance
Effective sensors of amyloid protein aggregates need to have high selectivity that detects the
aggregated conformations but not their non-aggregated conformers, high sensitivity, high
signal to background ratio, and high affinity. Sensors additionally need to be nonprotein
specific, that is, selective for the aggregate conformations of a range of protein protomers.
Our results show that OPE1− and OPE2+ bind specifically and selectively to Aβ40
fibrils over Aβ40 monomers at a concentration significantly lower than that usually used for
ThT and induce 10 to 30-folds higher fluorescence intensity than ThT (Figure 3-5 A1 and B1).
To quantitatively assess sensor performance, selectivity of OPEs toward Aβ40 fibrils at a 5 to
1 protein to sensor molar ratio was analyzed. The amyloid detector factor (ADF) was calculated
using (eq 1),135 where F(dye-in-buffer), F(dye+fibrils) and F(dye+monomers) are the integrated emission
intensities for sensor alone, sensor in the presence of fibrils, and sensor in the presence of
monomers, respectively.
𝐴𝐷𝐹 =

𝐹("#$%&'()'*1) − 𝐹("#$%,-.-,$)1)
𝐹("#$2'.2(0&&$))

(1)

Positive ADF values indicate selective sensing of fibrils over monomers, while negative ADF
values indicate selective sensing of the monomers. ADF values close to zero indicate no
selective sensing, which for the ethyl ester terminated OPEs could be due to a lack of binding
to either the monomeric or the fibrillar conformation of the protein. As shown in Table 3-3,
all three sensors yielded positive ADF values for Aβ40 sensing, indicating that they are all
selective sensors of Aβ40 fibrils over Aβ40 monomers. ThT was the least selective with an
ADF value of 0.53 ± 0.1 that is closest to 0. The cationic OPE2+ was the most selective with
the highest ADF values; an ADF value of 11 ± 1 was obtained for longer fibrils prepared in
Tris buffer and an ADF value of 7.4 ± 0.5 was obtained for shorter fibrils prepared in PB buffer
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(Table 3-3). Selectivity of OPE1− (ADF values of around 2.5) was intermediate between ThT
and OPE2+.
Sensitivity is another important performance metric of sensors. For amyloid sensors,
sensitivity depends on binding affinity and the magnitude of induced fluorescence. To compare
sensitivity of the three compounds for detecting Aβ fibrils, their limits of detection (LOD) were
determined (eq 2),147,148 which indicates the lowest protein concentration that can be detected
by each sensor with a high degree of certainty. Fluorescence of the sensors at various protein
concentrations were determined and the protein concentration corresponding to LOD was
calculated by using the slope of the signal vs concentration correlation (eq 2).
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝐿𝑂𝐷 =

3𝜎
𝑆

(2)

where σ is the standard deviation of the dye alone (blank) and S is the slope of the signal vs
concentration correlation (Figure S5). As shown in Table 3-3, LOD values are in the
submicromolar range for all three sensors. LOD values of ThT are consistent with previously
reported values.149 OPEs and ThT display similar LOD values for both Aβ40 fibrils and both
OPEs display lower LOD values compared to that of ThT.
Finally, the affinity of ThT, OPE1−, and OPE2+ binding to Aβ40 fibrils was evaluated
through the determination of the dissociation constant (Kd) (Table 3-3). Binding curves were
obtained for the dyes in the presence of Aβ40 fibrils produced in Tris and PB buffers (Figure
S6). OPEs can bind as single molecules or as complexes, particularly to planar binding sites
on the fibril surface. Indeed, OPEs have been shown to form J dimers upon binding to HEWL
fibrils.42 As described previously, the ethyl ester terminated OPEs have multiple bindinginduced unquenching modes, including backbone planarization, hydrophobic unquenching,
and formation of superluminescent OPE-complexes. Each mode contributes to fluorescence
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enhancement, and backbone planarization and OPE-complexation additionally result in
spectral shifts. To account for potential OPE-complexation, binding curves were fitted with a
Hill coefficient (h) (Figure S6). Fitted parameters are summarized in Figure S6 and Table 33. Values of h for ThT are close to 1, indicating independent binding of ThT to fibrils. The h
values for the OPEs were around 1.5, indicating moderate positive cooperativity binding,
which could be contributed by OPE-complexation. Importantly, Kd values for OPE1− and
OPE2+ were in the sub-micromolar range (Table 3-3). These values were lower than that
obtained from ThT, indicating that the OPEs exhibit higher affinity toward Aβ fibrils.

Table 3-3 Amyloid Detector Factor (ADF), Limit of Detection (LOD), and Dissociation
Constant (Kd) for ThT, OPE1−, and OPE2+ Sensing of Aβ40 Fibrils Produced in pH 8.0 Tris
and in pH 7.4 PB

Taken together, both OPEs display higher selectivity and affinity than ThT toward
Aβ40 fibrils when tested at 1 μM sensor concentration. While sensing parameters of ThT were
similar between the fibrils produced in the two different buffer conditions, some variabilities
in OPE sensing parameters were seen. OPE2+ exhibited higher selectivity for the longer fibrils
prepared in Tris than the shorter fibrils prepared in PB. OPE1− exhibited higher binding
affinity toward the shorter fibrils than the longer fibrils. To resolve the cause of these
differences, additional investigations of OPE-fibril binding and fibril structures are needed.

54

3.3.4 OPE Sensing of Aβ42 Oligomers and Fibrils
In addition to high selectively, sensitivity and affinity, useful amyloid sensors also need to be
nonprotein specific, that is, capable of sensing the common amyloid conformation of a range
of proteins involved in neurodegenerative diseases. To this end, we evaluated the capability of
OPE1− and OPE2+ to detect aggregates of two additional amyloid proteins: amyloidβ (1−42)
(Aβ42) and α-synuclein. Aβ42 is the more amyloidogenic form of Aβ5 and α-synuclein forms
the Lewy bodies found in the brains of PD patients.150 The deposition of Aβ40 and Aβ42 in
the brain as amyloid plaques is a pathological hallmark of AD.151 Because the deposition of
Aβ42 starts prior to Aβ40, these fibrils constitute a suitable target for testing OPEs sensing.151–
154

Aβ42 fibrils were produced by incubating 45 μM peptide in pH 7.4 20 mM PB at room
temperature for 72 h. Unincubated and incubated samples were imaged using TEM (Figure 36). In contrast to unincubated Aβ40 samples where very few features were seen (Figure 3-2 A
and C), unincubated Aβ42 samples showed a large number of globular features of about 10.6
± 1.9 nm in diameter (Figure 3-6A). These are likely oligomeric aggregates from either the
incomplete solubilization of the peptide or aggregates that were already formed due to the
peptide’s high aggregation propensity.155,156 Incubated samples showed an abundance of long
fibrils with characteristic twists (Figure 3-6B). To further characterize the unincubated Aβ42
sample, the sample was centrifuged, and the supernatant was analyzed by SEC (Figure S7)
and dynamic light scattering (DLS). SEC chromatograms of unincubated Aβ42 show the
presence of a large peak at 21 min that likely corresponds to monomeric Aβ42. However, this
peak is broad and with shoulders at 17 and 20 min, indicating the presence of larger size
species. Additionally, the hydrodynamic radius (Rh) of the unincubated Aβ42 sample
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measured by DLS was around 30 nm. Taken together, both results revealed the presence of
soluble and heterogeneous higher molecular weight species in the unincubated Aβ42 sample,
or soluble oligomers. With incubation, the oligomer population first became enriched (blue
chromatograph of 2.4 h incubated sample in Figure S7) before they are depleted with fibril
formation, where only one smaller monomer peak was observed after 72 h incubation (red
chromatograph in Figure S7). The Rh value of the 72 h incubated sample, after centrifugation
to remove insoluble aggregates, was around 3 nm, corroborating the loss of soluble oligomers
with the formation of Aβ42 fibrils. Our results thus indicate that there were abundant
oligomeric, prefibrillar aggregates present in the unincubated Aβ42 sample and that after
incubation most of the soluble Aβ42 formed fibrils.

Figure 3-6 TEM images of unincubated (A) and incubated (B) Aβ42. Scale bars represent
200 nm.
Fluorescence spectra of ThT, OPE1− and OPE2+ were measured in the presence of
unincubated (oligomeric) and incubated (fibrillar) Aβ42 at 5 μM peptide with either 1 μM OPE
or 20 μM ThT (Figure 3-7). As shown in Figure 3-7, ThT and OPE1− exhibited small
fluorescence increases with oligomeric Aβ42 and displayed large fluorescence increases in the
presence of fibrils. Strikingly, OPE2+ showed large fluorescence enhancements with both
prefibrillar and fibrillar aggregates of Aβ42. Thus, all three sensors effectively detected the
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fibrillar conformation of Aβ42. The cationic and larger OPE2+ additionally detected Aβ42
oligomers, making it potentially a more useful sensor for disease detection. The emission peak
of OPE2+ in the presence of Aβ42 oligomers is slightly red-shifted from that measured for the
sensor alone (462−469 nm) and is blue-shifted from its emission peak in the presence of Aβ42
fibrils (462−445 nm) (Table 3-4). These different spectral features indicate different modes of
binding induced fluorescence turn-on, which could be due to differences in binding sites
(hydrophobic grooves vs planar binding sites for example) that promote different
photophysical changes in the bound OPE or OPE complexes. More detailed studies on dyeprotein interactions will be needed to resolve the different dye binding modes. Although the
spectral difference of OPE2+ binding to oligomers vs fibrils demonstrated here is not large
(∼25 nm), it does demonstrate the potential of OPEs to detect and distinguish between different
conformational states of Aβ42 aggregates.
Table 3-4 Maximum Excitation and Emission Wavelengths of ThT, OPE1−, and OPE2+
Sensors in the Presence of Aβ42 Unincubated and Fibrils
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Figure 3-7 Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1), OPE1−
(A2), and OPE2+ (A3) alone (black) and in the presence of Aβ42 monomers (blue) and Aβ42
fibrils (red). Fluorescence was recorded in the presence of 5 μM protein and 1 μM OPEs or 5
μM protein and 20 μM ThT.
3.3.5 OPE Sensing α-Synuclein Aggregates
The main pathological hallmark of Parkinson’s disease is Lewy bodies composed of αsynuclein fibrils.157,158 However, oligomeric αsynuclein aggregates have been found to play a
central role in Parkinson’s disease neurodegeneration including disrupting mitochondrial
function, autophagy and lysosomal degradation, membrane homeostasis, endoplasmic
reticulum function and synapses, and can induce inflammation.150,159–161 Furthermore,
oligomers can also propagate between neurons leading to cell-to-cell spreading of α-synuclein
pathology.150,159,160 In this study, the wild type (WT), as well as three single mutants, A30P
and A53T involved in early onset of Parkinson’s disease,157,158 and E35K designed to produce
small oligomers,158,159 were used to test OPE sensing. A30P has been shown to aggregate
slower than WT,92 while A53T has been reported to exhibit faster fibrillization.162 To evaluate
the efficacy of OPE sensing of early aggregates and mature fibrils, we evaluated the binding
selectivity of both OPEs toward prefibrillar and fibrillar αsynuclein aggregates over monomers
and compare them to ThT.
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As shown by TEM images in Figure 3-8, except A53T, all other α-synuclein proteins
appeared monomeric at day 0. After 6 days of incubation, prefibrillar aggregates (>30 nm of
diameter) were present, and after 16 days of incubation, mature fibrils were observed. In the
case of the fast aggregating A53T, at day 0, the protein was already in an elongated aggregate,
and after 6 days of incubation, fibrils were present. Emission and excitation spectra were
recorded for ThT, OPE1−, and OPE2+ in the presence of the four α-synuclein proteins at days
0, 6, and 16 (Figure 3-9) at 1 μM sensor and 5 μM protein concentrations. The ADF values of
the three sensors were calculated (Table 5) and dyes that exhibited positive sensing (ADF > 1)
are indicated in yellow on the TEM images.
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Figure 3-8 TEM images of unincubated (A, D, G, J), 6 day (B, E, H and K), and 16 day
incubated (D, F, I, L) α-synuclein. Four different isoforms of α-synuclein were images: wild
type (A−C), A30P (D−F), E35K (G−I), and A53T (J−L). The name of the sensor capable to
detect the different forms of α-synuclein appears in each TEM image in yellow (ADF > 1).
The asterisk indicates that A53T at day 0 was not completely monomeric. Scale bar
represents 200 nm.
In the presence of unincubated (day 0) WT, A30P, and E35K proteins, fluorescence
spectra close to background were obtained for all three sensors, indicating no sensing of
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monomers. In the presence of fibrils made from all four proteins (day 16), all three sensors
displayed fluorescence enhancements. Similar to the sensing of Aβ40 and Aβ42 fibrils, OPEs
exhibited larger fluorescence enhancements compared to ThT (2- to 20-fold higher for OPE1−,
6- to 100-fold higher for OPE2+). Although fluorescence enhancements were observed from
ThT, ADF values lower than 1 were obtained in the presence of WT and E35K fibrils which
indicates poor fibril selectivity, while both OPEs showed higher fibril selectivity of all αsynuclein proteins tested (ADF value >1). Thus, compared to ThT, OPEs are superior sensors
for α-synuclein fibrils and exhibit higher selectively, higher fluorescence signal, and are more
robust, that is, capable of sensing fibrils of all α-synuclein proteins tested.
Importantly, the capability of the three sensors to detect prefibrillar α-synuclein
aggregates was tested. ThT was only able to detect A53T aggregates after 6 days of incubation
(ADF > 1), while both OPEs detected prefibrillar aggregates of WT, E35K and A53T (Figure
3-9 and Table 3-5). No significant fluorescence enhancement was observed for the 6-day
incubated A30P sample where some oligomers were observed by TEM (Figure 3-8E). This
could be due to the lower abundance of oligomers as A30P exhibits a slower aggregation rate
(Figure S8). Finally, despite the high OPE fluorescence enhancements observed in the
presence of both prefibrillar and fibrillar conformations of α-synuclein, no significant
differences in the features of OPE spectra (for example, shifts in excitation or emission peaks)
were seen between sensors bound to oligomers and fibrils. Thus, although OPEs can selectively
detect both prefibrillar and fibrillar aggregates of α-synuclein, these sensors cannot distinguish
between the different aggregate conformations.
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Figure 3-9 Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1−D1),
OPE1− (A2−D2), and OPE2+ (A3−D3) alone (black), in the presence of α-synuclein at day 0
(blue lines), day 6 (red), and day 16 (green) of incubation. Four isoforms of α-synuclein were
evaluated: WT (A), A30P (B), E35K (C), and A53T (D).
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3.4 Conclusions
In this study, we investigated two novel PE-based sensors, OPE1− and OPE2+, for the selective
detection of amyloid protein aggregates over monomers and compared their performance to
the widely used ThT dye. Prefibrillar and fibrillar aggregates of six AD and PD associated
amyloid proteins were tested, Aβ40, Aβ42, wildtype α-synuclein, and 3 α-synuclein mutants.
Compared to ThT, OPE1− and OPE2+ are more selective sensors for Aβ40, Aβ42 and αsynuclein fibrils. OPEs displayed sub-μM binding constant and protein concentration limits of
detection of Aβ40 fibrils, both of which are lower than those determined for ThT. OPE2+
exhibited the highest sensitivity and significantly, detected prefibrillar Aβ42 and α-synuclein
aggregates that ThT did not detect. OPE1− also selectively detected α-synuclein prefibrillar
aggregates. ThT is known to detect fibrillar aggregates by intercalating into the β-strands in
the β-sheets.20,163 Due to the multiple binding-induced unquenching modes of OPEs, including
backbone planarization, hydrophobic unquenching, and formation of superluminescent OPEcomplexes, our results show that OPEs bound to and detected a wider range of aggregate
conformations compared to ThT. Although the exact nature of the binding mechanisms are
unclear, planar features on fibril surface can serve as sites for OPE binding, which can lead to
backbone planarization induced fluorescence enhancement. Binding to prefibrillar aggregates,
particularly those with increased surface hydrophobicity, could be mediated by hydrophobic
interactions which result in hydrophobic unquenching. The superior sensing capability of
OPEs demonstrated in this study point to the potential of these new sensors to overcome the
two major limitations of current probes, the inability to detect a wide range of amyloid
aggregate conformations, including the more disease relevant oligomeric, prefibrillar
aggregates, and the inability to simultaneously detect aggregates of different proteins.
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Overcoming these limitations promises significant advancement in the detection of the myriad
of protein aggregates involved in the early stages of AD and PD.
3.5 Methods
3.5.1 Materials
Synthetic amyloid β-40 (Aβ40) purified by reverse phase HPLC (purity > 95%) was purchased
from Peptide 2.0 (Chantilly, VA). The recombinant amyloid β-42 (Aβ42) and α- synuclein
proteins were produced and purified as previously described.161,164 The plasmids coding for αsynuclein wild type (WT) and three mutants (A30P, E35K, and A53T) were generously
provided by Dr. Roland Riek (ETH Zurich), and the plasmid coding for Aβ42 was provided
by Dr. Park (Chosun University, South Korea). Phosphate buffer (PB) was prepared with
sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous
purchased from Thermo Fisher Scientific (Waltham, MA). Tris was purchased from BioRad
(Hercules, CA). Sodium chloride (NaCl), ammonium hydroxide (NH40H) and dimethyl
sulfoxide (DMSO) were acquired from EMD Millipore (Burlington, MA). 1,1,1,3,3,3Hexafluoro-2-propanol (HFIP) was purchased from Sigma-Aldrich (St. Louis, MO). Copper
grids, 400 mesh, covered by a Formvar film and 5−10 mm carbon layer were purchased from
Ted Pella (Redding, CA). Aqueous uranyl acetate 2% was purchased from Electron
Microscopy Sciences (Hatfield, PA). Thioflavin T (ThT) (MW: 318.85 g/mol, extinction
coefficient at 412 nm (ε412nm) in water: 3.6 × 104 M−1 cm−1)20 was acquired from ACROS
Organics (Belgium). OPEs were synthesized and purified by previously published
procedures74 (OPE1−: 724.79 g/mol and ε370nm in water (3.92 ± 0.013) × 104 M−1 cm−1;
OPE2+: 1002.64 g/mol and ε378nm in water (8.29 ± 0.033) × 104 M−1 cm−1).
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3.5.2 Aβ40 Aggregation
Synthetic Aβ40 (4329 g/mol, ε280 nm = 1490 M−1 cm−1, pI = 5.5)165 was solubilized in DMSO
at 50 mg/mL. The peptide was sonicated in a bath sonicator for 1 min and was centrifuged at
14,000 g for 15 min. The supernatant was collected, and the peptide concentration was
determined by measuring the absorbance at 280 nm with a Nanodrop (Thermo Fisher
Scientific, Waltham, MA). Aβ40 was then stored in −70 °C until use. Two incubations were
set up. First the protein was diluted in 40 mM Tris pH 8.0 buffer containing 150 mM NaCl and
0.01% w/v sodium azide.138 Second, the protein was diluted in 50 mM PB pH 7.4 buffer
containing 100 mM NaCl and 0.01% w/v sodium azide.140 For both incubations, the final
protein concentration was 100 μM and the protein was incubated at 37 °C for 21 days under
quiescent condition. Every 2 to 3 days a sample was collected for characterization.
3.5.3 Aβ42 Aggregation
Purified and lyophilized Aβ42 was solubilized in 100% HFIP at 1 mg/mL and was sonicated
for 30 s. Then, the protein was dried under vacuum overnight and stored at −70 °C for up to 1
month. Aβ42 was solubilized in 0.1% NH4OH at 1 mg/mL (222 μM) and was then diluted to
45 μM in pH 7.4 20 mM PB. Protein was incubated at room temperature for 3 days under
quiescent condition.
3.5.4 α-Synuclein Aggregation
Four isoforms of α-synuclein proteins were used: wild type (WT) and three single point
mutants (A30P, E35K, and A53T). The lyophilized α-synuclein protein was first solubilized
to 300 μM in pH 7.4 10 mM PB, 300 mM NaCl and then incubated at 37 °C on a vertical rotor
at 50 rpm for 16 days.166
3.5.5 Fluorescence and Absorbance Measurements
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ThT and OPEs fluorescence spectra in the presence of Aβ40 was measured with the PTI
QuantaMaster 40 steady state spectrofluorometer (HORIBA Scientific, Edison, NJ). ThT was
mixed with Aβ40 at a 4 to 1 molar ratio (20 μM ThT to 5 μM protein) or 1 to 5 molar ratio (1
μM ThT to 5 μM protein) in 10 mM PB. OPE1− and OPE2+ were mixed with the protein at a
1 to 5 molar ratio (1 μM OPEs to 5 μM protein) in 10 mM PB. After 30 min of incubation at
room temperature in the dark, samples were transferred to a quartz cuvette (Starna cells Inc.,
Atascadero, CA) and the emission and excitation spectra were recorded. The emission spectra
were obtained at excitation wavelengths 440, 390, and 414 nm, for ThT, OPE1−, and OPE2+,
respectively. The excitation spectra were recorded at emission wavelengths of 480, 450, and
470 nm for ThT, OPE1−, and OPE2+, respectively. Experiments were performed in triplicates.
Absorbance spectra were measured in a quartz cuvette (PerkinElmer, Waltham, MA) on a
Lambda 35 UV/vis spectrometer (PerkinElmer, Waltham, MA) at a molar ratio of 1 to 5 (1 μM
sensor to 5 μM protein) between 250 and 700 nm.
3.5.6 TEM Imaging
Aliquots of protein solutions were first diluted in Milli Q water to 5 μM, and 4 μL of the diluted
solution was added to a glow discharged (Harrick Plasma Cleaner, Carson City, NV) copper
grid. The protein was allowed to adsorb for 5 min. After wicking away the excess solution with
a blotting paper, the grid was negatively stained four times, each time using 4 μL of 2%
aqueous uranyl acetate for 1 min. Between each staining step, the excess of uranyl acetate was
wicked away with a blotting paper. Finally, the grid was air-dried for 30 min before imaging.
TEM images were taken with the HITACHI HT7700 transmission electron microscope
(Hitachi High Technologies Corp., Tokyo, Japan). The beam current and the accelerating
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voltage were 8.0 μA and 80 keV, respectively. Images were analyzed by using ImageJ.99 The
fibril widths and lengths were estimated from 5 different images.
3.5.7 Circular Dichroism Spectroscopy
The secondary structures of unincubated Aβ40 monomers and fibrils produced after 21 days
of incubation were analyzed by circular dichroism spectroscopy (CD). The protein solution
was first desalted by transferring 250 μL of Aβ at 100 μM into an Amicon Centrifugal Filter
(Millipore Sigma, Burlington, MA) with 3 kDa cutoff. A volume of 4 mL of 10 mM PB was
added, and the protein was centrifuged at 3500 rpm for 10 min. This washing step was done
twice, and the final protein-containing retentate was brought back to 250 μL. The protein
concentration was checked by Bradford assay (Sigma-Aldrich, St. Louis, MO), and the protein
was diluted to 25 μM (108 μg/mL) in 10 mM PB and analyzed on an AVIV 410 CD
spectrometer (AVIV, Lakewood, NJ) in a quartz spectrophotometer cell with a path length of
1 mm (Starna cells Inc., Atascadero, CA). CD spectra were collected between 190 and 300 nm
with an average reading time of 15 s. Data were then converted into molar ellipticity [θ].167
3.5.8 Binding Constants
The binding constants of ThT, OPE1−, and OPE2+ to fibrillar Aβ40 was obtained from a
constant protein concentration binding assay.168 Triplet samples of 5 μM protein and varying
concentrations of sensor (0−30 μM for ThT, or 0−2 μM for OPE1− and OPE2+) were prepared
and emission spectra were obtained for each sample. Background (sensors alone) subtracted
integrated intensities were calculated and plotted against sensor concentration for each sensor
and the binding constants were fitted using a nonlinear regression curve assuming site specific
binding and using a Hill coefficient to account for any binding cooperativity.
3.5.9 Size Exclusion High Performance Liquid Chromatography (SEC)
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The unincubated and incubated Aβ40 and Aβ42 samples were analyzed by SEC to separate
and quantify the amounts of soluble oligomers and monomers present in the samples. Before
injecting the sample on the HPLC column, 70 μL of 100 μM(Aβ40) or 45 μM (Aβ42) was
centrifuged for 15 min at 14,000 rpm. Supernatant (65 μL) was injected on a BioSec-SECs3000 (Phenomenex, Torrance, CA) column that was already equilibrated with 10 mM
phosphate buffer saline (PBS) at pH 7.4 at 0.5 mL/min on Agilent 1100 series system (Agilent
Technology, Santa Clara, CA). Absorbance at 215 nm was monitored. Background signal was
subtracted using Agilent ChemStation software, and percentage of soluble protein was
calculated relative to the proteins present in the unincubated samples.
3.5.10 Dynamic Light Scattering (DLS)
The hydrodynamic radii (RH) of Aβ42 samples were determined by DLS. Samples at 45 μM
were centrifuged (15 min at 14,000 rpm) to remove large particles and dust. Supernatant was
loaded into a quartz microcuvette and analyzed with a DAWN HELEOS II light scattering
detector (Wyatt Technology Corporation, Santa Barbara, CA). Scattering intensity was
collected at 90° of the incident beam and recorded for 10 min. Data were analyzed using the
cumulant analysis method using the ASTRA 5.3.4.20 software to yield RH values.169
3.5.11 Statistical Analysis
Statistical analysis was carried out using JMP Pro 13 (Cary, NC). The integrated intensities of
the emission spectra obtained from the sensor alone, the sensor in the presence of monomers
or fibrils were compared by using a two-tailed t test with a p-value ≤0.05.
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3.6 Supporting Information

Figure S1: Size exclusion chromatograms of Aβ40 monomers (unincubated) and fibrils
(incubated for 21 days) in Tris buffer (A) or PB buffer (B). 65 μL at 100 μM samples were
centrifuged and analyzed by HPLC SEC.

Figure S2 Circular dichroism spectra of unincubated Aβ40 in two different solutions.
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Figure S3 Absorbance spectra of ThT (A1 and B1), OPE1- (A2 and B2) and OPE2+ (A3 and
B3) in the presence of monomeric (blue) and fibrillar (red) Aβ40 incubated in pH 8.0 Tris (A)
or pH 7.4 PB (B), compared to sensor alone (black). The sensor concentration was 1 µM and
the protein concentration was 5 µM.
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Figure S4 Integrated intensity of ThT, OPE1- or OPE2+ (1 µM) in the presence of monomeric
and fibrillar Aβ40 (5 µM) incubated in pH 8.0 Tris (A) and pH 7.4 PB (B). A t-test was run to
evaluate the significance of the difference between sensor alone, un-incubated (Day 0) ans 21day incubated (Day 21) Aβ40. The asteriks indicate a significance difference between two
conditions compared with a p-value ≤ 0.05.

Figure S5 Linear correlations between fluorescence integrated area of ThT (A), OPE1- (B)
and OPE2+ (C) (1 µM) versus Aβ40 concentration. Data were fitted to a linear fit on OriginPro
with R2 ≥ 0.95. The intercept and slopes values are summarized in the table below.
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Figure S6 Binding assay profiles of ThT (A1 and B1), OPE1- (A2 and B2) and OPE2+ (A3
and B3) to Aβ40 fibrils produced in pH 8.0 Tris (A) or pH 7.0 PB (B). These saturation binding
assay curves were obtained by fitting the data to a nonlinear regression assuming site specific
biding with binding cooperativity on OriginPro 9. Experiments were performed in duplicates
and error bars represent standard deviations. The maximum specific binding (Bmax), the Hill
coefficient (h), the dissociation constant (Kd) and the R2 values are summarized in the table
above. OPE has been shown to form complexes at concentrations higher than 10 µM which
leads to fluorescence red-shift peak sharpening. To isolate OPE/fibrils binding from OPE
complexation the binding assay was done at OPE concentration lower than 2 µM.
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Figure S7 Size exclusion chromatograms of Aβ42 unincubated, 2.4 hr incubated and 24 hr
incubated at room temperature. 65 µL of 45 µM samples were centrifuged (15 min at 14,000
rpm) to remove insoluble species and the supernatant was injected into the size exclusion
column (BioSep-SEC-S3000 from Phenomenex)

Figure S8 TEM images of α-synuclein WT (A) and A30P (B) after 6 days of incubation.
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Chapter 4 Conjugated Polyelectrolytes for Detecting Tau-Derived Paired
Helical Filaments
(This chapter is being prepared for submission and will appear Salomon L. Alires, Florencia
A. Monge, David G. Whitten, and Eva Y. Chi.)

4.1 Abstract
The pathological hallmark of many neurodegenerative diseases is the deposition of misfolded
proteins. For microtubule stabilizing protein tau, the protein becomes hyperphosphorylated and
it will form intracellular neurofibrillary tangles. Currently, there is no reliable method to detect
these tangles in vivo to diagnose and confirm pathology. In recent work we have shown that a
new class of synthetic sensors oligo-p-phenylene ethynylenes (OPEs) selectively detected the
beta-sheet rich fibrillar protein conformation of model amyloid proteins and in vitro prepared
disease related Aβ. OPE’s sensing modes rely on the hydrophobic backbone rotation restricted
and dye-dye interaction producing large fluorescent enhancements under visible light
wavelengths. In this study, we tested the sensing capability of OPEs on tau hexapeptide
306

VQIVYK311 (PHF6). This sequence is found in the third repeat microtubule-binding domain

of the tau protein and its hyperphosphorylation is noted to be critical in the formation of
neurofibrillary tangles. Two types of tau-derived PHF6 were synthesized and purified:
aggregation prone N-acetyl-PHF6 (Ac-PHF6) and non-aggregating standard N terminal PHF6
(NH3+-PHF6). The peptides were tested with three sensors: anionic OPE12-, cationic OPE24+,
and the more commonly used thioflavin T. Incubation of Ac-PHF6 in water at two conditions
reproducibly resulted two different fibril morphologies. Fibril morphology was characterized
by transmission electron microscopy and circular dichroism. Thioflavin T only detected one
type of Ac-PHF6 fibril, whereas OPE12- selectively detected both types and displayed a much
higher affinity for the fibril. We were able to show that OPE12- is an effective sensor for PHF6
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fibrils, potentially providing a new imaging modality for studying and tracking tau filaments
in many neurodegenerative disorders.
4.2 Introduction
Aberrant phosphorylated tau protein is linked with a host neurodegenerative diseases that
include: Alzheimer’s and Parkinson’s disease, frontotemporal dementia, and chronic traumatic
encephalopathies amongst a spectrum of tauopathies170–173. Tau protein is a microtubuleassociated protein expressed mainly in the axons of the central nervous system174. Its chief
function involves assembly and stabilization of microtubules. Still it has functions associated
with signal transduction, organelle transport, and cell growth175,176. Tau may exist in one of six
isoforms with lengths of 352 and 441 residues that differ mainly by the number of three or four
repeat units in the C-terminal half generated by alternative mRNA splicing177. The repeat units
are termed the microtubule binding region (MTBR) and in concert with its flanking regions,
facilitates attachment and stabilization of the MTBR178,179. It is thought that
hyperphosphorylation of tau due to dysregulation of post-translational modifications (e.g.
ubiquination, acetylation, methylation, glycosylation) is culpable in impairing microtubule
attachment, resulting in an unbound protein with susceptibility to aggregate and form beta
sheet rich tau fibrils, paired helical filaments (PHFs). Polymerization of PHFs engender
neurofibrillary tangles which are the hallmark of many diseases175,180–183. A region associated
with tau self-assembly occurs by the hexapeptide 306VQIVYK311 or commonly referred to as
PHF6 in the third repeat binding domain of the tau molecule184–188. A recent cryo-EM analysis
of PHF6, identifies this fragment as forming the N-terminal cross β-sheet structure that is
essential for tau filament propagation189,190. In addition, the hexapeptide has a propensity to
undergo a conformational change from random coils into organized β-sheet structure
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mimicking full-length tau191,192. Based on its aggregation propensity and ability to recapitulate
important fibril forming properties, PHF6 is widely used as a model to screen for amyloidreducing compounds189,193.
The self-assembly of PHF6 is a shared characteristic seen in a amyloidogenic proteins
regardless of their native fold, charge, and function1,2. Typically, oligomers rich in parallel or
antiparallel motifs stack perpendicular to the direction of growth and become laterally
superimposed with other inchoate structures136. The complex assumes an interdigitating steric
zipper with hydrophobic side chains orienting inward136,185,194–196. Interestingly, under
identical conditions, mature fibrils tend to grow adventitiously due to distinct molecular
assemblages136. Furthermore, treatments aimed at targeting specific protein configurations
must also contend with molecular-level structural polymorphisms.
The available technology identifies mature protein aggregates through histochemical
staining with Thioflavin T (ThT) and Congo Red (CR)20,29,163,197–199.. These molecules detect
fibrillar protein conformation by changes in their spectral features. This is through a cast of
linear-shape aromaticity and restricted intramolecular rotation when bound to the hydrophobic
surface grooves on the fibril42. Although helpful to confirm diagnosis postmortem in vivo
diagnosis remains a challenge, there is also a lack of detection tools to aid in tracking
fibrillation processes and identifying smaller oligomeric protein aggregate species.
Advancements of molecular probes with photochemical fluorescent characteristics and
selectivity for the aggregated conformer have been developed to achieve this purpose122,126,200.
More recently, a class of novel sensing molecules has been studied for the detection
and selectivity of amyloid forms, based on a phenylene-ethynylene backbone with carboxy
ester end groups and charged side chains. Oligo-p-phenylene ethynylenes (OPEs) have been
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used as antimicrobial agents due to their affinity for negatively charged bacterial cell
membrane and their singlet oxygen generation capacity42,73,78,201,202. Among the library of
OPEs available (OPEnx; where n is the number of repeat units and x is the charge) OPE12- and
OPE24+ share non-protein specificity and are among the most selective for the β-sheet enriched
fibril128 over the proteins monomeric fold regardless of the protein charge at biological pH.
The OPE molecules have a defining signature of spectral properties including: low fluorescent
yield in water, bathochromic shifted j-aggregates bands, and induced circular dichroism (CD)
when bound to amyloids42. OPEs electrophilic ethyl ester end groups are solvent-dependent
and subject to reverse nucleophilic attack in water; this deactivates the excited singlet state of
the oligomer thereby exhibiting a quenching effect—an excellent baseline from which to
measure amyloid-sensing in the same environment203. An amyloid acts like a scaffold for OPE
attachment that resembles a running bond pattern due to steric hindrance among charged side
chains78. This binding mode results in a redshift of both absorption and fluorescence spectra
along with enhanced maxima bands42,43,204. These conditions provide the mechanism for “turn
on” fluorescence which is dependent on restricted linearity and stabilization of the conjugated
backbone of OPEs.
In this study we characterized OPEnx – fibril interactions with OPE12-, OPE24+, and two
fibril morphologies created through different aggregation protocols of the aggregation
sensitive N-acetyl-PHF6 (Ac-PHF6). We used non-aggregate forming standard N terminal
PHF6 (NH3+-PHF6) to serve as the monomeric state of comparison. Our work is to develop
and introduce sensors that can identify amyloid arising from a range of protein, with ranging
fibril morphologies, and in different aggregation states.
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4.3 Results and Discussion
In the present study, we used tau-derived PHF6 which is a widely chosen model protein to
screen for the aggregation propensity of full-length tau. Currently, molecular probes designed
to track amyloid burden have limited effectiveness and therefore the need for more robust
diagnostic methods must be developed. We used two variants of PHF6: aggregation prone AcPHF6 and non-aggregating NH3+-PHF6 and compared cationic and anionic oligo-(p-phenylene
ethynylene) against thioflavin T in tracing mature PHF6 filaments, Figure 4-1.
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Figure 4-1 A-C The chemical structures of OPE12-, OPE24+, and thioflavin T respectively. D
and E the chemical structures of Ac-PHF6 and NH3+-PHF6 at pH 7.4 respectively. The positive
charge, negative charge, hydrophilicity, and hydrophobicity are designated by blue, red, green,
and orange respectively. Hydrophobic and hydrophilic regions colored for the peptide only.
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4.3.1 PHF6 fibril protein morphology is varies according to incubation conditions
Acetylation has been shown to be a disease specific modification of tau related to
Alzheimer’s Disease. Aggregation prone PHF6 has been identified as a motif that promotes
beta sheet formation. We prepared two types of fibrils arising from different aggregation
conditions. Type A Ac-PHF6 fibrils were prepared by solubilizing the protein at 2 mg/mL in
water and incubating the sample at 70˚C for two days . Type B Ac-PHF6 fibrils were made
through a 5-day incubation at 75˚C and 3 mg/mL protein solubilized in water. Type A fibrils
were found to have a 10.6 ± 1.5 nm diameter while Type B fibrils were 10x larger in
diameter at 118 ± 11 nm (Figure 4-2). In addition, the morphology of the fibrils resembles a
cylindrical shape for both types. Experiments involving unincubated Ac-PHF6 at a
concentration of 3 mg/ml resembled protofilaments with intertwining fibers (not shown). We
can assume that perhaps the aggregation seeds polymerize into intertwining fibers that
eventually become filled in laterally leading to a cylindrical morphology.
Unincubated, Ac-PHF6 samples prepared for TEM analysis (Figure 4-2) resemble
granules that is not apparent in fibrillar images. TEM images of NH3+-PHF6 (Figure 4-2B)
has characteristic black dots throughout. Non-acetylation had the effect of preserving the
monomeric state of PHF6. At the pH of solubilization and subsequent experiments containing
10 mM sodium phosphate, the net charge of Ac-PHF6 and NH3+-PHF6 are 0 and +1
respectively. According to previous studies, it has been demonstrated that aggregation is
favored when a peptide’s overall net charge is closer to neutrality205. Thus, despite the same
amino acid hydrophobicity, the electrostatic repulsion of positive charges is enough to negate
aggregation of NH3+-PHF6. The inability to aggregate is evidenced by fluorescence
measurements with all three fluorophores with NH3+-PHF6 (Figure 4-4G-L) and no increase
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in signal was observed relative to the control. In fact, non-acetylation had the effect of
attenuating OPE12- in fluorescence measurements.

Figure 4-2 Negative stain transmission electron microscopy of PHF6 peptides. A unincubated
Ac-PHF6. B NH3+-PHF6. C type A fibrils with an average diameter of 10.6 ± 1.5 nm. D type
B fibrils with an average diameter of 118 ± 11 nm. Errors reported are standard errors.

4.3.2 CD Characterization of PHF6 Peptides
Circular dichroism spectroscopy was carried out and scanned in the far to mid UV range of
180-300 nm to characterize the secondary structures of Ac-PHF6, NH3+-PHF6, and the fibril
types (Figure 4-3). Units for the CD spectrometer (Aviv Biomedical, Lakewood, NJ) was
converted to mean molar ellipticity to account for concentration and mean residual weight.
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Figure 4-3 Characterization of the secondary structures of PHF6 peptides (84 µg/mL; 168
µg/mL for NH3+-PHF6) through circular dichroism in 10 mM sodium phosphate (pH 7.4).

Ac-PHF6 is rich in antiparallel β-sheet indicated by a positive band from 190-204 nm
with a peak at 198 nm and a minimum at 218 nm206,207. Interestingly, CD absorbance of type
A fibrils has only a broad negative band beginning at 199 nm with a minimum occurring around
218 nm; a signal that corresponds to having a high fraction of extended β-sheet structure206,208.
This implies that after incubation for 2-days at high heat, type A fibrils have a palimpsest of
antiparallel motives however it is overshadowed through polymerization in the form of
extended β-sheet. Type B fibrils resemble Ac-PHF6 in signal but much lower in magnitude;
this signal is likely a mix of β-sheet structure. NH3+-PHF6 is rich in random coil as shown by
a negative peak that is sharpened around 195 nm193. In a previous study with NH3+-PHF6, it
has been shown that peptides with the tendency to form a random coil secondary structure has
been associated with a slow rate of polymerization208. This corroborates earlier findings that
NH3+-PHF6 has little to known aggregation propensity compared to its acetylated counterpart.
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4.3.3 OPE12- selectively detected Type B Fibrils
Fluorescence emission (Figure 4-4G-L) was implemented to determine the effectiveness of
each sensor in detecting PHF6 aggregates. Peak absorption wavelengths taken from sensorType A fibrils (not shown) was used to excite fluorescence samples as shown in Table 4-1.
Subsequent fluorescence experiments found a slight enhancement when testing various
wavelengths based on excitation maxima.
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Figure 4-4 Excitation (A-F) and emission (G-L) fluorescence spectra of PHF6 peptides (21
µg/mL) with the sensors in 10 mM sodium phosphate (pH 7.4). A, G, D, and J are OPE12-. B,
H, E, and K are OPE24+. C, I, F, and L is Thioflavin T. NH3+-PHF6 plotted against emission
spectra only.
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Table 4-1 Excitation and maximum emission wavelengths used for fluorescence spectra of
each sensor. Amyloid detection factor and sensitivity values obtained from integration of
emission spectra. Errors reported are standard errors.
ADF

Sensitivity

Excitation
Wavelength
(nm)

Max
Emission
Wavelength
(nm)

Ac-PHF6

Type A

Type B

Ac-PHF6

Type A

Type B

OPE12-

375

440

1.15 ± 0.36

1.91 ± 0.19

9.78 ± 1.06

1.83 ± 0.45

2.74 ± 0.18

10.4 ± 1.08

OPE24+

378

446

-0.39 ± 1.12

0.04 ± 0.39

0.08 ± 0.73

1.23 ± 0.66

1.42 ± 0.12

1.32 ± 0.18

Thioflavin T

412

480

-0.27 ± 0.10 -0.19 ± 0.03

0.37 ± 0.28

0.91 ± 0.21

1.01 ± 0.03

1.35 ± 0.30

Sensor

Generally, there was a higher detection of Type B fibrils over Type A fibrils,
unincubated Ac-PHF6, and NH3+-PHF6. Ac-PHF6 was only detected by OPE12-. The overall
net charge of NH3+-PHF6 at pH 7.4 is +1, favoring hydrostatic interplay with OPE12- and ThT
while repulsion is expected with OPE24+. When mixed with OPE12-, it had the effect of
attenuating the fluorescence signal while no measurable difference was seen with OPE24+ or
ThT. It’s clear that the electrostatic attraction between PHF6 peptides and the sensors has merit
however the combination of high fibril hydrophobicity and attachment resulting in the sensor’s
restricted rotation was the only factor in activating “turn on” fluorescence.
The association of Ac-PHF6 and OPE12- are similar in profile and is marked by a
modest fluorescence enhancement and a bathochromic shift relative to the control as shown in
Fig. 4-4G and J. The presence of a shoulder centered around 440 nm for OPE12- alone and
when mixed with the peptides was observed. This shoulder is sharpened drastically for type A
fibrils when mixed with OPE12- and although it is still present with type B fibrils, the signal
waxes until reaching the fluorescence peak at 512 nm. The combination of OPE12- and type B
fibrils had the apogee of fluorescence enhancement versus background fluorescence observed
in this experiment.
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OPE24+ did not detect Ac-PHF6, NH3+-PHF6, and the fibril types, Figure 4-4H and K.
There was a mild fluorescence enhancement observed with type A and NH3+-PHF6 with
OPE24+ but this increase was found to be not significant. The general profile of the emission
bands includes a peak fluorescence around 440 nm for the fibril types and two shoulders
approximately 10 nm apart. ThT did not selectively sense Ac-PHF6, NH3+-PHF6 or type A
fibrils as shown by Figure 4-4I and L. However, there was a large fluorescence enhancement
with the combination of type B fibrils and ThT that is indicative of sensing. This was
corroborated with experiments with ThT at 1 µM concentration and type B fibrils
(Supplemental Figure S1). ThT had the most predictable emission profile with peaks around
477 nm for all PHF6 peptides. Maximum emission wavelengths of the sensors were recorded
(Table 4-1) and absorbance in the form of excitation spectra was produced (Figure 4-4A-F).
Regardless of fibril type, excitation fluorescence enhancement was observed with OPE12- and
ThT and a small enhancement was seen only with type B fibrils when mixed with OPE24+. The
excitation spectra of OPE12- with the fibril types (Figure 4-4A and D; red and cyan traces) has
two characteristic peaks: one appearing from the range of 315-337 nm and another from 399427 nm. The peak excitation wavelength was consistently 421 and 422 nm for type A and type
B fibrils respectively. OPE24+ excitation profile has two prominent peaks from 321-340 nm
and 391-403 nm for both types of fibrils (Figure 4-4B and E). Interestingly, the sensor alone
had slightly higher intensity as shown in Figure 4-4B. The maxima peaks were determined to
be 399 and 400 nm for type A and type B respectively. In general, ThT has two excitation
peaks occurring from 287-315 nm and 385-415 nm (Figure 4C and F) and a marked
fluorescence enhancement was observed in the presence of the fibril types (red and cyan
traces). For type A fibrils the peak appears at 299 nm and for type B fibrils it appears at 401
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nm making the maximum excitation wavelength difficult to determine. In Fig. 4F, the signal
of ThT with type B fibrils was similar to unincubated Ac-PHF6 from the start of data collection
until ~350 nm where the fibrillar sample shown enhancement from 385-415 nm and the AcPHF6 signal flattened. Interestingly, there was a blueshift observed with ThT in the presence
of unincubated Ac-PHF6 and type B fibrils relative to the control however they all had a similar
peak around 401 nm.
To quantitatively compare each sensor in the detection and selectivity of higher order
protein aggregates as compared to the monomeric conformer (NH3+-PHF6), amyloid detection
factor or ADF was computed (Figure 4-5A).

𝐴𝐷𝐹 =

𝐼&'()'*%1$.1-) − 𝐼,-.-,$)%1$.1-)
𝐼1$.1-)

(1)

Where, 𝐈&'()'*%1$.1-) is the integrated emission intensity of fibrils mixed with OPE or ThT,
𝐈,-.-,$)%1$.1-) is the integrated emission intensity of NH3+-PHF6 with OPE or ThT, and
𝐈3$.1-) is the integrated emission intensity of OPE or ThT alone in buffer. These values of
integration are based on Figure 4-4G-L and the bounds of integration begin with the first and
last emission signal. The higher the value in the positive direction, the more selectivity toward
the fibril, while negative values means more affinity toward the monomer. Values at or near
zero indicate non-distinguishable sensing for either conformation. ADF values and standard
errors are reported in Table 4-1.
OPE12- clearly has affinity toward fibril formation with an ADF value of 9.78 for type
B fibrils and it also detected type A fibrils and Ac-PHF6 to lesser degrees. The secondary
structure of Ac-PHF6 as shown in Figure 4-3 (blue trace) has an antiparallel β-sheet enriched
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conformation which may affirm why OPE12- showed slight selective affinity towards this
conformation. OPE24+ has minor positive values for both fibril types and showed monomeric
affinity in the presence of Ac-PHF6, however fitted error bars indicate non-distinguishable
sensing. ThT has monomeric affinity in the presence of both Ac-PHF6 and type A fibrils and
slight positive sensing for type B fibrils with a value of 0.37. In general, ThT has nondistinguishable sensing for all PHF6 categories.
To assess the fluorescence enhancement following the interaction with a sensor and a
higher order protein aggregate as compared to the sensor’s fluorescence intensity alone in
buffer, a sensitivity assay was carried out, Figure 4-5B. The parameters of the equation are
defined below. Sensitivity values and standard errors are reported in Table 4-1.
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =

𝐼&'()'*%1$.1-)
𝐼1$.1-)

(2)

The fluorescence enhancement measured between OPE12- and type B fibrils saw the
highest sensitivity value of 10.35. This value is roughly 3.7 times the next highest value of
2.74 and was the combination of OPE12- and type A fibrils. OPE12- and Ac-PHF6 exhibited a
modest sensitivity value of 1.83 and was still higher than the other sensors tested. OPE24+ and
ThT had sensitivity values for all PHF6 categories ranging from 0.9-1.4 that is indicative of
little to no positive sensing.
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Figure 4-5 The quantitative performance of the sensor in detecting higher order PHF6
aggregates. A The comparison of each sensor based on the amyloid detection factor. B
compares the sensitivity or fluorescence enhancement of each dye upon binding to the peptide
over background fluorescence.

4.3.4 Induced CD Signatures of Ac-PHF6 with OPE12- Confers Complexation
Maturation of unincubated Ac-PHF6 undergoes various symmetric states, thus leading to
distinct optically active CD signatures. OPE compounds on their own are optically inactive
however when placed in the framework of chiral system, production of a chiral supramolecular
complex is the expected result209. To better understand the interaction between OPEs and Ac-
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PHF6, CD measurements were taken where OPEs absorb light to determine if OPE altered the
geometric profile of Ac-PHF6 (Figure 4-6)42.
The relationship between OPE12- and Ac-PHF6 shows large optical rotary dispersion
and an inflection point between 400-450 nm; this phenomenon is known as the negative cotton
effect210. The effect is more pronounced for Ac-PHF6 and is thought to be an approximate
measure of α-helical content210,211. Post-incubation of Ac-PHF6 at the conditions specified for
type A fibrils, resulted in a less amplified negative cotton effect. This led to the insight that not
only was unincubated Ac-PHF6 comprised of mainly antiparallel β-sheet but also contained a
mixture of α-helix.
In stark contrast to OPE12-, the association between OPE24+ and PHF6 did not produce
any noteworthy signals characteristic of a complexed fluorophore. This result along with
miniscule ADF values taken together, indicates that OPE24+ is not an effective sensor for
detecting PHF6 under these conditions.
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Figure 4-6 Induced circular dichroism spectra of PHF6 peptides (84 µg/mL) with 10 µM OPE
in 10 mM sodium phosphate (pH 7.4). A OPE12-; B OPE24+.
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4.3.5 OPE12- Exhibits J or H Binding Signatures Based on the Fibrillar Surface
Based on CD measurements (Figure 4-6A) and high ADF and sensitivity values (Figure 4-5),
we can conclude that OPE12- (i) detects and forms a complex with PHF6 aggregates and (ii)
binds most favorably to higher order PHF6 aggregates. To expound the emission differences
and the apparent vacillation between shifting maxima between OPE12- and the fibril types, we
carried out two fluorescence experiments.
We assumed that the surface area of the fibril scaffold is culpable in dictating how
OPE12- forms complexes (Figure 4-7A). In previous studies, it has been observed that OPE12undergoes predominantly J-aggregation; that is, upon binding to a fibril surface, it will
assemble in an off-center arrangement with in-line transition dipoles preventing high energy
output whereby maxima bands shift toward a lower energy state78. Our idea is that saturation
of the fibril surface may result in a complete superimposed self-assembly which is more likely
despite electrostatic repulsion among charged side chains thus providing a curve consistent
with H-aggregate formation. To test our theory, we prepared a batch of type B fibrils and fixed
the concentration to 21 µg/mL while increasing the concentration of OPE12- to determine if
saturation of the binding surface will shift the peak from 512 nm and promote the peak of 441
nm as observed in Figure 4-4G and J. To study the shifts, we normalized the emission spectra
of all the samples.
In general, concentrations of OPE12- ranging from 1-9 µM alone in buffer has peaks
around 470 nm. When 1 µM OPE12- is mixed with type B fibrils we observe a broad emission
maximum centered at 507 nm with the addition of the shoulder at about 440 nm. In the presence
of 3.5 µM OPE12-, this shoulder is enhanced and sharpened including a hypsochromic peak
shift to 498 nm. The shoulder is sharpened drastically at 444 nm and is the only peak observed
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with the addition of a 6 µM and 9 µM concentrations of OPE12. These results confirm our
suspicion that a high concentration of OPE12- must fully saturate the binding pockets provided
by the fibril and inconsequently overlap regardless of electrostatic repulsion between charged
side chains.
To establish our previous findings of OPE12--fibril assembly, we subjected type B
fibrils to intervals of flash freezing and sonication to produce truncated fibrils; this was done
to increase the surface area of the fibrils and theoretically provide more binding pockets for
OPE12- attachment (Figure 4-7B). We successfully produced truncated fibrils as shown by the
TEM image inset of Figure 4-7B. When mixed with OPE12-, it had the effect of completely
dampening the shoulder at 440 nm as well as enhancing and red-shifting the maximum slightly.
In accordance with previous thought, increasing the surface area of the scaffold increased the
probability of individual OPE12- attachment or production of a complex consistent with Jaggregate stacking. A schematic was drawn up in Figure 4-8 to capture this behavior in detail.
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Figure 4-7 Determining how OPE12- binds in the presence of type B fibrils (21 μg/ml) in 10 mM
sodium phosphate (pH 7.4). A normalized fluorescence emission of increasing µM OPE12concentration alone (dashed lines) and with type B fibrils (solid lines). B fluorescence emission of
OPE12- (1 µM) with regular and truncated type B fibrils. Accompanying TEM images of intact and
truncated fibrils are an inset of spectrum B.
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Figure 4-8 Proposed illustration of unbound OPE12- and complexing with type A and B fibrils.
OPE12- and the fibril types are drawn to scale relative to each other.

4.3.6 Saturation of Type B Fibrils with OPE12- Models Positive Cooperativity
As demonstrated previously, the long type B scaffold has many receptor sites that can
individually fit many OPE12- molecules before sequential or sensor-sensor stacking was
observed212. In order to evaluate the molecular affinity of OPE12- and intact type B fibrils, a
binding saturation assay was carried out and provided in Supplemental Figures S2. We
modeled the binding curve of OPE12- with the Hill equation to gain insight if asymmetric
binding in the form of cooperativity was at work213:
𝐹,45 𝑥 .
𝑦=
𝐾" + 𝑥 .

(3)

where, 𝑦 is OPE12- integrated emission intensity, 𝐹,45 is OPE12- integrated emission intensity
at saturation, 𝑥 is the concentration of OPE12-, 𝐾" is the apparent rate disassociation constant,
and 𝑛 is the Hill coefficient. OPE24+ and ThT had little to no information indicating a robust
association with type B fibrils therefore they were excluded from this assessment.
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In keeping with the tendency for OPE12- to form complexes at high concentration, we
evaluated OPE12- in the presence of a fixed concentration of type B fibrils (21 µg/mL) and
gradually increased the concentration from 0.5 µM up to 3.5 µM. The binding curve is
sigmoidal in shape with a low micromolar 𝐾" value of 1.11; the Hill coefficient was calculated
to be 4.45, indicating strong positive cooperativity, which is consistent with sensor selfassembly recurring in this study.

4.4 Conclusions
Tauopathies are common comorbidities in many neurodegenerative disorders that for many
reach an inexorable state of burden that cannot be mitigated. Hyperphosphorylation of tau
imputed to post-translation modifications results in an unbound protein that is susceptible to
aggregation. Sites on the tau protein such as PHF6 make for a great model for in vitro studies
due to its aggregation promoting tendency apart from full-length tau. In this study, we did
parallel testing of OPEs against the industry standard, ThT, for sensing the fibril types
incubated from acetylated PHF6.
Our results show that unincubated Ac-PHF6 readily undergoes aggregation as
suggested by agglomerated artifacts and CD measurements confirming a secondary structure
rich in extended and antiparallel β-sheet and α-helix—this was established by the dampened
cotton effect post-incubation with OPE12-. Furthermore, having a β-sheet rich structure helps
to explain the fluorescence enhancement and shift when interacting with OPE12-. When
incubated at the conditions specified for type A, filaments with a mean diameter of 10.8 nm
were produced. Increasing the concentration, the temperature, and the time of incubation
resulted in fibers roughly 11 times larger in diameter (Figure 4-2D). NH3+-PHF6 in contrast
had no aggregation propensity that is evidenced by a TEM image showing no higher order
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aggregates, low fluorescent yield with the three probes, and a secondary structure related to a
slow rate of polymerization. These properties of NH3+-PHF6 helped to serve as the monomeric
form of PHF6 for calculating ADF and sensitivity values in Figure 4-5.
OPE12- consistently outperformed OPE24+ and ThT in sensing Ac-PHF6 filaments.
Although ThT detected type B fibrils to some degree, an insignificant ADF value points to the
contrary. Also noteworthy, is that ThT was measured at 20 times the concentration of OPEs
and still lacked significant detection. The emission profile of OPE12- was key in understanding
the mechanism of how the dye binds and exhibits “turn on” fluorescence. There may be several
molecular factors at work, however we have demonstrated that saturation of the fibril surface
lead to a blueshift in fluorescence; this occurs due to overlap of OPE12- in spite of repulsion
among charged side chains. Increasing the available binding pockets allows more single-bound
OPE12- or stacking in the form of a J-aggregate allowing for a redshift in fluorescence.
In summary, this study helps to shed light on the potential for biofluorescent probes in
detecting disease-related tau protein that is associated with many neurodegenerative diseases.
To date, amyloid tracking is in its infancy regarding detection of multiple disease-related
proteins as well as selectivity for toxic higher order oligomeric aggregates. Our results
highlight that OPEs and in particular OPE12-, has immense potential and perhaps may
accompany therapeutic modalities for the treatment of many neurodegenerative diseases in the
near future.
4.5 Experimental Procedures
4.5.1 Materials
Excluding OPEs and PHF6, all reagents were obtained commercially and used without further
purification. The detailed synthesis of OPEs were characterized and reported previously43. ThT
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used for sensing experiments obtained from Thermo Fisher Scientific (Waltham, MA). All
component reagents required for solid-state synthesis of PHF6 obtained from Millipore Sigma
(St. Louis, MO). Rink amide resin was purchased from Chem-Impex International (Wood
Dale, IL). Acetonitrile (ACN), Milli-Q water purification system, buffer components, and
trifluoroacetic acid (TFA) was supplied by Millipore Sigma.
4.5.2 Fmoc Solid-Phase Peptide Synthesis
PHF6 peptides were manually synthesized in a 25 mL column with a polyethylene filter and
rinsed with dimethylformamide (DMF); it was drained through a plastic stopcock under
vacuum into a round collection flask before conducting synthesis. Approximately 0.19 g of
rink amide resin (0.3-0.8 meq/g, 200-400 mesh) was measured and placed in the column. The
volume of reagents and solvents added for each step was maintained at 4 mL to allow for
optimal solvating and swelling of resin unless otherwise stated. Prior to synthesis, the resin
was allowed to swell with (2 x 3 min) of dichloromethane (DCM) and DMF (3 x 2 min). It was
then placed in DMF for 25 minutes. The deprotection of resin and amino acids was performed
using a solution of 20% piperdine in DMF (3 x 3 min). Washings between deprotection and
amino acid addition were carried out with DMF (3 x 2 min). The amino acids were added in
reverse order to exposed amine groups following deprotection214. The ratio of resin to amino
acid was limited to 0.53 mmol/g to avoid undesired alkylations215. Coupling was implemented
by 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) at 1:1
molar ratio to amino acid to ensure complete activation. The following equation was used to
calculate the amount of amino acid and corresponding HBTU
0.53 𝑚𝑚𝑜𝑙
𝑀𝑊 𝑜𝑓 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑣𝑒 𝑔𝑟𝑜𝑢𝑝
× 𝑟𝑒𝑠𝑖𝑛 𝑤𝑒𝑟𝑖𝑔ℎ𝑡(𝑔) × 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 (4) ×
𝑔
𝑀𝑊 𝑜𝑓 𝐻𝐵𝑇𝑈
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The amino acid and HBTU was dissolved in 2 mL of 10% % N,N-diisopropylethylamine
(DIEA) in DMF and added to the column. The reaction was left for 15 minutes and a ninhydrin
test was used to monitor the process. If there was successful addition, deprotection was carried
out otherwise more DIEA was added to the reaction mixture and tested again. Stepwise
deprotection and coupling of amino acids was repeated until the peptide sequence was
complete. After assembling the hexapeptide, the peptide was acetylated with 20% acetic
anhydride in DMF (7 mL/g per resin in column). The reaction was checked with a ninhydrin
test for completion. For preparation of NH3+-PHF6, acetylation was excluded. After synthesis
was complete, the resin was allowed to dry in the column. Deprotection was then carried out
for NH3+-PHF6 only. The resin was swelled in DMF (2 x 2 min) followed by methanol (1 x 2
min) and two washings of DMF and DCM (2 x 2 min, each). Cleavage of the peptide and
removal of the side chain protective groups was accomplished by a solution of 90% TFA in
DCM and left for 4 hours. The TFA layer was deposited into a clean round collection flask and
the TFA was removed by rotary evaporation at 30 ˚C. The fraction was diluted with 25 mL of
Milli-Q water, placed in a -80 ˚C freezer, and lyophilized.
4.5.3 PHF6 Purification
Unpurified PHF6 was solubilized in Milli-Q water and filtered through 0.45 µm ADVANTEC
(Vernon Hills, IL) syringe with cellulose acetate disposable filter. It was purified with Agilent
(Santa Clara, CA) reverse phase high-pressure liquid chromatographer through a 3.5 µm
Agilent ZORBAX Eclipse XDB-C18 column and equilibrated with buffers A (Milli-Q H2O +
0.01% TFA) and B (ACN + 0.01% TFA). The eluted fraction was collected approximately
21.5-23 minutes, placed in 20 mL glass vial, and undergone rotary evaporation at 30 ºC. The
remaining fraction was desiccated using lyophilization overnight.
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4.5.4 Incubation of Ac-PHF6
Purified Ac-PHF6 was solubilized in Milli-Q water at a concentration of 2 mg/mL and
incubated on a heat block at 70 ºC for 48 hours (type A fibrils) to promote aggregation. 5-day
incubated Ac-PHF6 was solubilized in Milli-Q water at a concentration of 3 mg/mL and placed
on a heat block at 75 ºC (type B fibrils). For both types, an unincubated aliquot was placed in
a 1.5 mL Eppendorf tube and placed in a -80 ºC freezer to prevent fibrillation. The
concentrations were verified using a Thermo Fisher Nanodrop Spectrophotometer (Waltham,
MA). Truncated fibrils were prepared by subjecting type B fibrils to repeated sonication-flash
freezing cycles (10 x 1 min). Additionally, the samples were pipetted back and forth
continuously with a 0.1-2.5 µL pipette for 10 minutes.
4.5.5 TEM Imaging
Formvar/Carbon 400 mesh with a grid hole size of 42 µm (Ted Pella, Redding, CA) was placed
in a Harrick Plasma Cleaner PDC-32G (Ithaca, New York) to remove organic contamination
from the surface. 4 µL of PHF6 peptides was added to a grid at a concentration of 20 µM and
let sit for 5 minutes after wicking off excess water. 4 µL of 2% uranyl acetate was added for
the negative stain contrast and let sit for 3 minutes, immediately following 3 x 1 min treatments
after wicking off dye excess. The grid was then allowed to dry for 30 minutes in open air and
placed into grid pads and labeled. Unincubated Ac-PHF6 samples were slowly thawed in ice
and added to grids to negate unwanted aggregation. Analysis and comparison of TEM images
was achieved by ImageJ. For each TEM image analyzed, the diameter was tabulated using 10
separate measurements with standard deviation values reported.
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4.5.6Fluorometry Assays
To evaluate OPE and ThT sensing, triplicate samples in 10 mM sodium phosphate (pH 7.4)
were prepared and transferred to a 40 µL quartz cuvette and read using a PTI Quanta Master
40 steady state spectrofluorometer (Horiba Scientific, Kyoto, Japan). A peptide concentration
of 21 µg/mL was mixed with OPEs and ThT at 1 µM and 20 µM concentrations respectively
for at least 30 minutes before beginning experiment. The wavelengths of excitation were
determined based on absorption measurements: 375, 378, and 412 nm for OPE12+, OPE24+, and
ThT respectively. The excitation spectra were recorded at peak emission wavelengths of 440,
446, and 480 nm for OPE12-, OPE24+, and ThT respectively. NH3+-PHF6 emission spectra was
used as the monomeric state for the quantitative comparison of the amyloid detection factor
and sensitivity of each sensor.
4.5.7 Circular Dichroism Spectroscopy
The secondary structure of the peptide was characterized in the range of 180-300 nm,
background subtracted, and converted from millidegrees into units of mean residue ellipticity
for comparison with diverse peptide residues167. PHF6 peptides when mixed with OPEs were
scanned in the range of 300-750 nm to determine if OPEs induced an absorbance signal and a
blank spectrum containing the sensor in buffer was subtracted from each sample to remove
background noise.
The samples contained 10 µM OPE (induced circular dichroism only), 84 µg/mL
unincubated and incubated Ac-PHF6, and 168 µg/mL NH3+-PHF6 concentrations in 10 mM
sodium phosphate (pH 7.4). The samples were transferred to 1 mm path length quartz cuvette
and read using Aviv 410 CD spectrometer (Aviv Biomedical, Lakewood, NJ) with a 15 second
averaging time.
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4.5.8 Describing the Type B – OPE12- Relationship
Fluorescence emission was carried out with OPE12- when mixed with type B fibrils (21 µg/mL)
in 10 mM sodium phosphate (pH 7.4). The prepared samples were left for 30 min and
transferred to a 40 µL quartz cuvette and read at 375 nm.
Duplicate samples of OPE12- ranging from 1-9 µM was mixed with type B fibrils and
the emission was normalized to visualize the spectral shifts. OPE12- at 1 µM concentration was
prepared with intact and truncated type B fibrils (described with the method above) and
prepared in triplicates.
4.5.9 Determining OPE12- Binding Constant
The binding curve was obtained from the integrated emission intensity of varying OPE12concentrations from 0.5-3.5 µM and mixed with fixed type B fibrils (21 µg/mL) in 10 mM
sodium phosphate (pH 7.4). The samples were prepared in duplicates and transferred to a 40
µL quartz cuvette and read at 375 nm. The samples were background subtracted and fitted
using the Hill equation in Origin Pro 2016 with standard error values reported.

Intensity´103 (cts sec-1)

4.6 Supplementary Information
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Figure S1 Fluorescence emission of Thioflavin T at 1 µM concentration with PHF6 peptides
(21 µg/mL) in 10 mM sodium phosphate (pH 7.4)
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Chapter 5 Ex vivo staining properties of Oligo-p-Phenylene Ethynylene – A
novel optical sensor selective towards amyloids
(This chapter will be submitted to Brain Pathology as Florencia A. Monge, Adeline M.
Fanni, Patrick L. Donabedian, Nicole M. Maphis, Shanya Jiang, Tia Donaldson, Benjamin
Clark, David G. Whitten, Kiran Bhaskar, and Eva Y. Chi. Ex vivo staining properties of
Oligo-p-Phenylene Ethynylene – A Novel Optical Sensor Selective Towards Amyloids)
5.1 Abstract
The identification of protein aggregates as biomarkers for neurodegeneration is an area of
interest for diagnosis and treatment development. In this work we present novel super
luminescent conjugated polyelectrolyte molecules as ex vivo sensors for tau paired helical
filaments and amyloid-b plaques. We evaluated the use of OPE12- and OPE24+ as
immunohistochemical stains for fibrillar protein pathology in transgenic rat (rTg4510), mice
(TgF344AD), and human frontotemporal dementia brain sections. OPE12- displayed selectivity
of tau paired helical filaments in fluorimetry assays and strong sensing of neurofibrillary
tangles in tissue. OPE24+ identified Ab plaque core pathology in rat sections. Both OPEs
stained brain tissue samples with limited background staining. This novel library of sensors
outperformed gold-standard dye Thioflavin T in sensing capacities while co-staining with
conventional antibodies AT180 and 4G8. The OPEs readily bound protein aggregates in vitro
and ex vivo, they are selective and rapid tools for identifying neurological protein inclusions.
Such OPEs can be useful in understanding pathogenesis and in creating in vivo diagnostically
relevant detection tools for these diseases.
5.2 Introduction
Proteinaceous deposits composed of rich beta-sheet structurers have become a hallmark
for neurodegenerative disorders. Following DNA translation, proteins are folded into their
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functional structure guided by thermodynamic interactions and with the help of other
chaperone proteins. Many proteins, independent of their amino acid sequence are driven by
poorly understood inter- and intramolecular forces to misfold leading to the formation of toxic
oligomers and then stable large beta-sheet rich protein aggregates19,216–218. Such is the case for
amyloid-beta (Ab) and tau proteins as they relate to Alzheimer’s Disease (AD) and other
tauopathies, respectively.
The Ab peptide varies in length, 36-42 amino acids, and is cleaved from the amyloid
precursor protein by the gamma-secretase. This peptide’s presence and function in the
neurological system is still debated but theories explain that it could be a metabolic by-product
with erratic pathological effects or also an antimicrobial peptide evolutionary derived for
innate immunity.219 Misfolded amyloid-beta (Ab) protein can aggregate extracellularly to
form senile plaques which are the pathological signature confirming Alzheimer’s Disease
(AD). Tau protein is expressed in the central nervous system and serves to promote
microtubule assembly and stability. There are six isoforms of the protein caused by alternative
splicing of the MAPT gene19 causing different protein sizes (352-441 a.a.). Its instability is the
result of an uncontrolled phosphorylation cascade108,220

This in turn increases its non-

microtubule bound state resulting in its intracellular aggregation to form neurofibrillary tangles
(NFTs). NFTs have been observed in a range of tauopathies including frontal temporal
dementia (FTD), Parkinson’s Disease, trisomy-13, and traumatic brain injuries, amongst
others. The protein aggregation process is a large topic of research that comes up in
neurological disease and pharmaceutical protein preparations221–224. This process has been
observed to appear prior to the symptomatic stage in neurodegeneration. Due to the damage
caused by the protein aggregation and the detrimental neurological effects caused by this, there
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is a need for a diagnostic tool capable of detecting protein misfolding and aggregation in the
early aggregate stage21.
The current state of technology for the detection of these amyloids, protein aggregates,
is limited to the use of stains Thioflavin T and Congo Red18,127,223. The molecular structure
generally consists of a rigid rod-like, conjugated, hydrophobic backbone that planarizes upon
binding to a b-sheet fibril, the hindered rotation causes a fluorescence response67,225,226.
Although not applicable for use in vivo, the structure has served as a springboard for a new
generation of diagnostic PET ligands aimed at visualizing protein amyloid plaques in the brain.
First came Pittsburgh Compound B, followed by FDA approved [18F] Florbetapir, [18F]
Florbetaben, and [18F] Flutemetamol227–229. The use of these PET agents is still limited to
confirm or rule out an AD diagnosis but cannot detect the presence or lack thereof, of other
protein aggregate populations. Tau NFT PET ligands are an expanding area of research.
Development of in vivo imaging agents targeting the identification of tau aggregate protein
conformations, over Aβ, include quinoline and benzimidazole derivatives, arquiline
derivatives, pyrido-indole derivative AV-1451, and the phenyl/pyridinyl-butadienylbenzothiazole/benzothiazolium -BB3 derivatives however a large part of this technology
remains in the research stage36,38,230–232. This field of detecting tau filaments is increasingly
relevant since NFT burden has been more closely linked to the cognitive decline and disease
prognosis in Alzheimer’s patients than amyloid-β plaque load or empirical symptom
observations233–235. Existing diagnostic efficiency lacks in its ability to prevent or halt
progressing pathology
Based on these limitations, there is an urgent need for the development of in vivo broad
protein aggregate sensing agents to aid in the understanding of the pathophysiology involved
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in dementia presented with protein aggregation comorbidities. Present protein aggregate
sensor development includes the synthesis and characterization of various classes of
compounds. Luminescent conjugated oligo-and polythiophene (LCOs, 20-23 LCPs, 24-26 and
bi-thiophene-vinyl-benzothiazoles bTVBTs 27) have been introduced for broad amyloid
identification122,236–238. Moving towards the development and introductions of more clinically
relevant sensors we previously tested a small library of synthetic polyelectrolytes, oligo-pphenylene ethynylenes (OPEs) ranging in size and electrophysical properties for their
specificity and affinity towards β-pleated sheets found in diseased proteins using two amyloid
protein models, bovine insulin and hen egg white lysozyme128. OPEs also have conjugated
backbones with rigid rod structures however they can be synthesized to include capping end
groups, charged side groups, and varying lengths, which have all been found to play a role in
the molecule’s solubility, fluorescent state, the affinity and selectivity for certain protein
conformations, and its binding capacity to the binding hydrophobic groove identified on the
backbone of fibrillar protein conformations40,74,135,239. From the library screening we identified
two small molecules, cationic OPE24+ and anionic OPE12- shown in Figure 5-1.42,135. Further
in vitro characterization included evaluating binding activity of these two sensors with
pathologically relevant proteins (Aβ40, Aβ42, α-synuclein wildtype, E53K, A30P, and A53T)
in their fibrillar and monomeric states. This research displayed OPEs superior sensing
capacities for pathological fibrils and pre-fibrillar aggregates in vitro compared to Thioflavin
T (ThT)240.
In this project we characterized, OPE12- and OPE24+, for their sensing capacities
towards tau tangles in transgenic mice model rTg4510, human frontotemporal dementia postmortem brain tissue, and Ab plaques in transgenic rat model TgF344-AD. OPE12- selectively
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detected NFTs ex vivo in both transgenic mice and human tissue. OPE24+ also bound NFTs in
mice and detected plaques in the rat tissue. We confirmed the OPEs binding to aggregates by
performing colocalization studies using protein specific antibodies AT180 and 4G8 for tau and
Ab respectively and protein structure by co-staining with Thioflavin T. Our results pose OPE
molecules as broad viable protein aggregate sensors with further research opportunities
regarding diagnostic applications towards treating neurological amyloidosis.

OPE12-

OPE24+

Figure 5-1 Molecular structures of oligo-p-phenylene ethynylenes (OPEs). OPE12- is a single
repeat unit sensor with sulfonate groups on its side chains. OPE24+ has two repeat units and
quaternary ammonium groups on its side chains. Both sensors have a conjugated backbone
with carboxy-ester end groups. These chemical moieties play a role in its detection capacity
and fluorescent signatures.
5.3 Results
5.3.1 OPEs are selective sensors of brain derived PHFs in vitro
We tested the two OPE’s selectivity and efficacy towards extracted tau paired helical
filaments (PHFs) in an in vitro assay. PHFs were extracted and isolated from transgenic mice
and FTD human tissue with the Sarkosyl-insoluble extraction protocol as previously
described241. The monomeric protein control was the longest tau isoform, recombinant tau44113. Extracted protein morphology and identity was confirmed using transmission electron
microscopy (TEM) images and western blot analysis with anti-tau Tau 12 antibody, specific
for the N-terminus of the human tau protein (Figure 5-2) The TEM displayed the extracted
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PHFs as long, twisted, fibril protein morphology from the mice and human samples (Figure
2A-B) and the western blot identified PHFs as seen by a band between 49-62 kD.
A. Mouse PHF

B. Human PHF

Control

Mouse Human
PHF
PHF

C. Tau 12

Figure 5-2 Transmission electron microscopy (TEM) images of brain derived paired helical
filaments (PHFs) and western blot analysis. A. TEM of (concentration) PHF isolated from 9month rTg4510 mice. B. TEM of (concentration) PHF isolated from human patients diagnosed
with frontotemporal dementia C. Western blot analysis of brain lysates with Tau12 to identify
the protein in the mice and human samples as human tau, through its specificity for the Nterminus. The mouse PHF was loaded at 10 times the human sample concentration.
When the OPEs are solubilized in water, following excitation, energy can be dissipated
through the solvent at the carboxy ester end groups, via nucleophilic attack from the water and
free rotation of the backbone72. OPE to fibril complexation is guided by Coulombic
interactions, hydrophobic interactions, and electrophile/nucleophile interactions74. As the
backbone of the OPE binds to the fibril, the rotation is limited and the now bound OPE can
also serve as a nucleation site for dye-dye stacking. We added OPE12- or OPE24+, at 1.6 µM,
with proteins, at 6.67 µg/mL, and measured the OPE fluorescence (Figure 5-3). In the emission
spectra, OPE12- in its unbound and non-complexed state, displays a smooth and minimal
fluorescence intensity (Figure 5-3B). In solution with tau-441 monomers there is a slight
increase in fluorescence, about 2000 fluorescence counts/second, and a red shift, centered
around 470 nm. In a solution with either mice or human PHFs, OPE12- ‘s fluorescence intensity
increases about ten-fold to the highest peak at 440 nm and five-fold to the 470 nm peak, using
the monomeric spectrum as baseline. OPE12- displayed selectivity for the fibril morphology
over the monomer protein. These sharp and broad spectral signatures indicate the formation of
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J and H aggregates, respectively, likely arising from different binding sites on the fibril surface
and OPE nucleation sites forming dye arrangement complexes242. The main theorized
differences in the dye stacking conformation lie in the dye molecule arrangement, “head to tail
staircase” or “ladder”74,243. These supramolecular aggregates serve as spectral modes of
molecular sensing which could provide insight and molecular signatures of fibril backbones.
To detect and quantify OPE’s fibril protein morphology selectivity we calculated an Amyloid
Detection Factor (ADF)135 defined as
𝐴𝐷𝐹 =

6*0-)$17$.7$ 8.9$.1'9#!"#$%&'(&) 2 6*0-)$1$.7$ 8.9$.1'9#!"#$*+,+*#(
6*0-)$17$.7$ 8.9$.1'9#!"#$*+,+*#(

.

Based on this calculation, ADF values >1 would indicate selective detection of the fibrillar
protein, ADF <-1 is selectivity for the monomeric protein conformation and -1 < ADF < 1
indicates no selective sensing. The calculated ADF values for OPE12- are a confirmation for
the visualization, OPE12- selectively detects the fibrillar protein morphology over the
monomeric (ADFOPE1:mousePHF 2.74 and ADFOPE1:humanPHF 2.62), Table 1.
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Figure 5-3 Fluorescence excitation and emission spectra of OPE12- and OPE24+ in solution with
extracted tau PHFs or full-length recombinant ta-441 monomer. The background fluorescence,
sensor alone in 10mM phosphate buffer pH 7.4, is represented by the black curve. OPEs in the
presence of recombinant tau-441 monomeric protein is shown by the green curve. OPEs in
solution with mice derived PHFs are show in red and in solution with human derived PHFs are
in blue. OPE concentration for this assay was set at 1.6 µM and proteins concentration was
6.67 µg/mL. OPE12- lexcitation: 360 nm lemission: 440 nm OPE24+ lexcitation: 370 nm lemission: 460
nm

Table 5-1 Amyloid Detection Factor (ADF) of OPE12- and OPE24+ for mice and human derived
PHFs

Mouse PHF

Human PHF

OPE12-

2.74

2.62

OPE24+

-0.21

0.55
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We did not observe the same turn-on event in the presence of PHFs with OPE24+ as we
did with OPE12- (Figure 5-3 C-D). There is a larger increase in intensity from the monomeric
background to the human PHF sample a spectral peak rise after 450 nm for both mice and
human PHF proteins. The tau monomeric protein carries a positive charge at physiological pH
7 which could attract the OPE24+ to bind and cause some fluorescence enhancement. This
sensor-monomer interaction also serves to shift the ADF value toward a negative value. The
difference between monomer and fibril fluorescence intensities is not large enough to yield >1
ADF values. The lack of selectivity towards the extracted PHF fibrils selectivity could be
attributed to the larger molecule size, it may have a harder time fitting into a binding groove
formed on the PHF fibril surface, or the electrostatic environment imposed by the quaternary
ammonium groups, or possibly its instability in solution causing it to aggregate on its own
resulting in the high background and leaving fewer molecules to insert into protein binding
sites.65,67,128. Even so, the sensor bound more actively to the human derived protein versus
mice derived likely due to fibril polymorphism giving rise to morphologically different
binding136,217. The in vitro results validated OPEs efficacy for the detection of paired helical
filaments derived from tissue. With this knowledge we moved forward to test the sensors ex
vivo detection proficiency.
5.3.2 OPE12- and OPE24+ ex vivo detection of NFTs in rTg4510 mice and human FTD
brain sections
To validate OPEs as selective sensors for fibrillar protein aggregates in ex vivo
environments we stained 9-month old transgenic rTg4510, 6-month old non-transgenic
C56BL/6j (B6) mice, and human frontotemporal brain sections. The rTg4510 mouse model
carries the P301L mutation in exon 10, associated with frontotemporal dementia and
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Parkinson’s linked to chromosome 17244. This model expresses human 4-repeat (4R) tau and
provides the three key elements observed in human neurodegeneration: NFT production in the
forebrain, neuron loss, and memory impairment244 while also expressing tau at thirteen times
the concentration of endogenous tau starting with occasional NFTs starting at 2.5 months
245,246

. For the mice brain sections, the animals were anesthetized and transcardially perfused

with phosphate buffer. The brain was removed with the left hemisphere immediately immersed
in 4% paraformaldehyde. For storage, awaiting analysis, the brain was place into a
cryoprotectant solutions. The brains were sectioned on a Leica Sliding Microtome 201 R into
30 µm sections. The sections were stained with a free-floating protocol. OPEs were diluted
into phosphate buffered saline (PBS) to 5 µM or 0.5 µM immediately before incubation.
Thioflavin T was used at two concentrations, 5 µM to match the OPEs and then 1.57 mM to
match literature protocols using 0.05% w/v (SI)247.
OPE12- and OPE24+ detected NFTs in transgenic mice sections at both 5 µM and 0.5
µM concentrations (Figure 5-4). At the higher concentrations OPE12- showed that it bound
selectively to NFTs in the cortex with minimal background staining. The OPE dyes are excited
at 405 nm causing auto fluorescent features to be imaged, we finished our stain protocol with
a 1% Sudan Black B solution in to block out lipofuscin fluorescence. (Figure 5-4A). The
fluorescence signal observed is somato-dendritic staining, with a flame like pattern as expected
in typical patterns of aggregated tau occurring in pathologies248. In the pathological human
FTD sections we also observe OPE12- detecting occasional NFTs. The non-Tg C56BL/6j
sections did not bind OPE12- , there was no fluorescence in these samples, the stain is relatively
inert in healthy fixed tissue and it was washed out. OPE12-‘s detection in both mice and human
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species indicates that our molecule binds to aggregates formed from various protein variants,
4R proteins found in the transgenic mice and 3R and 4R isoforms in human pathology249.
OPE24+ at 5µM stained NFTs in the transgenic mice section and human FTD sections
but the fluorescence observed was higher and we observed more background staining
compared with its anionic counterpart (Figure 5-4C). We speculate that OPE24+ may be
binding to other disease related factors possibly dystrophic neurites or inflammatory
artifacts250. In the non-Tg sections there is fluorescence turn-on indicating non-specific binding
events. While the exact binding targets other than NFTs for OPE2+ are not clear, based on the
original signal observed in the brain sections of wild-type mice, it could be possible that OPE24+
may be binding to endogenous mouse tau, nuclear material, or other smaller amyloidogenic
tau aggregates251. We stained sections at 10x lower concentrations in an effort to diminish the
background fluorescence in non-Tg sections while maintaining NFT selective detection.
OPE12- staining remains robust in the transgenic mice and human sections although the
fluorescence intensity is lower (Figure 5-4B). OPE24+ at 0.5 µM displays more selectivity by
a noticeable decrease, better signal-to-noise ratio in non-NFT staining in rTg4510 and human
sections. The non-Tg staining is still present but less prominent.
For comparison, we stained the sections from the same animals with ThT at 5 µM. At
this concentration we did not see NFT detection (Figure S1 A). This, matching OPE
concentration, is 300-times lower than the average protocol found in literature 0.05% (w/v)
equivalent to 1.56 mM247. Staining these samples with a 0.05% ThT solution yielded robust
NFT detection as expected in the Tg mice and human tissue (Figure S1-B)244. For the
remainder of the study, all ThT stains were performed at the higher 1.57 mM concentration.
Due to the non-specific binding pattern displayed by OPE24+ in this animal model and the

112

definitive results from OPE12- in selectively detecting brain derived PHFs and in the brain
sections, we moved forward with colocalization studies only with OPE12-.

C56BL/6j (WT)

rTg4510

Human FTD

5 µM OPE12-

A

0.5 µM OPE12-

B

5 µM OPE24+

C

0.5 µM OPE24+

D

Figure 5-4 Confocal microscopy images taken of the cortex of wildtype C56BL/6j mice (left
column) transgenic rTg4510 mice (middle column), and human frontotemporal dementia (right
column) ex vivo brain sections. A-B. 5 µM OPE12- detects NFTs in rTg4510 mice and human
section and limited to no fluorescence in the wildtype sections. B. 0.5 µM OPE12- continues to
detect NFTs in mice and human tissue, the wildtype sections has no fluorescence at this lower
concentration. C-D. Tissue stained with 5 µM OPE24+ and 0.5 µM OPE24+. The higher OPE24+
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concentration detected NFT in mice and human in addition to non-NFT feature. The wildtype
sections displayed high levels of background fluorescence. At the lower concentration, we
maintain NFT detection and lower background non-specific staining. Scale bars 25 μm.
5.3.3 OPE12- displays a similar binding pattern to historical amyloid stain Thioflavin T
In the primary colocalization study we used 5µM OPE12- followed by1.57 mM ThT in a
free-floating protocol on the same rTg4510 and hFTD sections. Co-localization of these dyes
would validate OPEs selectivity toward beta-sheet rich protein aggregates. To visualize the
colocalization the two fluorophores were excited separately OPE12- lexcitation 405 nm ThT
lexcitation was 458 nm then the resulting images were merged to observe any overlap (Figure 5).
We observed some direct overlap (yellow, right column), between the OPE12- signal (green,
left column) and Thioflavin T fluorescence (red, middle column) on NFTs. In the mice (Figure
5A), the OPE12- channel displayed some more NFTs than did the ThT channel, however, it also
highlighted some non-NFT artifacts. Based on the seen morphology, the non-NFT binding
could be to nuclear material, as ThT has been found to be bind252. We flipped the order of stain
to see if ThT would detect more NFTs than OPE, but we saw the same pattern, more NFTs
through the OPE channel. This could serve as an indication of OPE12- ‘s higher affinity for
NFTs in rtG4510 than ThT. In the human FTD tissue, the fluorescence signal from each
channel is very similar and have almost complete overlap, the OPE12- performed on par with
the high concentration ThT stain.
Considering the excitation wavelength and emission spectra of these dyes are near each
other, we characterized single stained sections to ensure the signal we observed was not bleedthrough from the neighboring channel. Collected spectra from single stained sections was
compared to the co-stained section’s spectra (Figure 5C). Single stained OPE12- excited at 405
nm has a peak near 460 nm and a generally higher fluorescence intensity than ThT which has
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a peak near 555 nm while excited at 458 nm (Figure C1). In co-stained tissue, the emission
spectra collected from each channel mirrors the peaks and intensity difference observed in
single stained sections. Therefore, we concluded the signal emitted from co-stained tissue was
that of independent dyes and not bleed-through. These results alongside the in vitro fluorimetry
results suggest that OPE12- is a superior sensor to ThT with apparent higher specificity and
higher sensitivity towards NFTs.

5 µM OPE12-

Merged

rTg4510

A

1.57 mM Thioflavin T

human FTD

B

C1

C2

C3

Figure 5-5 Colocalization of OPE12- and Thioflavin T signal in rTg4510 mice and human
tissue sections. Tissue was stained with 5 µM OPE12- followed by 1.57 mM ThT. A. Confocal
microscope images of rTg4510 and B. human FTD brain. The green signal in the left column
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is OPE12- signal, the middle column in Thioflavin T signal in red, and the last column is the
two images overlaid to show colocalization signals in yellow. There is more NFT staining in
the OPE channels for both specie’s brain sections. Scale bars 25 μm. C. Emission spectra from
single stain and co-stained sections. C1. In blue is 5 µM OPE12- excited at 405 nm. In red is
156 mM ThT excited at 458 nm. C2. Normalized emission spectra of each dye on a co-stained
section. C3. Raw intensity emission spectra from co-stained sections.

5.3.4 OPE12- displayed colocalization with protein specific anti-phospho tau antibody
AT180
To validate OPEs selectivity towards tau NFTs, we co-stained rTg4510 and hFTD
sections with OPE12- and anti-phospho-T231 AT180 antibody. Hyperphosphorylation of tau
on threonine 231 is one of the well-established neuropathological markers of tau pathology245.
We incubated free floating tissue first with 5 µM OPE12- then AT180 (1:500) and the
corresponding conjugated Alexa Fluor 555 (AF555) (1:1000) fluorophore. We observed a
striking co-localization of the OPE12- with AT180 in the cortical neurons in rTg4510 and
cortical human FTD brain sections (Figure 5-6). Some non-NFT, based on AT180 positive
NFT staining, can be seen in the OPE channel. The OPEs are not protein specific which may
be the cause for this background signals, nuclear or cytoplasmic artifacts with hydrophobic
pockets or strong charges could bind and unquench the OPE molecules. In the human sections,
the antibody detects two NFTs and OPE12- detects part of the NFTs but the image seen in the
merged picture does not show a direct overlap in signals, close in proximity though, and limited
non-NFT OPE signal overall. We did not expect an all-inclusive signal overlap pixel by pixel
because there are factors unaccounted for, which more research is needed to resolve. For
example, there could be competitive binding events and more characterization of OPEs nonsequence specificity in tissue. The AT180 channel displays a fluorescence intensity, brighter
images, likely due to the engineered AF555 fluorophore and the AT180 specificity for the
phosphorylate tau site. For further and more accurate colocalization analysis, further
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fluorophore optimization and super resolution imaging could provide more insight. We
performed co-localization studies with anti-phospho tau antibody AT8 targeting
phosphorylated serine 202 and threonine 205 but did not observe co-localization in these
sections (data not shown). This binding site is only a couple of amino acids away from those
targeted by AT180. This lack of co-localization of AT8 and OPE12- could be caused due to
competitive binding at those phosphorylated sites, as they lay in the fibril anatomy or the
antibody and secondary fluorescent molecules may hinder the OPEs from binding to the more
preferred binding sites found closer to the core or the paired helical filaments13,253.
5 µM OPE12-

1:500 AT180

Merged

rTg4510

A

C

human FTD

B

Figure 5-6 Confocal fluorescence images of sections co-stained with 5 µM OPE12- and antiphosphor tau AT180. A. Images of rTg4510. B. Images of human FTD. The left column
displays images through the OPE channel, the middle is the AT180 antibody signal visualized
with Alexa Fluor 555, and the right column in the merged images displaying colocalization of
the two channels with a yellow tint. Scale bars denote 20 μm. C. Emission spectra of OPE12excited at 405 nm and AF555 excited at 555 nm collected from the mice section.

5.3.5 Quantitative Analysis comparing OPE12- with AT180
We compared OPE12- NFT detection to AT180 by quantifying the percent of positive pixels in
single stained sections. We took images, applied a threshold to subtract background
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fluorescence and, using Fiji’s Analyze functions, reported the number of positive pixels in the
image (Figure 5-7). OPE12- NFT detection in the cortex and the hippocampus had a large
variability, this led us to split up the quantification. The rTg4510 mice display early NFT
formation in the cortex and progressively in the hippocampus, by 9-months the animals are
severely impaired and have large degrees of neurodegeneration. OPE12- did not bind the
hippocampal NFTs as efficiently as the sequence specific AT180. We postulate that its binding
sites could be hindered or morphologically different than the older NFTs in the cortex
otherwise the lack of tissue due to degeneration leads to less staining244. OPE12- had a
significant difference between the % positive area detected in rTg4510 cortex versus the
C56BL/6j (Figure 5-7A). Similarly, AT180’s % positive area had a significant difference in
the cortex, the difference in the hippocampal detection was not statistically significant.
Generally, the OPE12- positive percentage area is higher than the AT180, likely caused by nonspecific binding that is left after subtracting the background. We have worked to characterize
binding events of OPE to a couple of proteins. Overall, OPE12- performed similar to the
antibody in detecting pathology in the transgenic animals in comparison to fluorescent signals
in the non-Tg tissue.
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A

OPE12-

B

AT180

Figure 5-7 Quantitative analysis performed on single stained sections of rT4510 mice with
AT180 or OPE12-. Single stained images were quantified (3 images taken per each sagittal
sections, 3 sections taken from 3 animals) by thresholding image to subtract background. The
percentage of positive pixels and the SEM was reported over the image area, 246 x 246 µm2.
A. OPE12- detected a larger number of NFTs in the cortex than the hippocampus, the areas
were quantified separately to observe differences between non-Tg and Tg. The fluorescence
signal detected in cortical neurons in Tg sections is significantly different than OPE12fluorescence detected in cortical neurons in the non-Tg animals. There was no difference in
between the hippocampus analysis. B. AT180 produced significantly more positive signals in
the cortex of Tg animals than the non-Tg. Representative confocal microscope images used for
the quantification. Scale bar represents 25 µm.

119

5.3.6 OPE24+ ex vivo staining of Tg344-AD rats
In previous studies we found OPEs detected in vitro Aß40 and Aß42 fibrils. The presence
of fibrils in solution would promote a fluorescence turn-on response and blue shift in the
spectra compared to the background fluorescence 240. Using the transgenic model TgF344-AD,
generated with a Fisher 344 background to have the “Swedish” mutant human APPSW and
PS1D9 mutations, we tested OPE12- and OPE24+ sensing capacity for fibril aggregate pathology
in rats. This novel rat transgenic model provides a unique opportunity for research because it
presents an animal model with the full of AD pathological markers, a human like etiology of
disease, and closer behavioral, morphological, physiological and genetic aspects 254,255. While
mice models have allowed us to explore AD, a majority of these animals are limited by their
lack of presentation of the full spectrum of disease markers such as neuroinflammation,
aggregation of phosphorylated tau, neuronal loss, and time dependent disease progression,
amongst others256. The TgF344-AD rats express 2.6 fold higher secretion of APP and 6.2 fold
increase in human PS1 abundance257,258. The tau present in the rats is endogenous tau, which
includes the same 6 isoforms as humans except in different ratios11. The pathology in this
model displays Ab plaques first, around 6 months with the plaque deposition increasing, 1082 fold, to 15-17 months as characterized by 4G8 antibody and Thioflavin S (ThS) staining257.
Endogenous rat phosphorylated tau NFTs are not confirmed until about 15 months of age258.
Spatial cognitive deficits are observed as early as 7-8 months with strong navigation
impairment at 10-11 months as tested with water maze and swim trajectories however large
cognitive declines and large pathology burdens are not observed until about 15 months of
age254. In this study we used brain sections from 10-month-old transgenic TgF344-AD and
non-Tg Fisher-344 rats. The sections through the same protocol to the mice, using a free-
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floating protocol in solutions of 5 µM OPEs, 0.05% ThT, or 1:500 dilution 4G8 antibodies. In
these animals, we visualized pathology in the hippocampus as this area is the focus for AD
involvement258.
At 10-months old these rats do not present with NFTs confirmed by a lack of AT180
signal, considering the age and previous characterizations of tau pathology (Figure S4).
Interestingly, the anionic OPE12-, had no apparent selective staining of Ab plaques or any
pathology in Tg rats while showing some non-specific staining. Based on the emission spectra,
the fluorescence collected from OPE12- is tissue autofluorescence as it has the same spectral
features as the spectra from unstained sections just with higher intensity (Figure 5-8B). The
staining pattern appears to highlight neuron bodies, based on compared H&E histological
stains or cytoplasmic condensations. The cationic OPE24+ molecule had selectivity towards the
Ab plaques (Figure 5-8B). At the 5 µM concentration we did not observe excess background
staining as we did in the mice, even in the non-Tg Fisher 344 sections. The spectra collected
from the OPE24+ Tg stained tissue, the spectral features look similar to what we see in in vitro
experiments with tau and Ab fibrils in solution.
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Fischer 344 (WT)

TgF344-AD

5 µM OPE24+

5 µM OPE12-

A

B

Figure 5-8 Confocal microscopy images of hippocampus in 10-month old non-Tg Fisher 344
and TgF344-AD rats staining for Aß pathology. A Sections stained with 5 µM OPE12- did not
detect any plaques in Tg sections. B Sections stained with 5 µM OPE24+ detected plaques by
binding strongly to the packed center of the plaque. C Emission spectra collected from stained
Tg and non-Tg sections.

Since the cationic sensor detected pathology in the rat model more readily, we moved
forward with a co-localization study using OPE24+ with 4G8 to validate the pathology
specificity staining of our sensor. The 4G8 antibody is specific the 17-24 amino acid
sequence. We stained OPE first, 1:200 4G8 second, and the corresponding Alexa Fluor 555
fluorophore at 1:1000. The OPE24+ signal was spatially correlated with the 4G8 signal around
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Aß plaques (Figure 5-9). The signal is not directly co-localized/overlapped but the OPE
sensor binds the dense core of the while the antibody finds its epitope in the diffused plaque
areas. This same staining pattern, from each sensor, is observed independently of each other,
single stained 4G8 stained sections also seem to bind diffuse plaque pathology (Figure S4
A). The dense core plaque is known to be rich in beta sheet fibrils while diffuse plaques are
more amorphous Aβ deposits 259,260. We stained the rat Tg and non-Tg sections with 5 µM
ThT and 1.57 mM ThT. The lower concentrations did have detectable fluorescence while the
higher one detected plaque occasionally and at a lower intensity than the OPE (Figure S3).

Figure 5-9 Confocal microscopy images of 10-month old TgF344-AD rats stained with
OPE24+ followed by Ab antibody 4G8 and AF555. The OPE binds strongly to the center of the
plaques while the antibody highlights the surrounding loose plaque. The scale bar represents
25 µm.
In testing OPEs with TgF344-AD rats we found that OPE24+ bound to the center of Ab
plaques, colocalizing with 4G8 antibody indicating an affinity for pathologically derived
human Ab protein. Previously we had only tested our sensors with in vitro preparations of the
Ab isoforms. We were unable to confirm a large number of NFTs with anti-tau AT180 in this
age group of transgenic rats which prevented us from testing OPEs ability to sense
phosphorylated tau in rats.
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5.3.7 OPEs are not toxic to N2a neuroblastomas
With our sights set on in vivo applications we consider it crucial to characterize the
toxicity of these novel phenylene ethynylenes. We tested OPEs toxicity on the N2A
neuroblastoma cell line via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) cell metabolism assay. This assay is based on live cells metabolizing soluble MTT and
producing insoluble formazan whose absorbance is measured at 490 nm and correlated with
cell viability261. All measurements were normalized to the formazan absorbance signal
observed from N2A cells without treatment. Cells were incubated at 37ºC, 5% CO2 in cell
media with OPE12- or OPE24+ at 1 µM, 5 µM, 10 µM or ThT at 1 µM, 5 µM, 1.57 mM for 24
hours. Following the incubation, we washed the cells with media and ran the MTT assay. We
did not observe significant loss of viability following the 24-hour incubation period from any
of the OPE concentration conditions. For ThT we did not see a loss of viability for the low
concentrations, for the high, 1.57 mM condition, we were unable to detect a positive
absorbance value at 490 nm (Figure 5-10). Cationic phenylene ethynylene possess biocidal
capacities through membrane rupture in dark conditions and singlet oxygen formation light
conditions

45,81

. Unlike bacteria, mammalian cell membranes have a large zwitterionic and

some ionic lipid composition which could lessen the electrostatic interaction between the
cationic phenylene ethynylenes the cell surface262,263.
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Figure 5-10 N2A cell viability was measured via the absorbance of MTT at 490 nm. Exposing
neuroblastoma N2A cells to OPE1- at varying concentrations (1 µM, 5 µM, or 10µM) did not
induce any detected toxicity. OPE2+ did not display any toxicity effects on N2A
neuroblastomas either. Thioflavin T was not toxic to this line of cells at 1 µM or 5 µM. We
tested the toxicity of the higher concentration Thioflavin T used for staining, 0.05% or
1.56mM, and it displayed complete toxicity on this cell line. No absorbance at 490 nm could
be detected for this experimental condition (bar not shown).

5.4 Conclusions
As our population ages, there is an increased need to develop diagnostically relevant tools to
aid in treatments for neurodegeneration. In previous work we found that these small repeat
conjugated phenylene ethynylenes have selectivity for protein fibrillar morphology, which is
relevant in the neurological diseases addressed here. In this study we worked to evaluate and
characterize OPEs capacity as an ex vivo amyloid sensing molecules. We used brain tissue
from wildtype (C56BL/6j, Fisher 344) and transgenic (rTg4510, TgF344-AD) mice and rats
along with some human tissue to incubate with OPEs and study their staining patters. OPE12selectively stained tau NFTs in mice and human tissue at 5 µM. Its positively charged

125

counterpart OPE24+ at 5 µM had non-specific binding in the transgenic and wildtype mice
sections but at a lower concentration, 0.5 µM, this problem was resolved and it too displayed
selectivity for binding tau NFTs ex vivo. We quantified the staining capacity for OPE12- in mice
and found that its staining power is higher than phosphorylated tau antibody AT180 if we
compare positive pixel counts in an image but qualitatively similar. In the same sections,
OPE12- co-localized on NFTs with AT180 or ThT for mice and human samples. In the rat AD
model OPE24+ displayed selectivity for Aβ plaques at 5 µM with minimal background
fluorescence and non-specific staining in the Fisher-344 wildtype sections. OPE24+ colocalized with Aβ specific antibody 4G8 on the same plaques but stained the core while the
antibody stained the more diffuse morphology. In the rat sections we did not observe consistent
OPE12- staining of plaques. The brain sections we had of rats did not yet display fibrillar tau
pathology for the OPEs to detect therefore we did not see NFT staining in rats. Lastly, we
evaluated the sensor’s toxicity on N2a cells using an MTT assay. Neither OPE caused loss of
cell viability through a range of concentrations, up to 10 µM.
Further ex vivo staining characterization could take place with older rat sections and a
library of antibodies to understand OPE binding sites more. Nonetheless we were able to show
that OPEs display selectivity for pathologically relevant protein aggregates in brain tissue at
magnitudes lower concentration that the current ThT standard. Ultimately this work paves the
way for the development and understanding of in vivo sensors for neurodegenerative diagnosis
as other ex vivo dye molecules have. We would like to introduce and characterize a new class
of in vivo sensors to aid in the staging of neurodegenerative disease to help patients and
physicians track clinical progression. The versatility of our OPEs opens the door for
neurodegeneration detection and general amyloidogenic disorder detection264.
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5.5 Materials and Methods
5.5.1 Dyes
OPE12- and OPE24+ were synthesized as previously reported74 and solubilized in water.
Water used was purified to a resistivity of 18.2 MW at 25ºC (Millipore Synergy UV purification
system, EMD Millipore, Billerica, MA). OPE concentrations were determined by measuring
their absorbance using UV/visible spectrophotometry (PerkinElmer Lambda 35 UV/Visible
Spectrophotometer) and extinction coefficients. For OPE12- we used extinction coefficient 3.92
x 104 L mol-1cm-1 and 8.29 x 104 L mol-1cm-1 for OPE24+. Thioflavin T was obtained from Thermo
Fisher Scientific (Waltham, MA) and used without further purification. To create the ThT
solutions, the powder was solubilized in 70% ethanol at 0.5% w/v (1.56 mM). All dye solutions
were stored in the dark, covered by aluminum foil, at -4 ֯C until use.
5.5.2 Tau441 monomers and PHF Extraction and Purification
The recombinant tau-441 monomers were provided by Dr. Rakez Kayed, prepared as
previously described265. The protein was prepared at 6.67 µg/mL by diluting in 10mM
phosphate buffer pH 7.4. Mice and human paired helical filaments were extracted through the
Sarkosyl extraction protocol as previously reported241. These procedures were carried out at
room temperature. The mice or human brain tissue were homogenized in 10 volumes of cold
buffer H (10 mM Tris-HCl, 1 mM EGTA, 0.8 mM NaCl, 10% sucrose, at pH 7.4). After
sonication and centrifugation, the supernatant was adjusted to 1% (w/v) N-laurylsarcosine and
1% β-mercaptoethanol to be incubated for 2 hours at 37 ºC with agitation. Next the solution
was centrifuged at 150,000g for 35 minutes. The pellet contained the sarkosyl-insoluble
fraction which was taken and washed multiple times in 1% sarkosyl in buffer H. Then, the
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pellet was resuspended in Buffer H with 1% CHAPS (w/v) and 1% β-mercaptoethanol (v/v) to
then be filtered through a 0.45 µM cellulose acetate syringe filters. This filtrated solution was
centrifuged at 35,000 rpm for 1 hour at room temperature. The pellet was collected and
resuspended in Buffer H with 1% β-mercaptoethanol (v/v) to be purified by layering over a
sucrose gradient and centrifuged at 35,000 rpm for 2 hours in Beckman SW 41 Ti rotor at 4
ºC. The sucrose gradient was composed of 6 mL of 50% sucrose and 4 mL of 35% sucrose in
buffer (10mM Tris 0.8 mM NaCl 1mM EGTA 0.1% β-mercaptoethanol, pH 7.4). Following
centrifugation PHFs were collected from the 35-50% layer interface with a syringe. Further
PHF purification was performed using chloroform/methanol precipitation. First with a 4:1
volumes of methanol to volume of protein is vortexed, then add a volume of chloroform, then
vortex. The sample is then centrifuged at 10,000 g for 5 minutes. The top methanol layer is
removed, and four more volumes of methanol are added, the solution vortexed and centrifuged
again at 10,000 g for 15 minutes. The PHFs are in the pellet, the supernatant is removed, the
pellet air-dried, and resuspended with cell-media. Protein concentration was determined with
a nanodrop (Thermo Fisher Scientific, Waltham, MA).
Western blot assay was carried out to confirm that the fraction isolated from extraction
was indeed comprised of the tau protein. Sample separation was performed via a 4%-12% BisTris Novex NuPage gels from Invitrogen then transferred to a polyvinylidene difluoride
(PDVF) membrane. The membrane was blocked with 5% milk then incubated with Tau12
antibody from Millipore at 1:10,000 dilution overnight followed by goat-anti mouse secondary
antibody from Jackson ImmunoResearch. For visualization the membranes were developed
using ECL reagent from Thermo Fisher Scientific with 5-minute exposures. The
immunoreactive bands were quantified using Image J software266,267.
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5.5.3 Electron Microscopy
The PHFs derived from mice and human tissue were deposited on a carbon coated cooper
grid and incubated for 5 minutes at room temperature. The solution was wicked off with
Whatman 1 filter paper. The grids were negatively stained with a 2% aqueous uranyl acetate
solution for 2 minutes. Following the stain, the grids were left to dry for at least 30 minutes
then imaged with the HITACHI H7500 transmission electron microscope equipped with an
Advanced Microscopy Sciences XR60 camera (Hitachi High Technologies Corp., Tokyo
Japan).
5.5.4 OPE toxicity on N2a through cell viability MTT assay
Neuroblastoma (N2a, ATCC®, City of Manassas, VA) cells were sustained in Dulbecco’s
Minimum Essential Medium (DMEM, ATCC®, City of Manassas, VA) supplemented with
10% Fetal Bovine Serum (FBS) and 100X Antibiotic-Antimycotic (Thermo Fisher Scientific,
Waltham, MA). The N2A cells were passaged by splitting them 1:10 cell: cell-media volumes,
incubated at 37ºC with 5% CO2. For the toxicity assay, the cells were plated on 96-well plates
at 3,2000 as live cell starting cell density and incubated over night to allow for cell attachment
in a 100 μL volume. To add the dye molecules to the cells, the cell media was switched and
replaced with 10% (FBS) Dulbecco’s Modified Eagle Medium (DMEM) plus final OPE or
ThT concentration needed, 1 µM, 5 µM, 10 µM or 1.56 mM for ThT. A 10% ethanol cell media
solution was also prepared as a negative control in cell viability. All samples were kept in the
incubator for 24 hours. To measure cell viability, cell media was replaced again with 10% FBS
DMEM and MTT (Promega, Madison WI) was added to each well. Samples were left in the
incubator for 4 hours before taking absorbance readings at 490 nm using the SpectraMax M2e
plate reader spectrophotometer. Each experimental condition was performed in quintuplets.
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5.5.5 In vitro OPE sensing
In vivo analysis was measured through fluorescence spectroscopy in quartz cuvettes using
a PTI QuantaMaster 40 steady state spectrofluorometer (HORIBA Scientific, Edison NJ).
OPEs were used at 1.6 µM and protein concentration was set at 6.67 µg/mL. OPE24+ excitation
wavelength was 370 nm and emission wavelength 460 nm. OPE12- was excited at 360 nm for
the emission spectra and 450 nm for the excitation spectra. Control OPE spectra was taken of
the dye alone in solution in 10 mM phosphate buffer pH 7.4. Recombinant tau protein (tau441) and tau oligomers were a kind gift from Dr. Rakez Kayed and were produced as
previously described265,268,269.
5.5.6 Brain Tissue Section Preparation
Transgenic tissue was from multiple 9-month-old rTg4510 and healthy control tissue
from multiple 6-month-old C56BL/6j. Following anaesthetization, mice were perfused with
phosphate buffer. As brains were removed, the left hemisphere was taken for immunochemical
assays and the right hemisphere the brains were then removed and fixed with 4%
paraformaldehyde in phosphate buffer. The brains were placed into a cryoprotection solution
(20% glycerol (v/v), 20% 0.4M Sorenson’s buffer, and distilled water) in preparation for
awaiting sectioning. A day before sectioning the brains were transferred to a cryostorage
solution (20mM phosphate buffer, 1% (w/v) polyviniylpyrrolidone-40, 30% (w/v) sucrose, and
30% ethylene glycol). To section, the brains were placed on the stage of the Leica Sliding
Microtome 2010R (Wetzlar, Germany), onto a flat surface made of frozen 30% sucrose
solution and then frozen using dry ice and ethanol. The brains were cut into 30 µm thick sagittal
sections, placed into 12-well plates into cryostorage solutions kept at 4 °C until
immunohistochemical staining was performed. In preparation to all stains, the sections would

130

be washed in PBS three times, with agitation, and blocked in standard blocking solution (5%
natural goat serum, 0.4% PBS-Triton X (EMD Millipore Burlington, MA) for one hour.
5.5.7 Ex vivo OPE and Thioflavin T Staining and Imaging
To stain the brain sections with OPEs, each OPE was diluted from the stock solutions to
5 µM with standard phosphate buffered saline (PBS) pH 7.2 The brain sections were then
immediately immersed and incubated in the staining solution for an hour at room temperature
covered by foil to prevent light exposure. The sections were then washed 3 times for 5 minutes
with PBS to remove excels dye. Thioflavin T was solubilized in 50% ethanol to a final
concentration of 0.05% (w/v) for staining. Sections were incubated with ThT for eight minutes
in the dark followed by two ten-second 80% ethanol washes then three water washes. Prior to
staining, the brain sections were washed in PBS to remove residual cryostorage solution, then
blocked with 5% normal goat serum for one hour at room temperature with rotation. Following
all staining treatments, the sections were mounted using VECTASHIELD Hard Set Antifade
Mounting Medium without DAPI (Vector Labs, Burlingame, CA) and allowed the medium to
harden at 4°C for at least 24 hours before any imaging took place.

5.5.8 Ex vivo Immunohistochemical Staining
Primary, AT180, and secondary, Alexa Fluor 555, antibodies were purchased from
Thermo-Fisher and used without further purification. AT180 was used at 1:500 and AF555 at
1:1000 dilutions from their stock (2mg/mL). Sections would be incubated in AT180 overnight
at 4°C while secondary incubation was done for one hour at room temperature in the dark.
Excess dye was removed following the incubation through PBS washes. To block lipofuscin
auto fluorescence signals, we treated the sections with a 1% Sudan Black B, purchased from
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Sigma Aldrich, solution for five minutes followed by a one minute rinse in 70% ethanol then
rinsing for five minutes in PBS five times. Following all staining treatments, we mounted the
sections using VECTASHIELD HardSet Antifade Mounting Medium without DAPI and
allowed the medium to harden at 4°C for at least 48 hours before imaging.

5.5.9 Imaging and Quantitative Analysis
All images were taken using the Leica TCS SP8 Confocal Microscope equipped with 405
nm diode laser line, white light laser, multi-argon lines, and Hybrid Spectral Detectors made
available to us through the University of New Mexico Cancer Research Center. OPE12- and
OPE24+ were excited using the 405 nm laser line with emission collected at 420-600 nm or
440-650 nm, respectively. Thioflavin T was excited using the 458 nm argon line with its
emission collected 460-650. Sections co-labeled with anti-phospho tau and Alexa Fluor 555
were excited using the tunable laser to excite the AF555 fluorophore with emission collected
560-700 nm. Initially all sections were imaged using the 20X immersion objective to identify
anatomy followed by the 63X immersion objective to collect images. Emission spectra
collected from the microscope was taken under lambda scan setting. Spectral points were taken
every 10-20 nm apart to create each spectrum.
To quantify OPE12- signal emitting from NFT-bound molecules all images were converted
to 8-bit to then apply a threshold to limit any background signal or remaining lipofuscin
fluorescence. To calculate the positive area, we used Fiji’s measure tool. The mean and
standard deviation were analyzed using Prism7 GraphPad software.

Bound OPE12-

fluorescence was activated with excitation at 405 nm and its emission collected at 420-600 nm.
OPE24+’s fluorescent properties were activated by excitation with 405 nm and emission
collected between 440-630 nm.
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5.6 Supplementary Information

Figure S1: Confocal microscopy images displaying positive control stains. In rTg5410
transgenic mice and in human FTD sections, the beta-sheet specific ThT dye co-localizes to a
small degree with tau-specific antibody AT180. Scale bars denote 20 μm.
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Chapter 6 Determining the blood-brain barrier permeability of Oligo-pPhenylene Ethynylene with the synvivoBBB microfluidic chip
Florencia A. Monge, Khe Hang Bich Bui, Devon C. Chisholm, David G. Whitten, Kiran
Bhaskar, Eva Y. Chi
(This chapter’s work was halted by laboratory closures due to shelter in place orders brought
on by the COVID-19 pandemic. Data collected are presented as preliminary data and the
future work section includes experimental next steps)
6.1 Abstract
For a century now Alzheimer’s Disease (AD) has been confirmed in tissue postmortem using
amyloid staining dyes such as Thioflavin T and Congo Red. However these results have poor
diagnostic significance. A large area of neurology research now includes the development of
biosensors for early diagnosis for neurodegenerative disorders which includes sensors which
could detect protein aggregates in vivo. Previously we have reported the use of novel oligo-pphenylene ethynylene (OPEnx) molecules as fluorescent sensors selective for fibrillar protein
pathologies in vitro with fluorimetry assays and ex vivo by staining brain tissue. In this work
we test their blood brain barrier permeability for the possible application for in vivo
visualization of protein inclusions that characterize degenerative disorders (AD and other
tauopathies). We evaluate OPEs hydrophilicity/lipophilicity through a modified partition
coefficient assay as single molecules and in complexes with oppositely charged detergents or
oppositely charged OPEs. Finally, we directly test permeability using a cell-based 3-D
microfluidic chip, Synvivo’s blood brain barrier on a chip with primary rat cells. The results
from this study will guide the research to test OPEs as in vivo protein aggregate sensors opening
the door for future sensing and therapeutic development.
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6.2 Introduction
As the first layer of defense against pathogens and harmful entities, the blood brain barrier
exists at the interface between the central nervous system (CNS) and blood circulation. The
blood brain barrier (BBB) is in part composed of endothelial cells lining the cerebral micro
vessels partnered with underlying astrocytes. This physical barrier is enforced with tight
junctions including zona occludins 1 (ZO-1), claudin-5, and occludins that connect the
epithelial cells and gap junctions separating ependymal cells and pia cells. Together these
protein complexes restrict the passage of proteins and in general hydrophilic and ionic factors
from the blood circulation into the cerebrospinal fluid (CSF)270–272. Although this highly
efficient system serves to protect and maintain homeostasis, it poses a challenge in the
development of drugs targeting the CNS. In order to enter the CNS, the molecule must be able
to permeate through the intercellular spaces composing the barrier and carry a balance between
lipophilic and hydrophilic character.
From our research we have identified two oligo-p-phenylene ethynylenes (OPEs) with
selective affinity for pathological fibrillar protein aggregates, anionic OPE12- and cationic
OPE24+

135,240

. We have used these OPEs in vitro to detect beta-sheet rich fibrils of tau

(extracted PHFs and PHF6

306

VQIVYK311), Aβ40, Aβ42, α-synuclein and ex vivo with

transgenic tauopathy mouse model rTg4510 and Alzheimer’s Disease rat model TgF344-AD
(Chapters 4-6). Based on the positive results we have seen; we are moving to further
characterize the OPE molecules for neurodegenerative diagnostic use in vivo. In vivo, animal
experiments are the gold standard however at this early stage in characterization we used an in
vitro blood brain barrier microfluidic chip. Traditional BBB models are static cell assays, such
as the Transwell, where a membrane separates neuronal cells from an endothelial layer. This

136

model lacks some relevant aspects, important in determining permeability and in vivo
microenvironments273. The synvivo BBB is a novel set up which provides a three-dimensional
blood brain barrier model with separate chambers to culture endothelial cells and cells from
the neurovascular unit (astrocytes, neurons, pericytes) that allows in vivo like interactions and
promotes healthy cell phenotypes through a porous interface and the capacity to apply shear
flow270,274–276.
6.3 Preliminary Data
6.3.1 Partition Coefficient
The partition coefficient, log (KOW) is a molecules physiochemical characteristic
indicative of solubility in two immiscible solvents, typically water and octanol. The ratio of
compound found in each solvent phase allows the calculation of KOW, a value that can serve to
predict BBB permeability based on the compounds lipophilicity 𝐾:; =

[:=>]+-./,+)
[:=>]0/.#(

. To

determine OPE’s KOW we used the well-established shake flask octanol-water partition
coefficient as previously reported277. A molecule must be lipophilic enough to be able to pass
through the lipid membrane but not so much that it is insoluble in water275,278. We compared
OPE values with that of caffeine and reported literature values (Table 6.1). Desirable log(Kow)
values for CNS targeting drugs would be 1 to 3 values and compounds with values below 0
are susceptible to renal clearance278. Our calculated values (<0) were outside the desired range
for CNS uptake. However, our experimentally measured values for caffeine was also out of
range of reported literature values (-1.38 vs. -0.09 to 0.8). These issues are likely caused by
our experimental set-up. During the collection of the absorbance samples post shaking, the
absorbance readings we were measuring were noisy and unlike expected spectra for OPE and
we were not able to define an extinction coefficient for these molecules in water saturated with
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octanol preventing us from defining concentration of the molecules in the water layer post
extraction. Instead, we moved forward by performing a more qualitative analysis of OPEs in
the octanol-water mixture. For this, we took advantage of the OPE’s molecules unquenching
in organic solvents and turn-on fluorescence mechanism when complexed with oppositely
charged detergents 78,134. The experimental set-up was similar to the shake-flask method with
the exception of a 15 mL centrifuge tube instead of a separatory funnel. This change facilitated
removing the emulsion at the octanol-water interface. We centrifuged the samples if the
emulsions did not disappear after a couple of days. We tested single OPEs, OPEs in addition
to oppositely charged detergents, and an OPE12—OPE24+ complex. We hypothesize the
complexes are characterized by a higher lipophilic character and reduced charged leading to
higher transfer into the octanol layer. To complex OPE12- we used positively charged
dodecyltrimethylammonium bromide (DTAB) and for OPE24+ we used negatively charged
sodium dodecyl sulfate (SDS).
Table 6-1 Shake flask derived log(Kow) values.277,278
Log(k)

Literature
values

OPE12-

-1.38

-

OPE12- + CTAB
5:1

-1.09

-

OPE24+

-1.51

-

Caffeine

-1.38

-0.09 to 0.0800

To form OPE-detergent complexes, we began making neutralized solutions by matching
the charges on OPE molecules with the detergents. In a similar fashion of matching charges on
OPEs to detergents we also thought to make an OPE:OPE complex hypothesizing that
cancelling the charges would provide a more lipophilic, more BBB permeable scenario. First
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is the OPE12-:DTAB solutions, Figure 6-1. Since the OPE-detergents solutions are solubilized
in the water first, fluorescent OPE is in the bottom, water layer before shaking as seen in the
top row of pictures. For OPE12- and OPE12-:DTAB solutions we observed the highest transfer
of fluorescence to the octanol layer with the higher detergent rations 1:10 and 1:100. At a
1:2000 OPE12-:DTAB ration, data not shown, we saw loss of fluorescence in octanol. The OPEdetergent complex serves to unquench and ‘deliver’ OPEs into the octanol. At higher detergent
ratios, detergent-detergent complexes are likely more abundant leaving OPE in the water phase
while the overall positively charged and small OPE-CTAB complexes at low ratios move into
octanol together. (DTAB critical micelle concentration 14 mM279).

Figure 6-1 Images of OPEs, CTAB, SDS, OPE12-:DTAB, OPE24+:SDS, and OPE12-:OPE24+
solutions in water-octanol partition under UV irradiation. The OPE-detergent complexes were
set with OPEs 1 µM and the detergent concentrations increasing from the charge neutralization
point. The solutions at 1:10 and 1:100 ratios had the most OPE12- transfer into the octanol layer
based on the fluorescence display in the top layer of the tube.
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To match OPE24+ we used a 1:4 ratio with SDS. Unlike the OPE12-, OPE24+ partitioned
into the octanol alone at 1 µM, in the neutralized 1:4 ratio solution, and the low 1:10 OPEdetergent ratio while progressively loosing fluorescence intensity as the detergent
concentration was increased, Figure 6-1. We hypothesize that the size of the sensor backbone
dictates its interaction with the detergent and octanol yielding these results. OPE12- is a single
repeat molecule which could need more detergent to create a lipophilic enough complex to
move into octanol while OPE24+’s longer backbone is enough for some partition without the
aid of detergent but if some is present this effect is exacerbated.
Lastly, the set-up using OPEs to complex with each other OPE24+:OPE12- only showed
partition with a 1:1 ratio, Figure 6-1. Similar to the OPE12- with DTAB condition, increasing
the positive charge or simply the number of molecules with longer hydrophobic backbones
might push the equilibrium of this solution to have more OPE in the octanol. With the
encouraging transfer of OPE into the octanol channel via complexation with detergent or other
OPE molecules, we moved forward to test these solutions through the synvivo BBB chip.
6.3.2 SynvivoBBB
The synBBB chip can recapitulate the general properties of BBB permeability
without the expense and difficulty associated with animal models. Pharmacokinetic
measurements can be made through this methodology. The system is designed to model the
neurovascular unit by having neural cells in the tissue compartment and endothelial cells in
the outer ‘vascular’ channels. The inlet and outlet tubing allow not only for seeding the chip
with cells but also applying constant flow to cells to induce tight junction endothelial cell
morphology, Figure 6-2. Following successful cell seeding, fluorescent solutions, such as
OPEs can be injected into the inlets of the vascular channels and if the molecules are
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permeable through the blood brain barrier, or in the case of the chip the pores and barrier
created by the cultured cells, fluorescence will be observed in the inner tissue compartment.
If the OPE fluorescence is enclosed to the apical chamber, it would indicate none to little
permeability through the BBB. However, if fluorescence is observed in the central chamber it
would indicate the OPEs crossing the engineered BBB and interacting with brain tissue cells.
This platform also provides fitting models to determine permeation rates which we can
utilize to further characterize our sensors.

Inlet
ports

Outlet
ports

Figure 6-2 Synvivo BBB schematic and illustrations. From Deosarkar S et al. 2015 PLOS
ONE. A&B Schematic of BBB and illustration showing cells in the vascular (blue) and tissue
compartment (red) C BBB chip shown with tubing and blue dye. The tissue chamber is 1575
µm(d) x 100 µm(h), the vascular chamber is 200 µm(w) x 100 µm(h) x 2762 µm(l), and the
pores are spaced at every 50 µm and sized 3 µm(w) x 3 µm(h) x 100 µm(l).

To culture cells onto the chip, we purchased rat brain microvascular endothelial cells
(RBME) and rat astrocytes from Cell Applications and followed their Cell Culturing Protocol
and synBBB culturing protocol previously established274,276,280. Ultimately, we aimed to have
complete RBME coverage in the outer vascular channels and dense astrocyte coverage in the
tissue chamber. Briefly, we coated chips with rat fibronectin (40 µg/cm2) overnight at 4º C,
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then again for 30 minutes right before seeding with cells. To seed cells we triptynized cell
cultures and flowed this solution (1.6-1.7 x 107 cells/mL) through the chip at 5 µL/minute until
cells reached 50-80% confluency. To finish we sealed off the tubing and incubated the chips
at 37 ºC for cell attachments, at least 24 hours before any other treatment.
In our first round of seeding cell on the chips we ran into some problems with the
established protocols. Images from the chips are shown in Figures 6-3 and 6-4. As it stands,
the protocol calls for seeding cells under flow. During the seeding of RBME cells, we observed
the cells through a light microscope and at the recommended 5 µL/min rate. The cells would
flow right through the chamber and if the flow is set for too long, the inlet tubing would be
blocked off by cells after a couple of minutes. Only a slight amount, ~10% confluency, of
RBME cells stayed in the vascular channel after closing of the tubing. There were two different
chip set-ups, RBME cells only and RBME/astrocyte co-cultured, and different stains were used
to visualize RBMEs, astrocytes, tight junctions, and nuclear features. All of the stains on one
chip would have overlapping emission so we split up the stains between these two differently
cultured chips to identify cells through cell specific markers (co-cultured chips) and visualize
tight junction expression (RBME only). To image the RBME only chip we fixed the cells with
4% paraformaldehyde, permeabilized with 0.1% Triton-X and incubated cells with AF488
Phalloidin, for imaging filamentous actin and with DRAQ5 for imaging the nucleus. Cells were
rinsed with PBS prior to imaging. The co-cultured chip was fixed and permeabilized following
the same procedure however we used GFAP and ZO-1 with secondary fluorophores, and
nuclear stain Hoechst 33343. Coating the chips with fibronectin should serve as an attachment
factor since fibronectin plays a large role in cell adhesion and migration. Although the chips
were coated twice, we did not have successful RBME attachment in the synBBB vascular
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channel with an active flow rate. In our image, Figure 6-3, we expected to observe filamentous
actin (green) but we only saw the occasional green bright spots in what appears to be the pores
between vascular and tissue chambers. The co-cultured chip was further subjected to flow rates
during incubation but after cells were given days to attach in order to induce tight junction
formation in the RBME. We did observe astrocytes in the tissue chamber (green) although low
in numbers. We did not observe tight junctions (red) but it is likely due to the lack of RBME.

RBME only

Co-cultured chip
Vascular Channel
Pores
Tissue Channel

Vascular Channel
Pores
Tissue Channel

Figure 6-3 Fluorescence images of synBBB chips cultured with endothelial cells and
astrocytes. Two chips were treated separately, one was cultured with RBME only (left) and the
second one was cultured with RBME and astrocytes (right). The chips were fixed and stained.
RBMEs were stained with filamentous actin stain (AF488 phalloidin) green and DRAQ5 in
blue. The co-cultured chip was stained for astrocytes with GFAP in green, Hoeschst 33342 in
blue, and tight junctions ZO-1 in red.

To move forward with testing permeability we had a chip co-cultured simultaneously with
the one fixed and imaged in Figure 6-3. Rather than fixing it, we kept the cells alive and flowed
an OPE solution through (2 µM OPE12-, 1 µM OPE24+) at 0.2 µL/min, Figure 6-4. Prior to
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imaging, the cells were in cell media in the incubator and we flushed the chip with PBS right
before. A syringe connected to tubing was flushed with OPEs and connected to the chip. We
took snapshots of the synBBB chip at 15, 30, and 45 minutes. At time 0 we can see fluorescent
punctate in the solution, the OPE complexes. At the 15-minute timepoint it appears one of the
fluorescent complexes made it through a pore, the pores are spaced at every 50 µm and are 3
µm in size, and onto the other side however at the 30 and 45 minute times. This fluorescence
does not disperse through the tissue chamber. As the time passes with flow, the fluorescent
points aggregate at the pores but do not go through. This chip is likely to have been missing
RBME cells in the vascular channel, as the previous chips were. The lack of fluorescence in
the tissue chamber could be due to the large OPE complex size, but it is difficult to draw
conclusions from this single experiment since we do not have RBME, the astrocyte cell density
is lowered, and further OPE complex size characterization needs to be carried out.

No flow

Vascular
chamber

t=0

t = 15 min

t = 30 min

t = 45 min

Tissue
chamber

Figure 6-4 Fluorescent images of co-cultured synBBB chip with OPE complex flow for 45
minutes. A 2:1 OPE12- to OPE24+ solution was flowed through a co-cultured synBBB chip at
0.2 µL/minute at room temperature. The images were composed by exciting using a 405 nm
diode laser, collecting emission at 400-600 nm, and taking snapshots at each time point.
6.4 Future Work
Due to the COVID-19 pandemic that promoted ‘stay at home’ orders during the 2020 Spring,
these experiments were halted and as of May 2020 could not be continued. The primary
endothelial and astrocytes had been split upon receiving the and aliquoted with these aliquots
stored in liquid nitrogen dewars.
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The primary set of experiments in future work would include troubleshooting cell
seeding on the synBBB chips and OPE complex size characterization. For increasing the cell
density our protocol changes were to load the cells onto the chip without the pump, manually
pressing the syringe while watching the cells through a light microscope. The lack of constant
flow could provide more time and connections for the cells to form attachments aided by the
fibronectin layer. Secondly, we are looking to seed cells twice simply to increase the number
of cells (from 106 cells/mL to a total of 108 cells/mL seeding concentration) and create a strong
layer of RBME in the vascular chambers and fill the tissue chamber to more closely mimic
BBB environment. Ultimately we are working to replicate the cell density seen in published
results prior to continuing the permeability assays274. Based on the quantitative partition
coefficient data we would like to test OPEs in detergent complexes, single OPEs, and more
OPE12-:OPE24+ ratios.
The preliminary results presented here lay out the future for this project. The results
should provide us with an idea and future directions for the use of OPEs as selective fibrillar
protein aggregates sensors in in vivo and possibly more diagnostically relevant scenarios. If
neither of the presented OPE molecules display permeability under the presented conditions, a
screening could be done with a larger library of OPEs focused on small, hydrophobic
molecules. Additional characterization of OPE complexes should be performed to determine
size (dynamic light scattering), fluorescence (fluorimetry), protein binding (fluorimetry with
solutions containing various proteins), and selectivity.
6.5Materials and Methods
6.5.1 General
OPE12- and OPE24+ were synthesized as previously reported and solubilized in water74. Water
used in all experiments was purified to a resistivity of 18.2 MW at 25ºC (Millipore Synergy
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UV purification system, EMD Millipore, Billerica, MA). OPE concentrations were determined
by measuring their absorbance using UV/visible spectrophotometry (PerkinElmer Lambda 35
UV/Visible Spectrophotometer) and extinction coefficients. For OPE12- we used extinction
coefficient 3.92 x 104 L mol-1cm-1 and 8.29 x 104 L mol-1cm-1 for OPE24+. All dye solutions were
stored in the dark, covered by aluminum foil, at -4 ֯C until use. SDS, DTAB, were purchased
from Sigma Aldrich (St. Louis, MO) and used without further purification. 1-octanol was
purchased from Alfa-Aesar (Haverhill, MA)
6.5.2 RBME and RA culturing
Rat Brain Microvascular Endothelial Cells (RBME), Rat Astrocytes (RA), RBME and RA
growth media, Trypsin/EDTA, Trypsin neutralizing solution, and HBSS (sub-culture reagents)
were all purchased from Cell Applications, Inc (CAI, San Diego, CA). The RBME cells were
received cryopreserved in the their 3rd passage, the RA were received cryopreserved in the 2nd
passage. Thawing and sub-culturing protocols were taken from the Cell Applications, Inc.
Reagents were thawed at 4 ºC but not warmed to 37 ºC, all of the experiments were performed
in a safety cabinet. To thaw and culture the cells the cryopreserved vials were taken from the
liquid nitrogen dewar and thawed quickly by placing the lower half of the vial in a 37 ºC water
bath for 60-90 seconds. For RA’s the cell suspension was placed into a T-75 flask containing
RA Growth Medium 15mL of RA Growth Medium. The cells were incubated at 37 ºC, 5%
CO2, and humidified for 24 hours to allow attachment. After 24 hours the growth medium was
changed to removed DMSO traces. After this the medium was changed every other day until
cells reached 60% confluency. Cells were sub cultured when RA’s reached 80% confluency.
To sub-culture RA’s, the cells were washed with HBSS, trypsinized, the neutralized with a
trypsin neutralizing solution from Cell Applications, Inc. The neutralized solution was
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transferred from a flask to a conical tube in which it was centrifuged for 550 minutes to pellet
cells. We removed the supernatant and resolubilized the cell pellet with RA growth medium.
We inoculated at 3000 cells per cm2 on a T-75 flask. For RBME’s the T-75 flask was coated
with CAI Attachment Factor Solution for 30 minutes at 37 ºC at 1mL per 10 cm2. After
removing this solution, we add 15 mL of RBME Growth Medium to which we add the freshly
thawed RBME cell suspension. The cells were incubated at 37 ºC, 5% CO2, and humidified
for 24 hours to allow attachment. After 24 hours the growth medium was changed to remove
DMSO traces. After this the medium was changed every other day until cells reached 60%
confluency. Cells were sub-cultured when RBME’s reached 80% confluency. To sub-culture
RBMES, the cells were washed with HBSS, trypsinized, the neutralized with a trypsin
neutralizing solution from Cell Applications, Inc. The neutralized solution was transferred
from a flask to a conical tube in which it was centrifuged for 550 minutes to pellet cells. We
removed the supernatant and resolubilized the cell pellet with RBME growth medium. We
inoculated at 10,000 cells per cm2 on a T-75 flask.
6.5.3 synBBB culturing and staining
AlexaFluor488 Phalloidin, Hoechst 3343,

Rabbit-Polyclonal

anti-ZO-1

antibody,

AlexaFluor488 goat anti-rabbit IgG secondary antibody, 10% Normal Goat Serum, and
AlexaFluor594 goat anti-rabbit IgG secondary were purchased from Life Technologies
Corporation (Carlsbad, CA). Anti-GFAP rabbit polyclonal IgG was purchased from
BioLegend (San Diego, CA). Triton X-100 was purchased from EMD Millipore (Burlington,
MA).
Prior to cell seeding, the synBBB chips were coated with rat fibronectin 40 µg/cm2
overnight at 4 ºC. The next day, the device was brought up to room temperature and coated
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with fibronectin 40 µg/cm2 again for 1 hour. The device was flushed with RA growth medium
and incubated at 37 ºC, 5% CO2 for 1 hour. Prepare astrocyte solution from confluent culture
to a 1.75 x 106 cells/mL density and inject into the tissue compartment at 5 µL/min with a PHD
Harvard Syringe Pump (Harvard Apparatus Holliston, MA). When astrocytes reach 50-60%
confluency, close the inlet and outlet tubes to the tissue compartment. To seed the vascular
channels, replace the medium with RBME growth medium, and inject RBME solution with
1.6 x 106 cells/mL RBME concentration. Inject solution into vascular channels at 5 µL/min
with a PHD Harvard Syringe Pump until cell reach 80-90% confluency. The chips were kept
in the incubator at 37 ºC, 5% CO2 overnight to promote cell attachment. The RBME only chip
was kept in the incubator for two more days beyond attachment with media change every day.
For the co-culture chips, after cell attachment the vascular channels were hooked up to the
PHD Harvard Pump and a 0.2 µL/min flow was applied for two days. The chips were in the
incubator and connected to syringes on the pump outside. Syringes with fresh media were
replaced each day and the syringes were covered in foil to limit light exposure.
The RBME only chips were fixed and stained to visualize filamentous actin and nuclear
material. The cells were fixed with 4% paraformaldehyde at room temperature for 10 minutes
then permeabilized with 0.1% Triton X-100 for 10 minutes. To stain, we used AF488
Phalloidin at a 1:20 dilution, in PBS to stain the cytoskeleton for 1 hour. The chip was rinsed
with PBS and then stained with DRAQ5 DNA at 1:80 dilution in PBS for 15 minutes. The chip
was washed one last time with PBS for 15 min, flushed with fresh PBS and closed off the
inlet/outlet tubing. The co-cultured chip was stained for astrocytes and tight junction. The cells
were fixed with 4% paraformaldehyde at room temperature for 10 minutes, permeabilized with
0.1% Triton X-100 for 10 minutes and blocked with 10% natural goat serum in 1xPBS at room
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temperature for 1 hour. In the vascular channel we added ZO-1 rabbit polyclonal antibody at
1:100 dilution in PBS overnight at 4 ºC. Next, we stained with AF594 goat anti-rabbit IgG
secondary at 1:1000 dilution in PBS for one hour at room temperature. In the tissue chamber,
for astrocytes, we used anti-GFAP at 1:250 in PBS overnight at 4 ºC. Next we used AF488
goat anti-rabbit at 1:1000 for 1 hour in the dark. Lastly, we stained the nucleus of cells in the
whole chip with Hoechst 33343 nuclear stain in PBS at 37 ºC for 10-15 minutes. The cells
were washed with PBS for 15 minutes and a last PBS rinse before closing off the inlet/outlet
tubes.
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Chapter 7 Characterization of a Luminescent Sensor for Selective
Detection of Amyloid Aggregates and Pharmaceutical Protein Aggregate
Applications
Adeline M. Fanni§, Florencia A. Monge§, Daniel Okoye, Gary A. Rosenberg, Kiran
Bhaskar, David G. Whitten, and Eva Y. Chi.
§

AMF and FAM equally contributed to this work

(This chapter has been edited to include pharmaceutically relevant protein aggregates. It was
previously titled Characterization of a Luminescent Sensor for the Selective Detection of
Amyloid Aggregates in Cerebrospinal Fluid)
7.1 Abstract
In this study, we reported the sensing properties of a fluorescent probe, oligomer p-phenylene
ethylene (OPE), for its diagnostic use in detecting neurodegenerative relevant protein
aggregates and aggregates affecting pharmaceutical protein solutions. We characterized the
detection of a large array of amyloid aggregates in phosphate buffer (PB) and biologically
relevant CSF. Amyloid aggregates deposition in the brain and an increase in amyloid-β
oligomer concentration in cerebrospinal fluid (CSF) in the pg/mL range have been correlated
with cognitive impairment which makes them ideal biomarkers for early Alzheimer’s disease
(AD) diagnosis. We also investigated OPE for the detection of pathologic oligomers in CSF
isolated from patient diagnosed with dementia through the Aβ-protein misfolding cyclic
amplification (Aβ-PMCA) assay. Two oppositely charged OPE were tested, the negatively
charged OPE12- and the positively charged OPE24+. In phosphate buffer OPE12- was a superior
sensor for the detection of a large array of amyloid aggregates compared to OPE24+. In fact,
OPE12- detected fibrils made of insulin, lysozyme, Aβ40 and PHF6 as well as htau oligomers,
while OPE24+ only detected fibrils composed of insulin, lysozyme and Aβ40. Despite
superiority of OPE12- in PB, this sensor was more sensitive to its microenvironment as it lost
its sensing properties in CSF, while OPE24+ maintained its selective sensing. Finally, OPE
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sensing properties were evaluated in CSF isolated from patients with dementia through the AβPMCA assay after spiking the samples with Aβ40 monomers. No detectable fibrillation was
observed neither from TEM imaging nor from OPE fluorescence. Further evaluation of the
Aβ-PMCA assay would be required to determine the feasibility of this assay to detect picogram
range oligomers. In our work to test detection of non-amyloid aggregates with bovine IgG
preparations we found the detection of these sensors is hindered in the highly viscous and
hydrophobic environment made by high concentration (>100 mg/mL) protein solutions.
7.2 Introduction
Abnormal protein misfolding and aggregation into β-sheet rich aggregates or amyloids,
is one of the main pathological hallmark of Alzheimer’s disease (AD)281,282 In AD, two main
proteins have been found to form amyloid aggregates, Amyloid-β (Aβ) and tau proteins which
accumulate under the form of amyloid plaques and neurofibrillary tangles in AD brains,
respectively5,281,283. These aggregates are produced through a nucleation-based polymerization
mechanism in which misfolded proteins aggregate into small oligomers and protofibrils which
are then used as seeds to form stable amyloid fibrils2,284–286 These aggregates have been found
to accumulate in the brain2 and more recently, Aβ oligomers have been found to increase in
cerebrospinal fluid (CSF)287,288 to reach a concentration in the order of pg/mL287. The
accumulation of amyloid aggregates in both the brain and CSF of patients suffering of AD was
directly correlated with cognitive decline and is believed to start decades before the
development of the symptoms289,290, which make them ideal biomarkers for early disease
detection.
To this day, there is a lack of a sensitive method for early diagnosis of AD. Disease
diagnosis is mainly based on symptoms evaluation and is confirmed through the detection of
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amyloid plaques in vivo which can be accomplished via Positron Emission Tomography
(PET)291–295. Additionally, other non-PET sensors such as Thioflavin T (ThT) are used for
post-mortem tissue analysis and definitive diagnosis Current PET and histological probes are
of limited application as FDA approved PET probes only detect amyloid plaques made of Aβ
protein38,63,296,297 and current histological probes are not good at detecting the early aggregates,
oligomers and protofibrils63. More studies are currently investigating the detection of Aβ
oligomers in CSF for AD diagnosis. A promising method which would ensure the detection of
Aβ oligomers at concentration as low as pg/mL is based on the Aβ protein misfolding cyclic
amplification assay (Aβ-PMCA)298,299. This method consists in using the seeding potency of
the oligomers and tracking the formation of amyloid fibrils in CSF with ThT after spiking the
sample with monomeric Aβ42299. To ensure efficient detection of protein aggregates in the
brain and in CSF, there is a need to develop new conformation-specific probe highly selective
toward amyloid aggregates made of different proteins, with low limit of detection, superior
selectivity to amyloid aggregates and low sensitivity to its microenvironment such as the
presence of glucose, salt, or non-amyloidogenic protein (albumin).
Oligomeric p-phenylene ethynylenes (OPEs) are water-soluble fluorescent probes
which were previously described to selectively detect amyloid fibrils rich in β-sheet over their
monomeric counterpart42,135,240. OPE sensing of amyloid fibrils is ensured through its
quenching by water molecules when free in solution and its large fluorescence turn-on upon
interaction to the hydrophobic β-sheet structures composing the amyloid aggregates72,74,129,133.
This fluorescence enhancement is driven by three main mechanisms: (1) hydrophobic
unquenching, (2) backbone planarization and (3) formation of OPE super-luminescent
complexes42,128,134. The negatively charged OPE12- and the positively charged OPE24+ (Table
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6-1) have been shown to detect amyloid aggregates made of a large variety of proteins: hen
egg-white lysozyme, bovine insulin, Aβ and α-synuclein proteins42,135,240. OPE12- presents high
binding selectivity toward the fibrillar conformation of all tested proteins,42,135,240 and was able
to detect α-synuclein oligomers but not Aβ42 oligomers240. OPE24+ displayed higher
fluorescence enhancement compared to OPE12- in the presence of fibrillar aggregates. OPE24+
was also better at detecting oligomers made of Aβ42 proteins240 but also presented nonselectively binding to the negatively charged insulin monomers which limited the selective
detection of insulin fibrils135.
In this study, we are evaluating the robustness of OPE for the detection of amyloid
aggregates in a complex physiological sample, CSF and non-amyloid aggregates as applied to
pharmaceutical based protein therapeutics. OPE sensing of amyloid aggregates (fibrils and
oligomers) made of a large array of proteins (lysozyme, insulin, tau and Aβ) was quantitatively
characterized in terms of selectivity, sensitivity and affinity. OPE background fluorescence
and sensing properties were evaluated in CSF. Finally, OPE sensing of amyloid oligomers in
CSF isolated from patients with dementia was investigated through the Aβ- PMCA assay.
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Table 7-1 OPE12- and OPE24+ structures. OPE12- is made of one repeat unit and present two
side chains each terminated with a sulfonate group. The positively charged OPE24+ is composed
of two repeat units and four side chains each terminated with a quaternary ammonium group.

7.3 Results and Discussion
7.3.1 Quantitative characterization of OPE sensing of amyloid aggregates
OPE12- and OPE24+ are two fluorescent probes previously described to selectively detect the
fibrillar conformation of a variety of amyloid proteins over the monomeric counterpart. To
further understand their sensing properties, we evaluated them in the presence of five amyloid
aggregates: lysozyme fibrils, insulin fibrils, Aβ40 fibrils, tau PHF6 fibrils and human isolated
tau (htau) oligomers (Figure 6-1). Tau PHF6 is the hexapeptide 306VQIVYK311 located in the
third repeat unit of the tau microtubule binding domain known to form the main core of tau
paired helical filaments (PHF),191,208 and was shown to be a relevant tau aggregation model.
This large array of amyloid aggregates was used to evaluate the robustness of OPE sensing
properties for the detection of highly polymorphic amyloid aggregates characterized by
different morphology (Figure 6-1) and net charge (Table 6-2). OPEs sensing was
characterized in terms of spectral signature, binding constant, and limit of detection. OPE12and OPE24+ fluorescence was recorded at 1 μM in the presence of the monomeric or aggregated
proteins at 21 μg/mL. OPE emission and excitation spectra are presented in Figure 6-2. To
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quantify the selective detection of the aggregated conformer over the monomeric counterpart,
we used the amyloid detection factor (ADF)

(𝟏)

𝐴𝐷𝐹 =
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(Equation 1)135,240 with F(dye in buffer), F(dye+fibrils) and F(dye+monomers) being the integrated emission
intensities of the sensor alone, sensor in the presence of fibrils, and sensor in the presence of
monomers, respectively. Based on this equation, positive ADF (>1) indicates selective
detection of the fibrillar conformers while negative value (<1) indicates higher detection of the
monomeric counterpart and ADF value close to 0 (-1<x<1) indicates no selective sensing of
either protein conformations. The ADF values generated for both OPE12- and OPE24+ are
summarized in Table 6-3.

Figure 7-1 TEM Images of lysozyme fibrils (A), insulin fibrils (B), Aβ40 fibrils (C), PHF6
fibrils (D) and human isolated tau (hTau) oligomers (E).
Table 7-2 Protein monomers characteristics: molecular weight (MW), isoelectric point (pI)
and net charge at pH7 .4
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As shown Figure 6-2, at 1 μM both OPE12- and OPE24+ were highly quenched in water
with a weak emission peak centered at 470 nm and an intensity of around 5x103 and 9x103
counts/sec, respectively. OPE quenching was assured through partial proton transfer with the
surrounding water molecules deactivating rapidly OPE excited state

83, 182 2-.

OPE1 displayed

no fluorescence enhancement in the presence of the monomeric proteins except for lysozyme
(Figure 6-2A). The weak OPE fluorescence turn-on in the presence of the monomeric
lysozyme might be driven by electrostatic interactions between the positively charged protein
(Table 6-2) and the negatively charged OPE. OPE12- displayed larger fluorescence
enhancement in the presence of all amyloid aggregates resulting in ADF values superior to 1
(Table 6-3) indicative of positive sensing. These results show that OPE12- sensing is not
affected by the charge or the morphology of the aggregates. Additionally, OPE12- was
characterized by different spectral signatures depending on the aggregates. In the presence of
fibrils made of Aβ40 and insulin, OPE12- excitation peak was red-shifted (375 nm to 394 nm)
while its emission peak was broad and blue shifted (447 nm). This bathochromic red shift
indicates the formation of J-dimers, as previously described42,240. In the presence of the htau
oligomers and lysozyme fibrils, OPE fluorescence was also characterized by a bathochromic
red shift but OPE emission was now characterized by two distinct features: one sharp peak at
442 nm and a shoulder at around 470 nm. The presence of two spectral features might indicate
two distinct binding modes. The sharper peak might be caused by the formation of more stable
J-dimers, while the shoulder at 470 nm might result from more disordered OPE complexes.
Finally, in the presence of PHF6 fibrils, OPE12- emission was red shifted (510 nm) and his peak
was broader which might indicate the formation of H-aggregates or more disordered OPE
agglomerates. The formation of H-aggregates in the presence of PHF6 fibrils might be related
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to a difference in the fibrillar structure. To better understand these different binding modes of
OPE12, the structure of the amyloid aggregates should be characterized at a molecular-level.
Table 7-3 OPE12- and OPE24+ sensing parameters – amyloid detection factor (AD), dissociation
constant (kd) and limit of detection (LOD)

In contrast, OPE24+ only selectively detected three amyloid aggregates out of five:
fibrils made of lysozyme, insulin and Aβ40 (Table 6-3). The lack of detection of htau
oligomers and PHF6 fibrils by OPE24+ might be caused by the size and/or the morphology of
the scaffold. Indeed, the small β-sheet scaffold generated by the hexapeptide PHF6 and the
globular structure of htau oligomers might not be suitable for optimal binding of the large
OPE24+ the presence of all three fibrils made of insulin, lysozyme and Aβ, characterized by a
sharp emission peak at around 450 nm and a red shifted excitation peak indicating the
formation of highly stable OPE24+ J-dimers. Finally, a weak OPE24+ fluorescence turn-on was
also observed in the presence of monomeric Aβ and monomeric insulin which might be due to
electrostatic. Additionally, similar fluorescence intensity and spectral signature were observed
in interactions between the negatively charged proteins and the positively charged OPE, as
previously described135,240.
To further characterize OPE sensing of amyloid aggregates, we determined both the
dissociation constant and the limit of detection (Table 6-3). An efficient amyloid probe needs
to have high affinity toward the aggregated conformation which can be characterized by the
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dissociation constant (kd). As shown in Table 6-3, in the presence of fibrillar aggregates both
OPE12- and OPE24+ present a kd value in the sub-micro molar range (0.16- 0.96 μM) and a Hill
coefficient “h” of 1.5 (Figure S1) indicative of positive binding cooperativity. In contrast, the
binding of OPE12- to htau oligomers is characterized by higher kd (1.23 μM) indicating lower
affinity, and larger h coefficient (4.17) showing higher level of cooperativity. The difference
in kd between fibrillar and oligomeric aggregates indicates that OPE12- binding affinity is
affected by the size and morphology of the scaffold.
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Figure 7-2 OPE12-and OPE24+ fluorescence spectra at 1 µM in the presence of six amyloid
proteins. Lysozyme, insulin, Aβ40, Ac-PHF6 and hTau under the monomeric (blue) or
aggregated (red) form. In the case of lysozyme, insulin, Aβ40, and PHF6, the aggregated forms
corresponded to the fibrillar conformation, while the oligomeric conformation was tested for
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hTau*. For PHF6, the non-acetylated peptide was used as monomers and the N-acetylated
isoform was sued to form fibril. The unincubated recombinant 441 tau protein was used as the
monomeric control for hTau oligomers.

The limit of detection (LOD) indicating the smallest protein concentration that OPE
can detect with high certainty, was also calculated as previously described240 LOD values
calculated for both OPEs were in the micro or sub-micromolar range (Table 6-3 and Figure
S2), with OPE24+ having the lowest LOD. Interestingly OPE12- presented similar LOD values
for lysozyme, insulin and PHF6 (between 0.52-0.85 μg/mL) but the LOD values were much
higher for both Aβ40 fibrils (2.24 μg/mL) and hTau oligomers (4.25 μg/mL). These results
indicate that OPE12- is less sensitive to hTau oligomers which is also supported by a lower
affinity (higher kd).
Overall, OPE12- was more efficient at detecting a wide range of amyloid aggregates
characterized by different morphology and charge compared to OPE24+a fluorescence signature
that can be used to distinguish amyloid aggregates (oligomers vs fibrils). This signature
indicates different binding modes which is mainly the result of different aggregate
morphologies.
7.3.2OPEs sensing of a mixture of fibrillar aggregates
OPEs are efficient probes for selectively detecting amyloid aggregates over their monomeric
counterparts. As neurodegenerative disorders are often characterized by the co-deposition of
amyloid aggregates made of different proteins,107–109 we evaluated OPE sensing properties in
the presence of a mixture of amyloid fibrils (Figure 6-3). OPE spectral features were
summarized in Table 6-4.
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Figure 7-3 OPE12-(1) and OPE24+ (2) fluorescence spectra in the presence of a mixture of
amyloid aggregates. A. 21 μg/mL Aβ40 fibrils and 21 μg/mL PHF6 fibrils. B. 21 μg/mL Aβ40
fibrils and 90 μg/mL PHF6 fibrils. C. 21 μg/mL Aβ40 fibrils and 21 μg/mL insulin fibrils. OPE
fluorescence was analyzed for the sensor alone at 1 μM (black), in the presence of Aβ40 fibrils
(blue), PHF6 fibrils (red), insulin fibrils (orange), both Aβ40 and PHF6 fibrils (green), and
both Aβ40 and insulin fibrils (purple). The excitation (dot line) and emission (solid line)
spectra were recorded for both sensors.

161

Table 7-4 Summary of OPE12- and OPE24+ spectral spectral features observed at 1 μM when
incubated alone (OPE background) or in the presence of a mixture of fibrils. A. OPE spectral
signature in the presence of 21 μg/mL Aβ40 fibrils and 21 μg/mL PHF6 fibrils. B. OPE
spectral signature in the presence of 90 μg/mL Aβ40 fibrils and 21 μg/mL PHF6 fibrils. C.
OPE spectral signature in the presence of 21 μg/mL Aβ40 fibrils and 21 μg/mL insulin
fibrils.

OPE sensing properties were first evaluated in the presence of both Aβ40 and PHF6
fibrils (Figure 6-3 A and Figure 6-3 B). OPE12- was previously shown to selectively detect
both amyloid fibrils with similar kd (Table 6-3) but the fluorescence intensity and spectral
signature generated with both aggregates were different: in the presence of PHF6 fibrils,
OPE12- had higher ADF value, its emission peak was broad and red-shifted indicating the
formation of H-aggregates; in the presence of Aβ40 fibrils, OPE12- emission peak was sharper
and was blue-shifted characteristic of J-aggregates (Figure 6-2 and Table 6-4). In contrast,
OPE24+ only detected Aβ40 fibrils and only weakly bound to PHF6 fibrils as shown by an ADF
value of 0.72 (Table 6-3). When both amyloid fibrils were present at equal concentration
162

(Figure 6-3A), OPE12- and OPE24+ emission intensities were similar to the sum of the emissions
recorded for both aggregates separately (OPE12667%;9:; %6:<=>%:9:;
667%$:<=>%):9:;

667%;9:; %6:<=>%:9:;
667%$:<=>%):9:;

= 0.93; OPE24+

= 0.93). OPE12- fluorescence signature generated in the presence of both

aggregates was similar to the one obtained in the presence of PHF6 fibrils alone with a peak
centered at 510 nm (Figure 6-3 A1). Interestingly, when Aβ40 fibrils concentration was fourtime PHF6 fibrils (Figure 6-3 B1), OPE12- emission was blue shifted and the spectral signature
was characterized by a sharp peak at 443 nm and a new shoulder at around 475 nm.
Additionally, OPE12- emission intensity generated in the presence of both fibrils was only half
of the sum of the emission recorded for PHF6 and Aβ fibrils separately (OPE12667%;9:; %6:<=>%:9:;
667%$:<=>%):9:;

= 0.54). The low fluorescence intensity in the presence of both fibrils and

the presence of a sharp emission peak at 443 nm and a shoulder at 475 nm might be explained
by the presence of both H and J-aggregates. These two types of aggregates are characterized
by different energy (J-aggregates display higher energy and so higher fluorescence increase)
and different lifetime (J aggregates have shorter lifetime)243. The presence of J-aggregates in
the sample would dominate the fluorescence and so the fluorescence generated by Haggregates might not be detectable. The contribution of both H- and J-aggregates could be
further analyzed through time-resolved fluorescence300. In the case of OPE12-, the emission
spectra obtained in the presence of both aggregates were very similar to the one generated in
the presence of Aβ40 and PHF6 fibrils separately (OPE24+

667;9:; %6:<=>%:9:;
667%$:<=>%):9:;

= 0.93).

OPE sensing properties were also evaluated in the presence of both Aβ40 and insulin
fibrils (Figure 6-3 C). OPE12- displayed similar spectral signature in the presence of both fibrils
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with an emission peak centered at around 442 nm. OPE24+ also had similar fluorescence
spectrum for both aggregates with a sharp emission peak at around 450 nm and a shoulder at
470 nm. Both sensors were able to detect the mixture of Aβ40 fibrils and insulin fibrils with
an emission intensity similar to the sum of the emission generated for both fibrils separately
(OPE12-

667%;9:; %6&,25)&,%:9:;
667%$&,25)&,>%):9:;

= 0.95; OPE24+

667;9:; %6&,25)&,>%:9:;
667%$&,25)&,%):9:;

= 0.71).

Overall, both OPEs detected a mixture of fibrils. OPE24+ presents a single spectral
signature for the detection of different fibrils however in the presence of a mixture of
aggregates its fluorescence enhancement reflects the amount of each fibrils. OPE12- presents a
distinct spectral signature depending on the aggregates detected. When two aggregates are
present in the samples generating different spectral features, OPE12- can be used to indicate
which aggregates is predominant.
7.3.3Characterization of OPEs background fluorescence in CSF
The search for a diagnostic tool to track amyloid biomarkers in biological fluids such as CSF
is where the field of dementia diagnosis is moving toward. To evaluate OPE sensing properties
in CSF, we first characterized OPE background fluorescence in healthy CSF at concentration
between 100 nM and 1 μM and compared it to its background fluorescence in phosphate buffer
(PB) (Figure 6-4A and B). CSF samples used in this study were purchased from Lee
Biosolutions and were collected from a pool of healthy patients (≥ 3). This commercialized
healthy CSF had an overall protein concentration of 263 µg/mL as defined through Bradford
protein concentration assay and contained highly hydrophobic proteins as observed by reverse
phase HPLC (Supplementary Figure S4).
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Figure 7-4 OPE12- and OPE24+ background fluorescence in 10 mM OB (A), in healthy CSF
(B), in 1XPBS (C) and in the presence of 4.5 g/L glucose (D). Both sensors were tested at 4
different concentration: 100 nM, 250 nM, 500 nM and 1 μM. The excitation (dashed line) and
emission (solid line) spectra were recorded except in the presence of PBS where emission was
only reported.
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As shown Figure 6-4A1 and A2, both OPEs had low background fluorescence in PB
at 100 nM which is explained by a rapid quenching of OPE excited singlet state by surrounding
water molecules trough proton transfer. Both OPEs displayed a weak fluorescence turn- on
with increase in concentration characterized by a weak and broad emission peak indicative of
the formation of dye complexes in a disordered micelle-like structure likely made of H-type
aggregates146. In CSF, OPE background fluorescence drastically increased by comparison with
PB (3 to 7-fold increase for OPE12- and 2 to 3-fold increase for OPE24+). For both sensors, this
increase in fluorescence intensity was also accompanied by a sharpening of the emission
spectra which might indicate the formation of J-aggregates. OPEs higher fluorescence in CSF
could be explained by a non-selective interaction with other biomolecules such as salt, glucose
or non-amyloidogenic protein301.
To further understand which biomolecules found in CSF is responsible for OPEs
fluorescence turn-on, we investigated OPE fluorescence in the presence of salt, glucose and
albumin (Figure 6-4 and Figure 6-5). To evaluate the effect of salt on OPE fluorescence, we
tested phosphate buffer solution (PBS) containing 137 mM NaCl and 2.7 mM KCl, a
comparable salt concentration to what is found in CSF (150 mM Na+, 3 mM K+ and 1.2 mM
Ca+)301. OPE12- did not display any increase in fluorescence intensity or change in spectral
signature in PBS, indicating that OPE12- fluorescence turn-on in CSF is not caused by the
presence of salt. In contrast, OPE24+ display large fluorescence enhancement in PBS at OPE
concentration higher than 500 nM which mimics closely the fluorescence spectrum generated
in CSF. Overall, the presence of salt might be one of the biomolecules responsible of OPE24+
fluorescence turn-on in CSF.
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Glucose is another molecule found in CSF at a concentration typically close to 4 mM
(0.72 mg/mL). To evaluate the interactions of OPE with glucose we tested a high glucose
concentration solution (4.5 g/L ~ 24.75 mM), higher than that found in CSF but also a middle
ground for glucose concentrations in cell culture formulations such as in Dulbecco’s Modified
Eagle’s Medium high glucose formulation in which OPE12- was also tested (Figure S5). In the
presence of 4.5 g/L of glucose, OPE12- (Figure 6-4 D1) and OPE24+ (Figure 6-4 D2) displayed
similar fluorescence intensity and spectral shifts compared to background fluorescence in PB,
indicating a lack of interaction of OPEs with glucose.
CSF is also known to be rich in protein (0.1-0.6 g/L). The most predominant protein
in CSF is albumin which is characterized by a cylindrical structure with polar outer walls and
a hydrophobic central core302. Knowing that OPE sensing of amyloid aggregates relies on
binding to their hydrophobic β-sheet structure, the hydrophobicity of albumin might lead to
non-selective interaction and non-selective fluorescence turn-on. To evaluate the interaction
of OPE to albumin we measured OPE fluorescence in the presence of bovine serum albumin
(BSA) known to present a similar helical structure than human serum albumin (HSA) and share
76% of sequence identity with the human isoform303,304. For this assay, OPEs fluorescence was
measured in the presence of 263 µg/mL of BSA which compare with the protein concentration
found in healthy CSF. In the presence of BSA, both sensors displayed enhanced fluorescence
similar to that seen in healthy CSF samples (Figure 6-5) suggesting that the main factor leading
to OPEs fluorescence turn-on in CSF is probably their interaction with albumin. This
interaction to non-amyloidogenic proteins might lead to a poor sensing of amyloid aggregates
in CSF. To compare OPEs interactions to BSA with amyloid aggregates, we analyzed their
binding constant and limit of detection (Figure S1 and S2). In the presence of BSA, OPE12167

and OPE24+ were characterized by kd values in the sub-micromolar range (0.78 ± 0.07 and 0.19
± 0.06 μM respectively), similar to the kd calculated in the presence of amyloid aggregates
previously described (Table 6-3). Additionally, both sensors had a hill coefficient close to 2
in the case of BSA and close to 1.5 in the presence of amyloid aggregates, indicating higher
cooperativity with BSA. Finally, the LOD for BSA was found to be 1.64 ± 0.2 μg/mL and 3.50
± 0.6 μg/mL for both OPE12- and OPE24, respectively. This LOD was higher than the one
calculated in the presence of amyloid aggregates (Table 6-3) indicating that both OPEs can
detect pathological protein aggregates at much lower concentration than BSA.

Figure 7-5 OPEs fluorescence at 100 nM in the presence of 263 µg/mL BSA and in CSF.
(containing 263 ug/mL proteins based on Bradford assay). Excitation (dashed line) and
emission (solid line) are represented.

Altogether, we found that both OPEs displayed higher fluorescence turn-on in CSF
compared to PB. For both OPEs, this fluorescence enhancement can be explained by their
interaction to biological molecules more particularly to albumin. Additionally, the presence of
salt seems to affect OPE24+ fluorescence but not OPE12-. Despite OPEs fluorescence turn-on in
CSF, we found that at the low concentration of 100 nM both OPEs present a minimal
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background fluorescence which should not alter their sensing properties. For this reason,
OPE’s sensing properties in CSF were investigated at 100 nM and not at the typical 1 μM.
7.3.4OPEs sensing of fibrillar and oligomeric proteins in CSF
OPEs high selectivity, sensitivity and affinity toward amyloid aggregates and their low
fluorescence turn-on in CSF at 100 nM make them promising for the detection of pathological
protein aggregates in this physiological sample. To assess OPE sensing properties in such
complex solution, we evaluated OPE’s detection of 21 μg/mL amyloid aggregates in CSF and
compared it to PB.
Previously described amyloid aggregates (fibrils made from insulin, lysozyme, PHF6
and Ab40, and oligomers made of htau protein) were spiked in CSF and PB. OPE12- and OPE24+
fluorescence spectra were recorded at 100 nM and are reported in Figure 6-6 and Figure 6-7,
respectively. The integrated emission areas were calculated and are summarized in Figure S6.
The detection of monomeric proteins was not evaluated because of the limited amount of CSF
sample which prevented the calculation of the ADF value. Positive sensing of spiked protein
was determined by using the protein detection factor or PDF, as described in Equation 2 with
F(dye in buffer) and F(dye+protein) being the integrated emission intensity of the sensor alone and
sensor in the presence of spiked protein, respectively. Similarly to the ADF, positive PDF value
(> 1) indicates positive protein detection. PDF values recorded in PB and CSF are summarized
in Figure 6-8.
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Figure 7-6 OPE12- fluorescence at 100 nM in the presence of 21 µg/mL amyloid aggregates in
PB (A and B) and spiked CSF (C and D). Five amyloid aggregates were tested: insulin fibrils,
lysozyme fibrils, PHF6 fibrils, Aβ40 fibrils and hTau oligomers. Both the excitation (A and C)
and emission spectra (B and D) were recorded.
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Figure 7-7 OPE24+ fluorescence at 100 nM in the presence of 21 µg/mL amyloid aggregates
in PB (A and B) and spiked CSF (C and D). Five amyloid aggregates were tested: insulin
fibrils, lysozyme fibrils, PHF6 fibrils, Aβ40 fibrils and hTau oligomers. As a control the
monomeric Aβ40 was also evaluated. Both the excitation (A and C) and emission spectra (B
and D) were recorded.

Figure 7-8 Protein detection factor (PDF) calculated for OPE12- (A) and OPE24+ (B) at 100
nM in the presence of amyloid aggregates (21 μg/mL) in PB (dark gray) or CSF (light gray).
As a control, the PDF value was also determined in the presence of Aβ40 monomers for

171

OPE24+. The red dashed line represents the PDF value equal to 1 used as a threshold to
determine positive detection.

OPE12- was previously described to detect all amyloid aggregates when tested at 1 μM
in PB. At 100 nM OPE12- still displayed a selective sensing of all fibrillar proteins in PB
(Figure 6-6B) by reaching fluorescence intensities between 5 to 9x103 counts/sec leading to a
PDF value superior to 1 (Figure 6-8A). However, this sensor failed to detect htau oligomers
as its PDF value was below 1. The loss of detection of htau oligomers at the low OPE12concentration of 100 nM might be explained by its lower affinity (higher kd) and higher LOD
compared to the other fibrillar proteins (Table 6-3). Overall OPE12- spectral signature in the
presence of all 4 proteins fibrils was similar to what was previously observed when OPE was
tested at 1 μM (Figure 6-2). When the amyloid aggregates were spiked in CSF, OPE12fluorescence was similar to its background fluorescence (Figure 6-6C and D) which led to a
PDF value close to 0. This lack of amyloid aggregates detection in CSF might be caused by
the presence of albumin for which OPE12- was previously described to interact with high
affinity.
The larger cationic OPE24+ was previously described to detect insulin, lysozyme and
Aβ40 fibrils when tested at 1 μM in the presence of 21 μg/mL protein in 10 mM PB (Figure
6-2)135,240 but was not able to detect either PHF6 fibrils or htau oligomers. Same sensing
pattern was observed when OPE24+ was used at 100 nM in PB (Figure 6-7A and B). When the
amyloid aggregates were spiked in CSF, OPE24+ maintained its sensing properties for the
fibrillar insulin, lysozyme and Aβ40 (PDF > 1) but also gained sensing of PHF6 fibrils (Figure
6-7A and B, Figure 6-8B). This new detection of PHF6 fibrils could be explained by CSF
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overall hydrophobicity. In such hydrophobic environment OPE24+ fluorescence quenching by
water molecules is attenuated which might lead to stronger fluorescence turn-on when bound
to fibrillar PHF6. The well-known fluorescent probe ThT was also tested at 100 nM in CSF
spiked with Aβ40 fibrils at 21 μg/mL (Figure S6). ThT displayed enhanced-fluorescence in
the presence of Aβ40 fibrils spiked in CSF compared to CSF background. However, this
increase in fluorescence led to a PDF value below 1 (0.72 ± 0.14) indicative of a poor sensing
of Aβ40 fibrils in CSF.
Overall, at 100 nM both OPEs detected amyloid aggregates in PB similarly to what
was observed when tested at 1 μM. In CSF, OPE12- lost its sensing properties while OPE24+
was still able to detect fibrillar insulin, lysozyme and Aβ40 and also gained detection of PHF6
fibrils.
7.3.5OPEs sensing of CSF isolated from patients with dementia
With the understanding of background fluorescence of OPE in CSF and with the knowledge
of OPE24+’s capabilities to detect amyloid aggregates in such complex environment, we
evaluated OPEs sensing properties in CSF isolated from two patients diagnosed with dementia
after neurological evaluation. As controls we also tested CSF obtained from two women
patients in labor and delivery units (L&D controls) as well as two older patients without
neuropathology (age-matched controls). All CSF samples were characterized in terms of
albumin, phosphorylated tau on threonine 181 (p-tau 181), Ab40 and Ab42 concentrations
(Table 6-5). Samples isolated from both L&D and age-matched controls contained albumin at
concentration between 0.12 and 0.28 mg/mL which is similar to the protein concentration
measured from the commercialized healthy CSF previously tested (0.26 mg/mL). Samples
isolated from patients with dementia contained higher albumin concentration (up to 0.59
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mg/mL) compared to the control samples, which might be due to a compromised blood-brain
barrier305. They are also characterized by higher p-tau 181, higher Ab40 and lower Ab42
content compared to L&D and age-matched controls.

Table 7-5 Protein concentrations in CSF samples isolated from L&D controls, age-matched
controls and patients with dementia. Four proteins concentrations are reported: albumin,
phosphorylated tau 181, Ab40, and Ab42. These concentrations were determined through
western blot analysis.

OPEs fluorescence at 100 nM generated in both L&D and age-matched controls was
measured and compared to the fluorescence recorded in the presence of the commercialized
healthy CSF (control CSF) (Figure 6-9 and Figure S8). OPE12- background fluorescence in
control patients was lower than the fluorescence measured in the commercialized CSF (3.5x103
vs 6x103 counts/sec). In the case of OPE24+ the opposite trend was observed (5x103 vs 3x103
counts/sec). The variation in OPE’s background fluorescence in different healthy CSF samples
by almost 2-fold indicates that other biological molecules present in CSF might also interfere
with OPE’s fluorescence.
OPE’s fluorescence was also monitored in CSF isolated from patients with dementia.
No significant difference in terms of intensity or spectral signature with either set of controls
were observed. A similar observation was made after diluting CSF by 10-fold in MilliQ water
to reduce albumin concentration in the sample (Figure S9). ThT fluorescence was also
measured at 100 nM in CSF samples isolated from patients with dementia (Figure S7). No
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significant difference between CSF controls and dementia CSF was observed with ThT. The
lack of detection of amyloid aggregates in dementia CSF by OPE12- and OPE24+ might be
explained by OPEs limit of detection previously reported to be in the microgram range, while
the expected oligomeric Aβ concentration in AD CSF should be in the picogram range287. A
second likely explanation for the lack of detection would be the absence of oligomeric protein
in CSF samples as the presence of oligomers has not been confirmed in patients with dementia.

Figure 7-9 OPE12- (A) and OPE24+(B) fluorescence at 100 nM in PB and CSF isolated from a
healthy commercialized CSF (control CSF), from L&D controls, age-matched controls and
patients diagnosed with dementia. Both the excitation (dashed line) and emission (solid line)
spectra are reported.
7.3.6Detection of amyloid aggregates in CSF through protein misfolding cyclic
amplification (PMCA) assay
The lack of OPE fluorescence enhancement in CSF isolated from demented patient
might be due to low oligomer concentration in CSF (pg/mL range) which is below OPE’s LOD
(μg/mL range). To overcome this low oligomer concentration, their seeding potency could be
exploited to promote the aggregation of monomeric Aβ through the protein misfolding cyclic
amplification assay (Aβ-PMCA). This assay was previously introduced by Soto et al., in
2014299. In this study they showed that a low concentration of 3 fM of oligomers can be
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detected through the Aβ-PMCA assay. They used the Aβ-PMCA assay in CSF isolated from
patient suffering of AD and found that these samples were characterized by a fast fibrillation
when spiked with Aβ42 monomers which was detectable with the fluorescent amyloid probe
ThT. Overall, they showed a significant difference in protein fibrillation between AD CSF and
control CSF.
As OPEs were previously described to be superior sensors compared to ThT for the
detection of amyloid aggregates, we investigated OPE sensing properties for the detection of
oligomers in CSF through the Aβ-PMCA. In this study, Aβ-PMCA assay was first evaluated
in PB by incubating 50 μM Aβ40 monomers in the presence of 2.6 μM Aβ40 seed protofibrils
at 37 ºC for 6 days143. The potential interference of albumin on the Aβ misfolding amplification
was also evaluated by incubating Aβ40 monomers and the seeds in the presence of 300 μg/mL
BSA. The Aβ-PMCA assay was finally assessed in CSF samples isolated from one dementia
patient and two age-matched controls where 50 μM Aβ40 monomers were spiked before
incubation at 37 ̊C for 6 days. The generation of amyloid fibrils through protein misfolding
cycle was analyzed by TEM imaging (Figure 6-10A) and by ThT, OPE12- and OPE24+
fluorescence (Figure 6-10B, C and D).
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Figure 7-10 Detection of the seeding activity of CSF isolated from age-matched controls and
from patients with dementia by Aβ-PMCA through TEM imaging (A) and ThT (B), OPE12(C) and OPE24+ (D) fluorescence. (A) TEM images were taken after 6 days of incubation (B),
(C) and (D). Fluorescence of the three amyloid sensors was measured at 100 nM in the presence
of 21 µg/mL protein. Error bars represent standard deviation from duplicate. As control, the
seeding activity of Aβ monomers alone (balck), Aβ monomers with seed fibrils (dark blue),
and Aβ monomers with seed fibrils and BSA (light blue) were monitored. Three CSF samples
were also tested: two samples from age-matched control (orange and purple) and one sample
from patient with dementia (red). In each CSF sample, Aβ40 monomers were spiked to reach
a final concentration of 50 µM.
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Figure 7-11 Detection of the seeding activity of Aβ40 protofibrils at different concentration
by the Aβ-PMCA assay after 6 days of incubation at 37 ºC through TEM imaging (A) and
ThT (B), OPE12- (C) and OPE24+ (D) fluorescence B, C, and D. Fluorescence of the three
amyloid sensors was measured in the presence of 100 nM sensor and 21 µg/mL protein.
As shown on TEM images (Figure 6-10A), Aβ monomers incubated alone after 6 days
at 37 ̊C formed very small features which are likely early oligomers, but no large fibrils were
produced. In the presence of Aβ protofibril seeds, Aβ monomers formed long and mature
fibrils. The fast fibrillation in the presence of protofibrillar seed is also supported by ThT,
OPE12- and OPE24+ fluorescent turn-on observed after only 1 day of incubation (Figure 6-10B,
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C and D). The effect of BSA on amyloid fibrillation was tested by incubating Aβ monomers
with Aβ seed protofibrils in the presence of BSA at 300 μg/mL. As shown on TEM, fibrils
were produced in the presence of BSA indicating that the high concentration of albumin found
in CSF should not inhibit the seeding potency of the amyloid aggregates. All three sensors
were tested for the detection of Aβ fibrils produced in the presence of BSA. Both OPE24+ and
ThT detected Aβ fibrils produced in the absence of BSA, while OPE12- exhibited a weaker
fluorescence turn-on. OPE12- poor detection of Aβ fibrils in the presence of BSA supports the
previous observation that OPE12- losses amyloid sensing in CSF due to its non-specific binding
to albumin. Finally, the seeding potency of CSF isolated from patients diagnosed with
dementia was tested and was compared to two CSF samples isolated from age-matched
controls. After 6 days of incubation in the presence of 50 μM Aβ monomers, oligomeric like
structure were observed in all three CSF samples, more importantly it appeared that more
aggregates were present in dementia CSF compared to control samples, however no large
fibrillar structure were observed. To further characterize the difference between all three CSF
samples, the amount of soluble oligomers would need to be quantify by size exclusion HPLC.
Despite a potential difference in the amount of oligomers, none of the amyloid sensors
displayed a selective fluorescence turn-on in demented CSF. The slow protein aggregation in
demented CSF might be related to a low “seedable” oligomer concentration in the sample. To
evaluate this hypothesis, we determined the lowest Aβ40 seed protofibrils concentration
capable of generating detectable Aβ40 fibrils through the Aβ-PMCA assay. As shown Figure
6-11A, Aβ40 seed protofibrils promoted fibrillation at concentration as low as 1 ng/mL which
was detectable by ThT and OPE12- but not OPE24+ (Figure 6-11B, C and D). The lack of
detection by OPE24+ would require further analysis as this experiment was only performed
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once. This seeding concentration of 1 ng/mL is still several order of magnitude higher than the
oligomer concentration reported in AD CSF (pg/mL range). Additionally, the minimal seeding
concentration calculated here is 1,000-fold higher than what was reported by Soto et al. in
2014 (3fM ~ 12.9 fg/mL)299 where Aβ42 monomers were used to spike CSF. This difference
might rely on the lower aggregation potency of Aβ40 compared to Aβ42306. To further
evaluate the Aβ-PMCA assay for the detection of oligomers in CSF, Aβ42 monomers could
be used instead of Aβ40 monomers. Another option would be to further optimize the incubation
condition used for the Aβ-PMCA assay as the temperature, pH and agitation have been
previously reported to have a significant influence on fibrillation kinetics307–309.
7.3.7OPE sensing of bovine IgG globular and amorphous aggregates
Protein based pharmaceuticals is a growing area of development for therapies targeting
an array of diseases. These therapies are typically delivered intravenously or subcutaneously
and should be in their monomeric morphology for therapeutic efficiency and patient health.
Subcutaneous delivery is preferred for patient convenience, compliance, and price. The hurdle
with the development of these therapeutics is the need for such large protein doses. At high
concentration conditions, proteins are prone to form a range of aggregates some reversible,
others not but both jeopardizing the drug’s quality, efficacy, delivery, and safety310.
Typical subcutaneous protein solutions concentrations of monoclonal antibodies are in
the range of 150 mg to 1.2 g per dose, these levels of proteins are necessary for drug
efficiency311. In this range of concentration, protein-protein interactions (electrostatics,
hydrogen bonding, hydrophobic) promote protein. The aggregates range in size from visible
to sub visible aggregates and monitoring the amount in solutions is crucial for patient health
and drug efficacy. If the protein aggregates are too many in numbers and/or too large the
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aggregates can mount an unwanted immune response and due the lack of soluble protein
monomers, less active drug is available. Technology for the detection of these aggregates
includes nanoparticle tracking analysis and flow microscopy amongst others. A problem with
this technique is the presence of other proteins and biological components that can hide
relevant aggregate from detection. Considering our work with OPEs and their detection in
biological like fluids, we tested if they would detect aggregates in high concentration bovine
IgG protein solutions.
We used bovine IgG (bIgG) as a proof of concept start of monoclonal antibodies at
high concentrations for economic ease. Using ultra-centrifugation, we prepared a 101 mg/mL
bIgG solution and separately heat stressed bIgG aggregate solution. Separately, we prepared
aggregated bIgG with heat stress as previously described312. The solution concentrations were
determined using nanodrop and kept at 4ºC until use. First, we characterized OPE fluorescence
in non-heat stressed bIgG high concentrated solutions. Second, we took highly concentrated
solutions and added aggregate seeds and monitored the fluorescence.
For visualization we took TEM images of both IgG conditions, Figure 6-12, shows
some small clumps in the sample from high concentration but in the heat stressed sample,
larger aggregates are more defined and observed. The samples deposited on the grid were at
50 ug/mL freshly diluted from the 101 mg/L. We took some of this solution and a freshly made
5 mg/mL solution to run through high pressure liquid chromatography size exclusion (HPLCSE) to calculate how much protein would have been lost to aggregation in the 101 mg/mL
sample, Figure 6-S11. We did not see a shift in the elution time to indicate dimer/aggregate
formation related to high concentration environments. The 5 mg/mL sample had a lower
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absorbance signal but these samples were only tested once, not allowing us to make
conclusions from the differences in intensity.
High concentration bIgG

Heat stressed bIgG

500 nm

Figure 7-12 TEM images of 50 µg/mL bovine IgG solutions. The left image is a sample taken
from a highly concentrated solution, 101 mg/mL. The image on the right is taken from a
solution of heat stressed proteins to form insoluble aggregates.
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Figure 7-13 OPE12- and OPE24+ fluorescence emission spectra in the presence of 21 µg/mL
heat-stressed bovine IgG (top), high concentration sample 101 mg/mL (middle row), and a
combination of both solutions.
Our goal was to test if either of the OPE molecules can detect aggregates in the high
concentration protein preparation. We performed fluorescence assays with heat stressed
aggregates, high concentration solutions, and then high concentration plus heat stressed
aggregates, Figure 6-13. The heat stressed aggregates had a mild dequenching effect on the
OPEs by doubling their background fluorescence intensity, OPE12- had a second peak
seemingly start to appear near 475 nm, OPE24+’s spectra seemed unchanged. With the high
concentration solutions, both OPEs had large increases in fluorescence and shifts in the spectra.
This large increase in fluorescence intensity is likely caused by the highly viscous environment
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the amount of proteins causes, at 21 µg/mL (Figure 6-S12) neither OPE detects bIgG in
solution even if the sample is diluted from the 101 mg/mL preparation.
We continued to test if OPEs had some selectivity for the heat stressed aggregates
against the 101 mg/mL high fluorescent background by adding seeds 2%, 5%, 10% (w/v). With
OPE24+ we saw a decrease in fluorescence as we increased seed concentration. Further testing
and repeated assays are necessary to see if this response is consistent. Possibly, seed aggregates
will take up solubilized monomers, serving as nucleation sites for monomers in the solution.
If this is the case, the OPE sensors in solution are not detecting this aggregate population,
therefore we loose fluorescence. Circular dichroism spectroscopy could provide us with more
knowledge regarding protein secondary structure in these different protein solutions. Under
these OPE concentrations and with bovine IgG proteins, we were unable to use OPEs as a
selective protein aggregate sensor in a high concentration solution (>100 mg/mL).

7.4 Conclusions
There is a continued need for the development of sensing technology for early
neurological disease diagnosis. Previous work demonstrated OPE as a promising sensor for
the detection of fibrillar and oligomeric pathological protein aggregates. In this study we
sought to evaluate OPEs sensing capabilities in a biological fluid, CSF. Through spectroscopic
assays, imaging techniques, and curve fitting we have characterized and gained an
understanding on how OPE12- and OPE24+ behave in CSF mainly composed of nonamyloidogenic proteins, salts, and glucose. Both OPEs displayed fluorescence turn-on in CSF
likely caused by their non-selective interaction to albumin and salt. Despite this fluorescence
enhancement, both OPEs show minimal background fluorescence when used at 100 nM. At
such low concentration, OPEs were still able to detect amyloid aggregates in PB but OPE12184

lost sensing activity in CSF while OPE24+ maintained its sensing properties. These two amyloid
sensors were also evaluated in CSF samples isolated from patients diagnosed with dementia
which resulted in the lack of sensing of pathologically relevant aggregates. The poor
performance of OPE is probably due to the low aggregate concentrations found in CSF in AD
patients (picogram range) which are several orders of magnitude lower than our calculated
limits of detection (microgram range), creating a hurdle for our sensors. To overcome the low
oligomer concentration in CSF, we investigated the protein misfolding cyclic amplification
assay by spiking CSF with monomeric Aβ40 which should undergo fast fibrillation in the
presence of oligomeric seed. This assay was previously described to detect oligomers at
concentration as low as 3 fM. Low protein fibrillation was observed CSF isolated from
demented patients resulting in a lack of sensing by OPE. This slow fibrillation might indicate
that the assay needs further optimization to ensure rapid fibrillation in the presence of low
oligomers seed concentration which could be achieved by changing the incubation conditions.
Finally, we tested it for its selectivity for non-amyloid aggregates geared toward its use in
detecting aggregates in protein-based therapeutics. The OPEs did not display selectivity
towards heat-stressed bIgG aggregates in a background bovine IgG solution. Despite these
results, we will continue to work with OPEs in various sensing applications. More
characterization needs to be done on the aggregates we prepared to understand OPE-bIgG
interactions and if this proves to be successful, move towards more relevant protein
preparations.
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7.5 Experimental Methods
7.5.1 Materials
Purified synthetic amyloid β-40 (Aβ40) was acquired from peptide 2.0. Bovine insulin, hen
egg white lysozyme and bovine serum albumin (BSA) were purchased from Sigma-Aldrich
(St. Louis, MO). N-terminus acetylated PHF6 (Ac-PHF6) and non-acetylated PHF6 (NH3+PHF6) were synthetized through a solid-phase synthetic method as previously described,208
and were purified by reverse phase HPLC. Human derived tau (htau) oligomers were
graciously provided by Dr. Kayed Rakez313. Recombinant tau 441 was produced and purified
as previously describe265. Human cerebrospinal fluid (CSF) sample pooled from ³ 3 healthy
donors was purchased from Lee Biosolutions (Maryland Heights, MO). CSF sample isolated
from patients diagnosed with dementia, from patients in labor and delivery units (L&D
controls) and from older patients without neuropathology (age-matched controls) were
graciously provided by Dr. Gary Rosenberg. All CSF samples were centrifuged at 8,000 rpm
for 8 minutes and supernatant was stored -20 ̊C until use. Dulbecco’s Modified Eagle’s
Medium (DMEM) F12 media and glucose were purchased from Sigma-Aldrich (St. Louis,
MO). Hydrochloric acid (HCl) was purchased from Merck, (Kenilworth, NJ). Sodium citrate
was acquired from Fisher Scientific, (Hampton, NH). Sodium azide, NaCl and dimethyl
sulfoxide (DMSO) were obtained from EMD Millipore (Burlington, MA). Tris was purchased
from BioRad (Hercules, CA). Phosphate buffer (PB) was prepared with sodium phosphate
monobasic monohydrate and sodium phosphate dibasic anhydrous purchased from Thermo
Fisher Scientific (Waltham, MA). Water was purified by MilliQ purification system (Millipore
Synergy UV) before use. ThT was acquired from ACROS Organics (Belgium). OPEs were
synthesized and purified by previously published procedures203.
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7.5.2Protein solubilization and preparation of amyloid aggregates
Hen egg-white lysozyme (Sigma-Aldrich, St. Louis, MO) was dissolved at 5 mg/mL in
10 mM sodium citrate pH 3 with 0.1 M NaCl. Protein concentration was verified by using
absorbance at 280 nm and the coefficient of extinction (2.63 L/(g.cm)83. Lysozyme protein was
then incubated at 70 ̊C for 48 hours under magnetic stirring to form fibrils. Insulin from bovine
pancreas (Sigma-Aldrich, St. Louis, MO) was solubilized in 25 mM HCl at 599 μM and was
incubated at 60 ̊C for 2 days under quiescent conditions. Synthetic Aβ40 (peptide 2.0,
Chantilly, VA) was solubilized in DMSO at 50 mg/mL. After sonicating the peptide for 5
minutes with the 550T Ultrasonic Cleaner (VWR International, Radnor, PA) and removing
any insoluble particle by centrifugation at 14,000 g for 15 min, Aβ40 was diluted in 40 mM
Tris pH 8.0 buffer containing 150 mM NaCl and 0.01 % w/v sodium azide. The protein was
then incubated at 37 ̊C for 23 days under quiescent conditions to ensure protein fibrillation.
Two tau hexapeptide

306

VQIVYK311 (PHF6) were synthesized by a solid-phase method as

previously described208: N-terminus acetylated PHF6 (Ac-PHF6) which is prone to fibrillation
and non-acetylated PHF6 (NH3+ -PHF6) known to remain monomeric during incubation208.
Peptides were purified by reverse phase HPLC (RP-HPLC) using an acetonitrile-water
gradient containing 0.1% TFA. Lyophilized peptides were solubilized in MilliQ water to reach
3 mg/mL. The exact peptide concentration was determined by using absorbance at 280 nm and
the coefficient of extinction (ɛ280nm = 1195.9 cm-1M-1 117 MWAc-PHF6 = 790 g/mol, MWNH3+- PHF6
= 748 g/mol). NH3+-PHF6 was stored in -70 ̊C until use, while Ac-PHF6 was incubated at 75 ̊C
for 5 days to form fibrils.
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For high concentration solutions bovine IgG (Innovative Research, Novi, MI) we used
protocols previously reported with modifications314. Bovine IgG was solubilized at ~ 18
mg/mL in de-ionized water. This solution was concentrated to 101 mg/mL by centrifugation
ultra-filtration using Amicon Centrifugal Filter with 30K cut-off. A volume of 2 mL of
solubilized protein was loaded in addition to 2 mL of 30 mM phosphate buffer pH 7.5. The
solution was centrifuged for 15 min at 4,000 rpm. Additional buffer was added followed by
centrifugation until the final protein volume was ~ 50-100 µL. The protein solution was
removed from the filter and its concentration determined via Nanodrop (Thermo Fisher
Scientific, Waltham, WA) with ɛ280nm= 210,000 M-1cm-1. For heat stressed IgG aggregates we
solubilized the protein into 10 mM sodium citrate buffer, 5% (w/v) sucrose pH 6 to make a 1
mg/mL solution and then placed it in a heat block at 74 ºC for 12 minutes312.
7.5.3 Aβ protein misfolding cyclic amplification (Aβ -PMCA) assay
Aβ40 monomers aggregate-free solution was prepared by solubilizing the peptide at 50
mg/mL in DMSO following by sonication for 1 minutes and centrifugation at 14,000 g for 15
min. The supernatant was stored at -70 ̊C until use. Solution of 50 μM Aβ40 monomers was
prepared in 50 mM PB and 100 mM NaCl. Aβ40 monomers were either incubated alone or in
the presence of 2.6 μM Aβ40 protofibrils or in CSF aliquots at 37 ̊C for up to 6 days. Aβ40
protofibrils were prepared through sonication of mature fibrils for 10 minutes with the 550T
Ultrasonic Cleaner (VWR International, Radnor, PA). These mature fibrils were initially
produced after 23 days of incubation of 100 μM Aβ40 monomers at 37 ̊C in 50 mM PB and
100 mM NaCl.
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7.5.4 Fluorescence Measurement
Thioflavin T (ThT), OPE12- and OPE24+ were solubilized in MilliQ water at concentration
between 100-250 μM. Dyes concentration were determined from their extinction coefficients
(MWThT: 318.85 g/mol and ɛThT412nm in water: 3.6 x 104 M−1cm−1, 43; MWOPE12-: 724.79 g/mol
and ɛOPE12-370 nm in water (3.92 ± 0.013) x 104 M-1cm-1; MWOPE24+: 1002.64 g/mol and ɛOPE24+
378 nm in water (8.29 ± 0.033) x 104 M-1cm-1 203. All dyes were sonicated before use with the
550T Ultrasonic Cleaner (VWR International, Radnor, PA) 4 times for 15 seconds to
breakdown any aggregates. OPE and ThT fluorescence spectra were recorded in a quartz
cuvette (Starna cells Inc., Atascadero, CA) with the PTI QuantaMaster 40 steady state
spectrofluorometer (HORIBA Scientific, Edison, NJ) at concentration between 100 nM and 1
μM for OPE or between 1 to 20 μM for ThT, in the presence of biological samples (amyloid
proteins, bovine serum albumin, glucose, PBS and CSF). After 30 minutes of incubation at
room temperature the emission spectra were recorded at the excitation wavelengths 390, 410
and 440 nm for OPE12-, OPE24+ and ThT, respectively. The excitation spectra were recorded at
the emission wavelengths of 450, 460 and 480 nm for OPE12-, OPE24+ and ThT, respectively.
Each fluorescence measurement was done in duplicate.
7.5.5 Binding Constant
OPE’s dissociation constant (kd) to protein was determined from a constant protein
concentration binding168. Briefly, OPE’s fluorescence was recorded at concentration between
0 - 2 μM in the presence of 21 μg/mL of protein. The integrated emission area of OPE was
calculated and was background subtracted with the corresponding OPE emission spectrum
recorded in 10 mM phosphate buffer (PB). The dissociation constant was determined from the
plot of emission integrated area versus sensor concentration. Kd were extracted from data
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fitting to a nonlinear regression curve assuming site specific binding and using a Hill
coefficient (h) to account for any binding cooperativity.
7.5.6 Limit of Detection
Limit of detection was defined as being the smallest protein concentration that can be
detected by OPE with high certainty and was calculated as previously described (Equation
3)240 LOD was determined as being three-time OPE’s background standard deviation. The
corresponding protein concentration was determined using the slope of the fluorescence signal
vs. concentration correlation where σ is the standard deviation of the dye alone (blank) and S
is

the

slope

of

the

signal

vs.

𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝐿𝑂𝐷 =
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7.5.7 TEM Imaging
Amyloid aggregates were imaged by transmission electron microscopy. The proteins were
diluted at 21 μg/mL in MilliQ water and were loaded onto a glow discharge grid. Bovine IgG
samples were imaged at 50 µg/mL in MilliQ water and loaded onto a glow discharge grid.
After letting the protein adsorb on the grid for 5 minutes, the excess of protein was wicked
away and then the grid was stained using 2% uranyl acetate through four consecutive staining
steps. The first one consisted in applying the stain for 3 min and the three last staining steps
consisted in applying uranyl acetate for 1 min only. Between each staining step, the excess of
stain was wicked away. After the last staining step, the grid was air dried for 30 minutes before
imaging with the HITACHI HT7700 transmission electron microscope (Hitachi High
Technologies Corp., Tokyo, Japan).
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7.6 Supplementary Information

Figure S1: Binding assay profiles of OPE12- (A) and OPE24+ (B) to six proteins present at 21
μg/mL (insulin fibrils, lysozyme fibrils, Aβ40 fibrils, PHF6 fibrils, hTau oligomers and
BSA). These saturation binding assay curves were obtained by fitting the data to a nonlinear
regression assuming site specific binding with binding cooperativity on OriginPro 9.
Experiments were performed in duplicates and error bars represent standard deviations. The
maximum specific binding (Bmax), the Hill coefficient (h), the dissociation constant (Kd)
and the R2 values are summarized in the table (C). OPE has been shown to form superluminescence complexes at concentration above 10 μM leading to fluorescence red-shift and
peak sharpening. To isolate OPE/fibrils binding from OPE complexation, the binding assay
was performed at OPE concentration bellow 2 μM.
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Figure S2: Linear correlations between fluorescence integrated area of OPE12- (A) and
OPE24+ (B) (1 μM) versus protein concentration. Seven proteins were tested: insulin fibrils,
lysozyme fibrils, PHF6 fibrils, hTau oligomers, Aβ40 fibrils, Aβ40 monomers, and BSA.
Aβ40 monomers were only tested with OPE24+. Data were fitted to a linear fit on OriginPro.
The intercept and slopes values are summarized in the table below.
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Figure S3: ThT fluorescence in the presence of a mixture of fibrils. (A) 21 μg/mL Aβ40 fibrils
and 21 μg/mL PHF6 fibrils. (B.) 21 μg/mL Aβ40 fibrils and 90 μg/mL PHF6 fibrils. (C.) 21
μg/mL Aβ40 fibrils and 21 μg/mL insulin fibrils. ThT fluorescence was analyzed for the sensor
alone (black), in the presence of Aβ40 fibrils (blue), PHF6 fibrils (red), insulin fibrils (orange),
both Aβ40 and PHF6 fibrils (green), both Aβ40 and insulin fibrils (purple). The excitation (dot
line) and emission (solid line) were recorded for both sensors. The additive fluorescence in the
presence of both fibrils was determined by calculating the following ratio (~ 1 meaning perfect
additive fluorescence):
Condition A: ThT
Condition B: ThT
Condition A: ThT

667%:9:; % 6:<=>%:9:;
6(67%$:<=>%):9:;
667%:9:; % 6:<=>%:9:;
6(67%$:<=>%):9:;
667%:9:; % 6:<=>%:9:;
6(67%$:<=>%):9:;

= 0.73
= 1.06
= 0.80

Figure S4: Reverse phase chromatogram of healthy CSF. 100 μL CSF were centrifuged (15
min at 14,000 rpm) to remove insoluble species and the supernatant was injected into the
Eclipse XDB C18 column (Agilent Technology, Santa Clara, CA) pre-equilibrated at 40 ̊C
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with 95% of mobile phase A (water containing 0.1% TFA) and 5% of mobile phase B
(acetonitrile containing 0.1% TFA). The proteins were eluted using a 5-100% linear gradient
of mobile phase B over 40 min. The absorbance at 215 nm was monitored. The main protein
peak was eluted at around 55% of mobile phase B.

Figure S5: OPE12- fluorescence (A) and absorbance (B) spectra in the presence of DMEM F12
media and Aβ fibrils. DMEM F12 media is composed of 15 mM HEPES, 0.055 g/L sodium
pyruvate 3.15 g/L glucose, unknown concentration of sodium bicarbonate and phenol red used
as a pH indicator. OPE12- spectroscopic change was analyzed in the presence of DMEM F12
media. (A) OPE12- emission recorded at 1 μM in 100% and 50% media reached an intensity of
around 25x103 counts/sec similarly to the fluorescence generated in the presence of 21 μg/mL
Aβ fibrils (5 μM). OPE1- emission spectrum recorded in the presence of media also present a
new spectral signature with a sharp peak at around 440 nm and a shoulder at around 470 nm.
This spectral signature indicates the formation of stable OPE complexed likely made of Jaggregates. (B) OPE12- absorbance spectrum in the presence of media was characterized by a
drastic right shift and sharpening also supporting the formation of J-aggregates.
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Figure S6: OPE12-, OPE24+, and ThT emission integrated area recorded at 100 nM in PB (A)
and CSF (B) spiked with amyloid proteins at 21 µg/mL. Asteriks indicate significant
differences with the sensor alone in buffer (PB or CSF) (t-test with a p-value ≤ 0.01)
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Figure S7: Thioflavin T background fluorescence spectra in PB, CSF, and in the presence of
Ab40 fibrils. Excitation and emission spectra of a 100 nM, 1 μM, and 20 µM Thioflavin T in
PB (A) and CSF (C). (B) and (D)Fluorescence excitation and emission spectra of 100 nM ThT
(blue) in PB and CSF solution compared to fluorescence spectra of spiked solutions with 21
μg/mL of Aβ40 in vitro fibrils. (red lines).

Figure S8: OPE12-, OPE24+, and ThT emission integrated area and detection factor in the
presence of CSF samples isolated from healthy patients or patients with dementia. Top:
Integrated emission intensity of OPEs and ThT displayed as a bar graphs. Grey bar represents
the dye (100 nM) in phosphate buffer, the black bar is the dye (100 nM) in purchased healthy
CSF. The red, green, and yellow bars are the sensors in CSF from dementia diagnosed patients,
labor and delivery controls, and age matched non-dementia diagnosed patients, respectively.
Bottom: The protein detection factor (PDF) of OPEs and ThT in CSF samples isolated from
healthy or demented patients. The red dashed-line representing the PDF value of 1 used as a
threshold to determine positive detection.
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Figure S9: OPE12-(A) and OPE24+(B) fluorescence at 100 nM in CSF samples diluted 10-fold
in water. Three CSF samples were tested: CSF from L&D controls, CSF age-matched controls
and CSF from patients diagnosed with dementia. Both the excitation (dashed line) and
emission (solid line) spectra are reported.
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Figure S10: Seeding potency of Aβ40 sonicated fibrils and CSF evaluation through ThT (A),
OPE12- (B) and OPE24+(C) fluorescence recorded at day 0 and after 1 and 6 days of incubation
at 37 ̊C.

198

50

control IgG

Absorbance
280 nm

40

concentrated IgG

30
20
10
0
0

15

30

45

Time (minutes)

Figure S11: High-pressure liquid chromatography size exclusion (HPLC-SE) of bovine IgG
samples. The column was loaded with 50 µg/mL of protein. The control IgG sample was from
a protein solution solubilized at 5 mg/mL. The concentrated IgG sample was from a 101
mg/mL protein solution. The HPLC-SE solutions were diluted, centrifuged, and loaded onto
the column.
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Figure S12: Fluorescence emission spectra of OPE12- (left) and OPE24+ (right) in solution with
21 µg/mL of bovine IgG diluted from a 101 mg/mL solution. The spectra are representative of
triplicate samples. Although the fluorescence is higher in both cases, there are no shifts in the
6('ABC:9:;)
spectra and the ratio 6
is > 2 (OPE12- = 1.56, OPE24+ = 1.75) which we interpret as no
9:;

selectivity. This concentration is not relevant to pharmaceutical detection ranges however it is
a control to understand the OPE-protein interactions.
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Chapter 8 Detergent-induced self-assembly and controllable
photosensitizer activity of diester phenylene ethynylenes
(This chapter has been published in PNAS and appears as Patrick L. Donabedian, Matthew
N. Creyer, Florencia A. Monge, Kirk S. Schanze, Eva Y. Chi, and David G. Whitten. 2017.
Detergent-induced self-assembly and controllable photosensitizer activity of diester
phenylene ethynylenes, PNAS, 114: 7278-7282)

8.1 Abstract
Photodynamic therapy, in which malignant tissue is killed by targeted light exposure following
administration of a photosensitizer, can be a valuable treatment modality but currently relies
on passive transport and local irradiation to avoid off-target oxidation. We present a system of
excited-state control for truly local delivery of singlet oxygen. An anionic phenylene
ethynylene oligomer is initially quenched by water, producing minimal fluorescence and no
measurable singlet oxygen generation. When presented with a binding partner, in this case an
oppositely charged surfactant, changes in solvent microenvironment result in fluorescence
unquenching, restoration of intersystem crossing to the triplet state, and singlet oxygen
generation, as assayed by transient absorption spectroscopy and chemical trapping. This
solvation-controlled photosensitizer model has possible applications as a theranostic agent for,
for example, amyloid diseases.
8.2 Introduction
Generation of reactive oxygen species as a product of photoexcited electronic states in organic
molecules can be a useful tool in a variety of applications. The possibilities of spatially
localized generation of reactive oxygen species (ROS) in response to irradiation are only just
beginning to be explored, despite the more than 100-y history of phototherapy in modern
medicine47, and are already in the clinic in the form of photo dynamic therapy (PDT) for
cancers of the skin, esophagus, and organ linings, actinic keratosis, and acne315,316.
Photodynamic destruction of pathogenic bacteria, viruses, and fungi is also under investigation
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for antibiowarfare applications, passive sanitization of hospital surfaces under room light, and
active sanitization of medical devices such as catheters81,317–320 A major drawback of
systemically dosed PDT photosensitizers, which are primarily porphyrins or their prodrugs321,
is their accumulation in the skin and eyes leading to long-lasting (weeks to months) post
therapeutic photosensitivity322. Generation of ROS out- side the target area can have multiple
deleterious effects by overwhelming endogenous ROS-dependent signaling cascades48. A
solution to these issues would be a localized photosensitizer whose ROS-generating properties
can be controllably activated, for example, in response to the binding to a target. The
motivation of the current study is to develop a tool for local delivery of singlet oxygen using
binding and self-assembly– mediated control of excited states. Under intra- or intercellular
conditions, 99% of singlet oxygen cannot travel more than 300 nm from the site of its
generation before it decays through the transfer of its electronic energy to vibrational modes
of water323; the presence of redox sites will reduce this effective distance further. This less than
300-nm radius, being less than a cellular length, indicates that an active photosensitizer in or
at a target cell will have minimal effect on adjacent cells. Previous investigations of switchable
photosensitizers by various groups have used a pH-activatable rubyrin derivative324, a
quencher- tethered Si(IV) phthalocyanine325 and pyropheophorbide326, and various borondipyrromethene (BODIPY) dye-based scaffolds327–329. Solvent microenvironment has been
used to selectively photo-oxidize protein330 and cellular targets328, but only using
intramolecular FRET quenching or solvent polarity effects on photoelectron transfer in
BODIPY monomers or covalently linked dimers. Control of photoexcited-state populations in
organic molecules by the presence of quenchers is a common strategy in engineering sensor
systems (Fig. 1). In the system at hand, the quencher is the network of solvating interfacial
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water molecules at the chromophoric esters of a p-phenylene ethynylene (OPE1 in Fig. 1), and
the tool for controlling the presence of the quencher is complexation of the dye with low
concentrations of an oppositely charged surfactant. Previous reports discovered that the
presence of ethyl ester substituents on a phenylene ethynylene chromophore (Fig. 2) causes
fluorescence to become highly quenched in water, presumably by quenching of the ex- cited
singlet state by a H-bonding or partial proton-transfer mechanism72,75,203. These dyes with low
fluorescence in polar aqueous environments and high fluorescence in nonpolar environments
are useful sensors for amyloid protein aggregates, to which they bind with moderate affinity42.
Furthermore, the presence of oppositely charged surfactants78, lipids331, or other scaffolds74
can induce these dyes to form J-type aggregates with enhanced emission and usefully placed
electronic transitions (i.e., in the visible rather than UV range)332. Because the excited singlet
state is upstream of triplet states and photosensitizer activity, as well as fluorescence (Fig. 3),
we hypothesized that ester-functionalized oligo-p-phenylene ethynylene (OPEs) would not
have significant photosensitizer activity when solubilized in water, but would gain both longlived excited triplet states and ROS generation when complexed with an oppositely charged
surfactant displacing the solvent. In this study, surfactant binding-activated unquenching of an
anionic OPE, OPE1 (Fig. 2) was characterized. Concomitant changes in the OPE’s excitedtriplet-state lifetime and ROS generation were tested using transient absorption spectroscopy
and chemical trapping, respectively.
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Figure 8-1 Schematic of DISA model of targeted singlet oxygen sensitization and optical
detection.

Figure 8-2 Structure of anionic OPE (Top) and pictures of 2 uM OPE1 in water or water
containing varying concentrations of cationic detergent CTAB under UVA illumination.
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Figure 8-3 Simplified Jablonski diagram of OPE1 electronic states. After excitation by photon
absorption (ABS) and fast internal conversion and vibrational relaxation (IC/VR) to the S1
state, three competing decay processes exist: first, nonradiative, solvent-mediated quenching
by internal conversion (IC), second, radiative decay by fluorescence (FL), and third, crossing
to the triplet manifold by intersystem conversion (ISC) and subsequent energy transfer (ET) to
produce singlet oxygen (1O2) from ground-state dioxygen. The relative rates of these three
processes determine the functional behavior of the system. Triplet states can be assayed by the
triplet-triplet TA process.
8.3 Results and Discussion
8.3.1 Detergent-Induced Self-Assembly and Unquenching of OPE Fluorescence
Addition of the cationic surfactant cationic surfactant cetyl trimethylammonium bromide
(CTAB) to a solution of anionic OPE1 in water resulted in dramatic changes to both the
absorbance and fluorescence emission spectra of OPE1 (Fig. 4). Addition of CTAB caused
significant increases in OPE1 fluorescence yield without significant distortion of peak
placement in the emission spectra (Fig. 4B). Similar unquenching was seen with amyloid
protein fibrils42 as well as carboxylated starches203 for a variety of ester-terminated OPEs with
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varying lengths. The enhancement of excited-singlet-state populations in the presence of
detergent opens the possibility of enhanced triplet production and promotion of singlet oxygen
generation (Fig. 4). Under the quenched conditions, no triplet states are available to sensitize
singlet oxygen, but when solvent is displaced by binding to a hydrophobic target, the
fluorescence is restored along with the potential for singlet oxygen generation.
The absorbance spectra of the OPE exhibit a redshift together with onset of
fluorescence and are similar to those previously reported for a cationic OPE with an anionic
detergent under similar sub micellar conditions78. The quantum yield of fluorescence of the
cationic analogue of OPE1 (di-quaternary ammonium salt) is 0.023 in water and 0.75 in
methanol75. Brightness of fluorescence has been observed to be identical between this
compound and OPE1. Upon addition of stoichiometric surfactant with the appropriate charge,
either compound regains fluorescence as bright as that in methanol. From these observations
and results, we postulate that the fluorescence quantum yield of surfactant-bound OPE1 is at
or near 0.75. The other 25% of excited states mostly contributes to the generation of singlet
oxygen. For both OPE1 and other OPEs with “ionic side arms,” this effect has been attributed
to the formation of a complex including an OPE dimer and several detergent molecules. This
detergent-induced self-assembly (DISA) is interesting in that there is no association between
or aggregation of either reagent in water at these concentrations; the ion-pairing and local
concentration effect of the surfactant is necessary to allow the OPEs to approach one another
and dimerize. The addition of 3 μM CTAB, a 3:2 ratio of detergent to OPE1, induces a spectral
shift indicating significant conversion of the OPE1 to a J dimer (Fig. 4A). Dynamic lightscattering results (SI Appendix, Fig. S8) indicate that CTAB micelles with and without OPE1
both have hydrodynamic radii of roughly 35 nm, with premicellar aggregates too small to
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reliably measure. As shown below, as well as activating fluorescence, DISA can induce a
photochemical reaction that is not possible without detergent by extending the lifetime of the
excited singlet state.

Figure 8-4 Absorbance (A) and fluorescence emission (B) spectra of samples containing 2.0
uM OPE1 and varying CTAB concentrations using λex 420 nm.
8.3.2 DISA – Controlled Generation of OPE1 Triplet Excited States
To gain direct information about the number of triplet excited states available to transfer energy
to singlet oxygen, the intensity and lifetime of the triplet–triplet absorption were measured by
transient absorption experiments (Figs. 5 and 6). Initially H2O solutions of OPE1 had no
detectable transient absorption after 35-ns delay (Fig. 5, Top), consistent with near-complete
quenching of the excited singlet state before intersystem crossing can occur (Fig. 3). Titration
of CTAB in 1-μM increments caused a transient absorbance peak centered at 600 nm to appear,
which became strong enough to measure its lifetime at 4 μM CTAB. The intensity of the
transient absorption saturated at about 10 μM CTAB (Fig. 6B), indicating that all OPE1 was
complexed at this concentration. Lifetime values (τ) of the triplet–triplet transient absorption
(TA in Fig. 3) were fairly constant at low CTAB concentrations (3–10 μM), averaging around
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25 μs, and decreased gradually at a higher CTAB concentration (8 μs for 49 μM) (Fig. 6B).
This decrease in τ could be an artifact of residual oxygen present, as foam formation in the
higher-concentration CTAB solutions prohibited the complete removal of oxygen from the
samples, or it could be the result of triplet–triplet annihilation due to the complexing action of
the surfactant bringing multiple ex- cited states into close proximity. The former explanation
seems more likely because, as noted below, generation of ROS by OPE1 continues to increase
with increasing CTAB concentration into the millimolar regime (SI Appendix, Fig. S2).
Interestingly, the OPE1 triplet–triplet absorption is significantly different in shape and
wavelength from that of the related dye without ester substituents (SI Appendix, Fig. S4),
indicating that either the esters have an impact on the electronic structure and the T1–Tn
transition or the triplet state is delocalized across a J dimer. The effect of changing groundstate absorption over the CTAB concentration range complicates the interpretation of the
spectra, but the lack of isosbestic points indicates that multiple singlet states may be involved,
supporting the presence of a monomer–J-dimer equilibrium in the OPE molecules.
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Figure 8-5 TA difference spectra of OPE1 (2 µM) in water with differing CTAB
concentrations. Initial delay was 35 ns and delay time increased in 3-µs increments until TA
returned to baseline. Oxygen was largely removed by bubbling with argon gas.
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Figure 8-6 Intensity (ΔOD) (A) and triplet lifetime (B) of triplet-triplet absorption in OPE1
(2µM) solutions containing varying concentrations of CTAB.
8.3.3 Solvent-Controlled ROS Generation Assayed by Chemical Trapping
To measure the chemical activity of the singlet oxygen produced by OPE1 as a result of DISA,
chemical-trapping experiments were carried out to detect the generation of ROS by OPE1. The
effect of OPE1 complexation with various concentrations of CTAB, below and above CTAB
critical micelle concentration (CMC), on singlet oxygen sensitization was assayed using 9,10anthracenediyl-bis(methylene)dimalonic acid (ADMA, SI Appendix, Fig. S3) as a chemical
sensor333. The ADMA is bleached in the near-UV by cycloaddition of oxygen across the central
ring of the anthracene chromophore, leading to a reduction in the absorbance band at 261
nm333.
Fig. 7 shows the absorption spectra of solutions of ADMA (1.5 μM), OPE1 (2 μM),
and varying below CMC concentrations of CTAB (0, 3, 7, and 11 μM) before (Fig. 7A) and
after (Fig. 7B) 3.5 min of 420-nm centered broadband light irradiation. Absorption spectra of
control samples containing the same concentrations of ADMA and CTAB, but not OPE1,
before (Fig. 7C) and after (Fig. 7D) irradiation are also plotted. These absorbance
measurements were not converted to quantum-yield values due to the strong local
concentration effects of the surfactant; the changes in absorbance are taken as a
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semiquantitative measure of singlet oxygen generation. The strong band at 261 nm arises from
ADMA and the lower energy transitions (above 300 nm) arise primarily from OPE1, with a
small contribution from the anthracene (Fig. 7C). When mixed with CTAB and ADMA, the
OPE1 bands in Fig. 8A show significant redshifts compared with OPE1 bands without CTAB
(Fig. 7A). The appearance of OPE1 vibronic structure is consistent with the formation of
surfactant-mediated J-type dimers78 complexed with detergent molecules. With irradiation at
420-nm light which is predominantly absorbed by the OPE1 (Fig. 4A), the ADMA peak at 261
nm shows CTAB-induced bleaching, indicating the onset of photosensitizer activity of OPE1
in the detergent- complexed state. The loss of absorbance at 261 nm results from singletoxygen-specific cycloaddition across the central ring of ADMA333. Controls of light irradiation
of ADMA alone (Fig. 7 C and D) indicate that the anthracene exhibits some CTABconcentration-dependent self-bleaching, consistent with more persistent excited states arising
from reduced local solvent polarity334. These results indicate that CTAB, an oppositely charged
detergent, mediates self-assembly of OPE1 monomers into J-type dimers with long-lived
excited states and both bright fluorescent emission and relatively efficient photosensitizer
activity72.
With an eye toward a future application in cellular delivery, we also tested the
robustness of OPE1 photosensitization by testing the compound at higher concentrations of
CTAB, near and above micellar concentrations. Fig. 8 shows the absorbance spectra before
and after irradiation of ADMA (21.4 μM) and OPE (21.4 μM) samples containing 0.5 mM
(below CMC) and 1.5 mM (above CMC) CTAB. Concentrations of ADMA and OPE were
raised in these samples to match the molar concentrations of CTAB micelles at 1.5 mM, using
an aggregation number of 70 for CTAB334. Fig. 8 shows the absorbance spectra of the samples
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before (Fig. 8A) and after (Fig. 8B) light irradiation. Note that the absorbance of the ADMA
peak of these high-ADMA-concentration samples were saturated at OD ∼2.0 (Fig. 8A). Using
Beer’s law, the absorbance of ADMA at 21.4 μM is expected to be ∼4.8. After light irradiation,
absorbance value of ADMA peak in samples containing 0.5 and 1.5 mM CTAB significantly
decreased to about 0.5 and 1.75, respectively (Fig. 8B), corresponding to ∼90% and 65%
bleaching. Control samples that contained ADMA and CTAB, but not OPE, were also prepared
and measured. As we had previously observed, self-bleaching of ADMA also occurred in these
high-CTAB-concentration controls. However, because OPE was the dominant absorbing
species in the samples at 420 nm, it is reasonable to conclude that ADMA bleaching in samples
containing OPE1 was primarily through photosensitization of OPE1. Although the effect of
ADMA self-bleaching cannot be quantitatively accounted for, these results confirm that DISAactivated OPE1 photosensitizer activity is retained at high detergent concentrations.
The proposed physical model for the response of OPE1 dyes to increasing surfactant
concentration is summarized in Fig. 9. In the absence of surfactant, OPE1 molecules are
dissolved as monomers in solution, and their singlet excited states are efficiently quenched by
solvent interaction resulting in low fluorescence and near-zero intersystem crossing. In the sub
micellar CTAB regime, OPE1–detergent interactions shield OPE1 from water quenching, and
lead to OPE1 J-type dimer formation and red shifting of the absorption bands. Similar effects
are seen in the micellar regime even as the equilibrium shifts back from J dimers to monomers.
As a result, detergent-complexed OPE1 exhibits increased fluorescence and availability of
singlet states for intersystem crossing.
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Figure 8-7 Absorbance spectra of samples containing 2 µM OPE1, 1.5 µM ADMA, and 0-11
µM CTAB before (A) and after (B)420-nm centered light irradiation and controls containing
1.5 μM ADMA and 0–11 μM CTAB, but no OPE1, before (C) and after (D) irradiation. CTABinduced bleaching above background was observed in the ADMA peak at 261 nm, concomitant
with redshifting and appearance of vibronic structure in OPE1 bands at 320 and 364 nm.

Figure 8-8 Absorbance spectra of samples containing 21.4 μM OPE1, 21.4 μM ADMA, and
0.5 mM or 1.5 mM CTAB before (A) and after (B) 420-nm centered light irradiation.
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8.4 Conclusions
The results of this study establish a bis(ethyl ester)phenylene ethynylene as a switchable
photosensitizer system, with DISA that causes the displacement of solvating waters by the
binding to a more hydrophobic target. Low concentrations of oppositely charged detergent
restored powerful photosensitizer activity to OPE1 while also generating a J band in
absorbance and in- creasing fluorescence emission 100-fold. DISA-mediated effects begin to
take hold with stoichiometric amounts of detergent, become strongest around a 5:1
CTAB:OPE1 ratio, and continue to be effective well into micellar regimes. These results
indicate that this or related molecules could be used to selectively photooxidize any
hydrophobic binding partner capable of desolvating the ethyl ester quencher groups. The
micromolar affinity of the OPE1 compound for amyloid fibrils represents an inviting direction
beyond oncology for singlet oxygen delivery, although the problem of delivering excitation
energy to target organs re- mains unsolved. Similar phenylene ethynylenes are also seen to
interact with various starch-based substrates203,320, making pathogenic fungi a possible target
as well.
Compared with previous efforts in the same field, the OPE-based system is attractively
compact, requiring no external quencher or specificity-granting conjugate. The quenchinggranting groups add little steric bulk, and the chromophore’s own binding profile can provide
specificity for several useful substrates. One downside of this approach is that reengineering
the binding profile to hit different targets or optimize binding without altering key
photophysical properties may be challenging. We are confident that continued efforts to
improve understanding and flexibility of this system will be successful. Overall these results
present ester-functionalized phenylene ethynylenes as an environment- switchable
photosensitizer with a mechanism for site-specific photodynamic therapy.
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Figure 8-9 Schematic of DISA of OPE1 and associated changes in the photophysical properties
of OPE1.

8.5 Materials and Methods
8.5.1 General
Synthesis and purification of OPEs including OPE1 has been described previously203.
ADMA and CTAB were obtained from Sigma-Aldrich Chemical Co. and used without
further purification. Water used in all experiments was purified to a resistivity of 18.2 MΩ by
a Synergy Millipore UV filtration system (EMD Millipore). Sizes of premicellar and micellar
CTAB and CTAB-OPE complexes were measured with dynamic light scattering on a
DAWN HELEOS-II light-scattering detector (Wyatt Technologies).
8.5.2 TA Spectroscopy
Triplet–triplet TA spectra were obtained using a pump– probe technique with the third
harmonic of a Nd:YAG laser (Continuum Surelite) as the pump illumination source and a Xe
flash lamp as the probe illumination source. Two transmission spectra (one from a region of
the sample illuminated by the pump beam) were obtained by passing the probe light through
a blaze grating onto a gated-intensified CCD camera, and their difference was used to
calculate the final TA difference spectra. The instrument was controlled using LabVIEW and
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postprocessing performed using MATLAB. A fast Fourier transform filter with a 20-nm
window was
Applied to spectra to reduce high-frequency noise and improve readability; the original data
can be found in SI Appendix, Fig. S1. The setup, including details of calibration, optical
diagrams, hardware, and timing electronics, has been described elsewhere335.
Solutions of OPEs (2 μM) were prepared at 0.8-OD absorbance at 355 nm
in a 10-mL, 1-cm-pathlength recirculating cuvette with magnetic stirrer. Samples were
excited at 355 nm with a constant pulse fluence of ∼20 mJ cm−2. The cuvette was sealed with
a rubber septum and the sample was sparged with argon for 30 min before each experiment.
Initial delay was set at 35 ns to allow time for triplet crossing. Delay time increased in 3-μs
increments between spectra until TA returned to baseline. A stock CTAB solution was added
to the OPE sample incrementally by syringe and the solution was sparged between readings.
8.5.31O2 Detection by Chemical Trapping
OPE1 concentration was determined by UV/visible spectrophotometry (PerkinElmer Lambda
35 UV/Visible Spectro- photometer) using an extinction coefficient of 3.92 × 104
Lmol−1·cm−1, identical to the cationic analog203. All spectroscopy was performed in 1-cmpathlength fused-quartz cuvette with 0.55 mL of solution. Samples containing varying
concentrations of OPE1, ADMA, and CTAB were exposed to light irradiation in quartz
cuvettes on a rotating carousel in a photochamber using eight LZC 420 lamps (Luzchem
Research Inc.), with emission centered at 420 nm and total incident power of 2.28 ± 0.028
mW cm−2 81. Low CTAB concentration samples (2 μMOPE1, 1.5 μM ADMA, and 0–11 μM
CTAB) were irradiated for 5 min, and higher-CTAB-concentration samples (0.5- and 1.5
mM CTAB) were irradiated for 3.5 min. For the 1.5 mM CTAB (above CTAB CMC)
samples, solutions were prepared with low (2 μMOPE1, 1.5 μM ADMA) and equal molar
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concentrations (21.4 μM) of OPE1, ADMA, and CTAB micelles. Using an aggregation
number of 70 for CTAB334, 21.4 μM was calculated as the concentration of micelles in a 1.5
mM CTAB solution Fluorescence samples for the determination of OPE unquenching and
aggregation were performed in quartz cuvettes using a PTI QuantaMaster 40 fluorometer.
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8.7 Supporting Information

Figure S1: Transient absorption (TA) difference spectra of OPE1 (2 μM) in water with
differing CTAB concentrations. Initial delay was 35 ns and delay time increased with 3 μs
increments. Oxygen was largely removed by bubbling samples with argon gas. This figure is
identical to Figure 6 in the manuscript but without FFT filter and baseline correction.
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Figure S2 Background subtracted changes in absorbance of ADMA peak at 260 nm after
irradiation.

Figure S3 Hetero-Diels-Alder cycloaddition of singlet oxygen to ADMA. The difference of
optical transitions between ADMA and the corresponding endoperoxide is the basis of its
functionality as a sensor. For ADMA used in this study, R = CH2CH(COOH)2.
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Figure S4 Transient absorption difference spectra in water of an OPE1 analogue without
esters, S-OPE-1-H (5 μM). This molecule exhibits a long-lived transient in water, as well as
singlet oxygen sensitization. The peak position and structure are also very different from OPE
1 (see Figure S5b).

Figure S5 Transient absorption difference spectra in methanol (a), in water (b), and in water
with stoichiometric CTAB of OPE1.
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Figure S6 TA difference spectra of OPE1 (2 μM) in water with micellar CTAB (1 mM).

Figure S7 Time-dependent self-bleaching of ADMA in the absence of CTAB or OPE.
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Table S1 Size parameters for micellar CTAB, micellar CTAB + OPE1, and sub-micellar
CTAB + OPE1, determined by dynamic light scattering (See Figure S8). *Submicellar CTAB
complexes produced variable data without good fits.

Figure S8 Representative DLS fitting data for (a) 1.5 mM CTAB and (b) 1.5 mM CTAB + 2
μM OPE1. Submicellar CTAB produced aggregates too small to analyze with DLS.
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Chapter 9 Summary and Future Work
This research described conjugated polyelectrolytes oligo-p-phenylene ethynylenes in their
transition from in vitro detection to ex vivo sensing and the beginning stages of in vivo
applications. Our aim is to add knowledge and provide a useful tool to aid in the early diagnosis
and treatment of neurodegeneration.
The work presented in Chapters 3-5 identified 2 OPEs (OPE12+ and OPE24+) as the most
selective for the fibrillar protein conformations using model amyloid proteins. Through this
study we gained an understanding about how OPE binding is affected by the molecules
structure, the backbone length, the charged side moieties, and the identity of the end groups.
Next we moved to test the sensors selectivity with disease relevant proteins. We performed
fluorimetry assays with OPEs in solution with Aβ40, Aβ42, α-Synuclein in Chapter 4 and tau
hexapeptide
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VQIVYK311 (PHF6) for Chapter 5. We found both OPEs bound the fibrillar

protein morphology over the monomeric counterparts. These binding events occurred with
higher binding affinities (sub-µM) when compared to Thioflavin T (Kd range 0.15 – 25
µM20,67), the current gold standard for amyloid detection. More notably, OPEs detected prefibrillar aggregates of α-Synuclein which ThT did not, pointing to the potential for OPEs as
early disease diagnostic tools. Moving into Chapter 5, OPEs continued to outperform ThT
detection across different protein morphologies seen on tau PHF6 fibrils, Type A and Type B.
With the in vitro sensing results, we moved to used OPEs as histochemical stains in mice, rat,
and human brain sections. Our work showed minimal non-selective background fluorescence
and strong staining of NFTs in rTg4510 mice with of OPE12- and OPE24+ at low µM- sub µM
concentrations. In TgF344-AD rat sections OPE24+ strongly bound the core of Aβ plaques.
Potentially, both OPEs could be used in concert to detect various protein pathologies co-
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existing in tissues. In ex vivo assays, OPEs had higher sensitivity than ThT for which we used
at mM concentrations. Lastly, Chapter 7, in one last aim to evaluate OPEs as protein aggregate
biosensors we worked to test the phenylene ethynylenes permeability through the blood brain
barrier. This project was interrupted by the COVID-19 pandemic however preliminary
partition coefficient shake-flask experiments suggest that single, ester terminated, with charged
side moieties OPEs, may have a difficult time permeating into the brain, the charged side
groups yield a more hydrophilic characteristic. To make OPEs more lipophilic we created 2:1
OPE12-:OPE24+ overall neutral complex and found this solution to transfer more readily into
the octanol layer and would possibly cross the blood brain barrier. We have plans to create
OPE-detergent complexes as lipophilic delivery vehicles as these also displayed higher OPE
fluorescence transfer into the octanol layer when compared to single molecules.
Parallelly we evaluated OPEs as pathological protein aggregate sensors in
cerebrospinal fluid and as sensors for detecting non-amyloid protein aggregates relevant to
pharmaceutical protein preparations. In Chapter 8 we report that these conjugated
polyelectolytes would not be the most efficient in diagnosing pathology from a CSF sample,
not for lack of selectivity but possibly limited by the molecules limit of detection. It is reported
that pathological protein concentrations in CSF are in the pg/mL287 range which is magnitudes
lower that OPE’s previously defined limits of detection (µM) although through an cyclic
amplification assay it was observed that this detection could be lower however further studies
must be done to confirm. Through this work we also characterized OPE behavior with a
number of biologically relevant molecules including albumin, glucose, and salts. This then led
us to test OPEs as sensors for amorphous aggregates that form during pharmaceutical protein
preparations. This project is still in its infancy as it was interrupted by COVID-19 pandemic.
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From this data we can conclude that this family of molecules may serve beyond pathological
protein detection and more characterization can be done to define and explore these fields.
Lastly, we report the use of OPE12- as a singlet oxygen generator with potential
therapeutic applications as in photodynamic therapies. Using an OPE-detergent (OPE12:CTAB) complex, we found that in a fluorescence turn-on state OPE12- can generate singlet
oxygen as detected by transient absorption and a chemical singlet oxygen trap ADMA. Since
this latter energy process is downstream of fluorescence, if there is no fluorescence, there is no
singlet oxygen generation. Essentially, we found the potential of OPE as a controllable system
to deliver and target oxidation, a switchable photosensitizer. The work to apply this oxidation
to disease relevant proteins was done and reported by Dr. Adeline M. Fanni. This work also
served as a springboard for the work of previous undergraduate student Jonathan Hulse in
testing how this system would be more applicable in biological systems including its effect on
lipid membranes. Using the same singlet oxygen chemical trap, he found that in the presence
of zwitterionic lipids OPE’s fluorescence is not activated therefore we would not expect to see
off-target membrane oxidation.
OPEs have proved to be multifaceted molecules. With amyloid protein aggregates,
these sensors could be the precedent for the development of PET ligands for early
neurodegenerative diagnosis and potential photodynamic therapy and as in vitro tools, with
multiple modes of detections, for researchers working in treatment development and
fibrillization characterization. Future directions for this work should be to conclude the
permeability studies using the 3-D cell based microfluidic chip as this will guide the direction
of in vivo applications of these specific biosensors. As it stands now permeability assays only
include astrocytes but could be changed to include more neuronal cells. The interactions of
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OPEs in cell culture must be evaluated to understand if OPE would interact with cells and if
so, would that change in the presence of amyloid fibrils. Further characterization of OPE
binding in fluorescence in non-amyloidogenic environments could take place to evaluate their
use in aggregate detection in the pharmaceutical field, move beyond testing with bovine IgG
and characterize the heat-stressed aggregates. As they stand OPEs are strong research tools for
studying protein aggregation processes, co-morbidities, pathogenesis, and oxidation. Overall
our work has demonstrated that OPEs can serve as powerful multi-mode detection sensors for
the detection of pathogenic fibrillar protein aggregates in vitro, ex vivo, and there is potential
for in vivo disease detection.
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